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DISCLAIMER 
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UPDATE STATEMENT 
A Toxicological Profile for Synthetic Vitreous Fibers, Draft for Public Comment was released in 
September 2002.  This edition supersedes any previously released draft or final profile.   
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology/Toxicology Information Branch 









































vii SYNTHETIC VITREOUS FIBERS
QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant toxicologic 
properties in a nontechnical, question-and-answer format, and it includes a review of the general health 
effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of 
exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are reported in 
this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone:  1-888-42-ATSDR or (404) 498-0110 Fax:  (770) 488-4178 
E-mail:  atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure history is 
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and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-
specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials incident.  
Volumes I and II are planning guides to assist first responders and hospital emergency department 
personnel in planning for incidents that involve hazardous materials.  Volume III—Medical Management 
Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients 
exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 
• Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and safety in 
the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and 
the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and 
health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356­
4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 
Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on human 
health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle 
Park, NC 27709 • Phone: 919-541-3212.
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: AOEC, 
1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 • FAX:  202-347­
4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and environmental 
medicine. Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone:  847-818­
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3. 	 Data Needs Review.  The Research Implementation Branch reviews data needs sections to assure 































A peer review panel was assembled for synthetic vitreous fibers.  The panel consisted of the following 
members:  
1. 	 Jeffrey I. Everitt, D.V.M., Senior Scientist, CIIT Centers for Health Research, Research  
Triangle Park, North Carolina; 
2. 	 Morton Lippmann, Ph.D., Professor of Environmental Medicine, New York University School of  
Medicine, Tuxedo, New York; 
3. 	 John A. Pickrell, Ph.D., D.V.M., Associate Professor of Environmental Toxicology, Kansas State  
University, Diagnostic Medical Pathobiology Department, Manhattan, Kansas; and 
4.	 Ernest McConnell, DVM, MS (path), DABT, DACVP, President, Toxpath Inc., Raleigh, North 
Carolina. 
These experts collectively have knowledge of synthetic vitreous fibers' physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and 
a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1 SYNTHETIC VITREOUS FIBERS
1. PUBLIC HEALTH STATEMENT 

This public health statement tells you about synthetic vitreous fibers (SVFs) and the effects of 
exposure to them.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  Synthetic vitreous fibers have not been detected in the 
1,647 current or former NPL sites.  Although the total number of NPL sites evaluated for these 
substances is not known, the possibility exists that synthetic vitreous fibers may be found in the 
future as more sites are evaluated.  This information is important because these sites may be 
sources of exposure and exposure to these substances may harm you. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it.  You may be 
exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to synthetic vitreous fibers, many factors determine whether you'll be harmed.  
These factors include the dose (how much), the duration (how long), and how you come in 
contact with them.  You must also consider the other chemicals you're exposed to and your age, 
sex, diet, family traits, lifestyle, and state of health. 
1.1 WHAT ARE SYNTHETIC VITREOUS FIBERS? 
Synthetic vitreous fibers are a group of fibrous inorganic materials that contain aluminum or 
calcium silicates and other trace oxides and metals, and are made from rock, slag, clay, or glass. 
These fibers differ from natural mineral fibers such as asbestos because they do not have a 
crystalline molecular structure.  The randomly oriented molecular structure of synthetic vitreous 
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1. PUBLIC HEALTH STATEMENT 
fibers: filaments and wools. The filaments consist of continuous glass filaments, while the wools 
are subdivided into glass wool, rock wool, slag wool, refractory ceramic fibers, and other types 
of newer fibers. The primary uses of synthetic vitreous fibers are for heat and sound insulating 
purposes, to reinforce other materials, and as filtration materials.  Glass wools are some of the 
most widely used insulating materials in homes and buildings.  The production and use of 
synthetic vitreous fibers has increased in recent years because these products are often used as a 
replacement for asbestos. 
A fiber is simply a long, slender particle. Technically, to be counted as a fiber, the particle must 
be at least 5 micrometers long (1 micrometer equals 1/1,000,000 of a meter and has the symbol 
µm), and have an aspect ratio of at least 3 to 1 or sometimes 5 to 1 (the aspect ratio is the ratio of
a fiber’s length to its diameter).  The diameter of a fiber is an important property because very 
thin fibers are more easily suspended in air than thick fibers, and they can be breathed in and 
deposited deep in the lungs. Only very thin fibers with diameters less than 3 µm are able to be 
breathed into the lower respiratory tract of humans.  Thicker fibers are deposited on the mucous-
lined surface of the upper respiratory tract, which includes the nose and mouth.  The World 
Health Organization (WHO) counts respirable fibers as particles with lengths greater than 5 µm, 
diameters less than 3 µm, and aspect ratios ≥3:1. Depending upon the way that they are 
produced, fibers can have relatively large or small diameters.  Generally speaking, glass wool, 
rock wool, slag wool, and refractory ceramic fibers have the smallest diameters, while 
continuous filament glass fibers have the largest diameters.   
See Chapters 4 and 5 for more information on the properties and uses of synthetic vitreous fibers. 
1.2 	 WHAT HAPPENS TO SYNTHETIC VITREOUS FIBERS WHEN THEY ENTER 
THE ENVIRONMENT? 
Synthetic vitreous fibers do not evaporate into air or dissolve in water.  They are generally not 
broken down to other compounds in the environment and will remain virtually unchanged over 
long periods.  Eventually, synthetic vitreous fibers will be broken down if the water or soil is 
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and disposal of synthetic vitreous fiber-containing materials.  Fibers with small diameters 
become airborne more easily than thick fibers, and can be transported by wind for longer 
distances. Synthetic vitreous fibers are not likely to move through soil. 
See Chapter 6 for more information on the behavior of synthetic vitreous fibers in the 
environment. 
1.3 HOW MIGHT I BE EXPOSED TO SYNTHETIC VITREOUS FIBERS? 
If materials containing synthetic vitreous fibers, such as insulation or ceiling boards in your 
home or where you work, are disturbed, synthetic vitreous fibers can become airborne.  When 
these fibers become airborne, you can be exposed to low levels of synthetic vitreous fibers 
primarily by breathing air.  Your skin and eyes can also be exposed to synthetic vitreous fibers if 
you install your own home insulation or come into contact with insulation in your home without 
using protective equipment such as gloves, protective glasses, or masks. 
The vast majority of exposure to synthetic vitreous fibers occurs to workers who produce or use 
synthetic vitreous fiber-containing products.  Employees at manufacturing facilities where 
synthetic vitreous fibers products are produced, as well as workers who regularly install or come
into contact with insulating material, are most frequently exposed to synthetic vitreous fibers.  
Workers involved in demolition work, as well as in building maintenance and repair, are 
potentially exposed to higher levels of synthetic vitreous fibers once these materials are 
disturbed. 
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1.4 HOW CAN SYNTHETIC VITREOUS FIBERS ENTER AND LEAVE MY BODY? 
If you breathe synthetic vitreous fibers, some will be deposited in the nasal and oral passages, 
and on the surfaces that line your lungs.  Most fibers deposited in the nasal and upper lung 
airways are removed by being carried away in a layer of mucous to the throat, where they are 
swallowed into the stomach. This usually takes place within a few hours.  Fibers deposited in 
the deepest parts of the lungs where gas exchange occurs are removed more slowly by special 
cells called macrophages.  Macrophages can engulf the fibers and move them to the mucous 
layer and the larynx where they can be swallowed.  Swallowed fibers and macrophages are 
excreted in the feces within a few days. 
Synthetic vitreous fibers deposited in the gas exchange area of the lungs also slowly dissolve in 
lung fluid. Fibers that are partially dissolved in lung fluid are more easily broken into shorter 
fibers. Shorter fibers are more easily engulfed by macrophages and removed from the lung than 
long fibers. Synthetic vitreous fibers dissolve more readily in the lung than asbestos fibers.  
Refractory ceramic fibers dissolve more slowly than most types of insulation (e.g., glass wools, 
stone wools, and slag wools). 
If you swallow synthetic vitreous fibers (by eating, drinking, or by swallowing fibers that have 
moved from nasal or lung airways to your larynx), nearly all of the fibers pass through your 
intestines within a few days and are excreted in the feces. 
If you get synthetic vitreous fibers on your skin or in your eyes, very few of these fibers, if any, 
pass through into your body. 
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1.5 HOW CAN SYNTHETIC VITREOUS FIBERS AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.   
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary.  Animal testing may 
also be used to identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method to get information needed to make informed 
decisions to protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Laws today protect the welfare of research animals, and scientists 
must comply with strict animal care guidelines. 
Synthetic vitreous fibers can cause irritation of the eyes and skin known as “fiberglass itch.”  
They can also irritate the upper respiratory tract (the nose, throat) and parts of the lung, causing 
sore throat, nasal congestion, and cough.  These effects usually go away with time.  Because 
most people are not exposed to high levels of synthetic vitreous fibers, serious health effects are 
not expected to happen in most people.   
Most of the information regarding the possible effects of repeated exposure to synthetic vitreous 
fibers in people comes from large studies of workers who make synthetic vitreous fibers.  Very 
few effects were detected. A few workers who made refractory ceramic fibers had pleural 
plaques on the lining of their chests.  These plaques did not seem to harm the workers.  Other 
workers who smoked could not breathe quite as well as smokers who did not work with 
refractory ceramic fibers.  Nonsmoking refractory ceramic fiber workers could breathe as well as 
other nonsmokers.  This suggests that repeatedly breathing in refractory ceramic fibers from
workplace air worsens the effects of smoking.  Pleural plaques and decreased breathing ability 
have not been found in workers who made glass wool and stone wool.  Other studies have found 
that the numbers of deaths from lung diseases, including lung cancer or mesothelioma, in groups 
of workers involved in the manufacture of glass wool, stone wool, or refractory ceramic fibers 
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a cancer of the membrane lining the lung.  Increased risk for mesothelioma has been found in 
asbestos workers, but increased risks for this cancer have not been found in workers involved in 
the manufacture of synthetic vitreous fibers. 
Results from animal experiments show that when synthetic vitreous fibers or other inhaled dust 
particles are deposited in the deepest part of the lung in high numbers, the lung responds with a 
process called pulmonary inflammation.  In this process, macrophage numbers in the lung 
increase so that they can engulf and move the fibers out of the lung.  When high numbers of 
fibers are deposited, the macrophages can become clumped together.  If pulmonary inflammation 
continues, the cells lining the lung may thicken from a process called bronchiolization.  
Bronchiolization may reduce the amount of oxygen that the body gets from the air during 
breathing. If exposure stops, deposited synthetic vitreous fibers slowly dissolve in the lung fluid 
or are moved out of the lung by the macrophages, and pulmonary inflammation disappears with 
time. 
Results from animal studies also show that repeatedly breathing high levels of some types of 
synthetic vitreous fibers may cause a slow buildup of scar-like tissue in the lungs and in the 
membrane surrounding the lungs.  This scar-like tissue does not expand and contract like normal 
lung tissue, and breathing can become difficult. This condition is called pulmonary fibrosis.  The 
types of synthetic vitreous fibers that cause this condition in animals stay in the lung for longer 
periods of time than the types that do not.  They are called durable or biopersistent synthetic 
vitreous fibers. Results from animal studies also show that repeatedly breathing high levels of 
durable synthetic vitreous fibers may also cause cancer of the lung and mesothelioma.  The most 
common types of glass wools, stone wools, or slag wools used for insulation are less durable 
than refractory ceramic fibers.  In rat studies, they did not cause the severe lung effects caused by 
the more durable refractory ceramic fibers.  
Scientists studying pulmonary fibrosis, lung cancer, and mesothelioma in animals from durable 
synthetic vitreous fibers have shown that the development of these conditions depends on four 
factors: dose, duration, dimension, and durability. Dose is the amount of fibers deposited in the 
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exposure are required for these conditions to develop.  Dimension refers to the length and 
diameter of the fibers.  Fibers with diameters greater than about 3 µm are not inhaled into the 
deepest regions of the lungs. Fibers with lengths greater than about 15–20 µm are not engulfed 
by macrophages, and are more likely to lead to lung injury than shorter fibers that are more 
readily removed by macrophages.  Durability refers to how readily a fiber dissolves in lung fluid.
Different types of synthetic vitreous fibers have different durabilities due to differences in 
chemical makeup.  Most synthetic vitreous fibers used as insulation in homes and buildings, such 
as fiberglass wools and stone wools, are more readily dissolved in lung fluid than are refractory 
ceramic fibers, which are used in insulation materials for furnaces.  Long, durable fibers 
deposited in the gas-exchange region of the lung can lead to long-term inflammation, pulmonary 
fibrosis, lung cancer, or mesothelioma. 
Levels of synthetic vitreous fibers in outdoor air, indoor air, and in most workplaces are usually 
well below levels that caused reversible pulmonary inflammation in animals or levels of durable 
synthetic vitreous fibers that caused pulmonary fibrosis, lung cancer, or mesothelioma in 
animals.  For example, levels of a refractory ceramic fiber that caused pulmonary fibrosis, lung 
cancer, and mesothelioma in rats are about one million times higher than levels of synthetic 
vitreous fibers detected in outdoor air close to synthetic vitreous fiber manufacturing factories, or 
indoor air from buildings with fiberglass or stone wool insulation. The levels experienced by the 
diseased rats are about 50 times higher than levels of synthetic vitreous fibers in the most dusty 
workplaces where insulation containing synthetic vitreous fibers was removed or installed. 
In 2002, the International Agency for Research on Cancer (IARC) considered all of the evidence 
regarding the possible carcinogenicity of synthetic vitreous fibers.  Much of the evidence was 
collected in the 1990s and was not available for earlier assessments made by the U.S. 
Department of Health and Human Services (DHHS).  IARC determined that refractory ceramic 
fibers are possibly carcinogenic to humans because of their high biopersistence.  IARC also 
determined that insulation glass wool, stone wool, and slag wool, and continuous filament glass 
were not classifiable as to carcinogenicity to humans because of inadequate evidence of 
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assessed the potential carcinogenicity of glass wool, stone wool, slag wool, or continuous 
filament glass, but has classified refractory ceramic fibers as a probable human carcinogen.  
See Chapters 2 and 3 for more information on how synthetic vitreous fibers may affect your 
health. 
1.6 HOW CAN SYNTHETIC VITREOUS FIBERS AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans.  
Because synthetic vitreous fibers are not absorbed into the body (when inhaled or ingested), it is 
unlikely that they would cause birth defects or be transferred in breast milk to nursing infants. 
Like adults, children who are exposed to synthetic vitreous fibers may experience irritation of the 
eyes, skin, and upper respiratory tract. Children breathe differently and have different lung 
structures than do adults.  It is not likely that these differences will cause a greater amount of 
synthetic vitreous fibers to stay in the lungs of children than in the lungs of adults.   
It is possible that exposure of young children to highly durable fibers could lead to pulmonary 
effects after very long latency periods.  However, there is no evidence to support this possibility, 
and the durability of many types of synthetic vitreous fibers in the lung is low.  This concern also 
has been raised for children exposed to asbestos fibers, which are more durable than synthetic 
vitreous fibers, but, as with synthetic vitreous fibers, there is inadequate evidence to support the 
idea that exposed young children may be at greater risk to develop pulmonary effects from
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1.7 	 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO SYNTHETIC 
VITREOUS FIBERS? 
If your doctor finds that you have been exposed to significant amounts of synthetic vitreous 
fibers, ask whether your children might also be exposed.  Your doctor might need to ask your 
state health department to investigate. 
Very low levels of synthetic vitreous fibers can be found in virtually all homes, buildings, and 
outside air, but there is little concern regarding these low levels.  The most important way that 
families can lower their exposures to synthetic vitreous fibers is to be aware of the sources of 
synthetic vitreous fibers in their homes and avoid exposure to these sources.  The most common 
source of synthetic vitreous fibers in a home is from insulating material that may be in your attic 
or walls. Damaged or deteriorating ceiling boards are another potential source.  As long as the 
materials are not physically disturbed or breaking down, the levels of synthetic vitreous fibers in 
the air should be very low. Relatively high levels of airborne synthetic vitreous fibers have been 
detected during the installation of insulating materials in attics, but these levels decline rapidly in 
1 or 2 days as airborne dust settles. If you are installing your own insulation, wear protective 
clothing and masks, and follow the recommendations provided by the manufacturer for installing 
this material.   
You can bring synthetic vitreous fibers home in the dust on your hands or clothes if you work in 
facilities that produce or use synthetic vitreous fibers, or install or remove materials with 
synthetic vitreous fibers. Your occupational health and safety (OHS) officer can and should tell 
you whether chemicals you work with are dangerous and likely to be carried home on your 
clothes, body, or tools. Your OHS officer can also tell you whether you should be showering 
and changing clothes before you leave work, storing your street clothes in a separate area of the 
workplace, or laundering your work clothes at home separately from other clothes.  Your 
employer should have Material Safety Data Sheets (MSDSs) for many of the chemicals used at 
your place of work, as required by the Occupational Safety and Health Administration (OSHA).  
Information on these sheets should include chemical names and hazardous ingredients, important 
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in your body, how to handle the materials properly, and what to do in an emergency.  Your 
employer is legally responsible for providing a safe workplace and should freely answer your 
questions about hazardous chemicals.  Either OSHA or your OSHA-approved state occupational 
safety and health program can answer any further questions and help your employer identify and 
correct problems with hazardous substances.  OSHA or your OSHA-approved state occupational 
safety and health program will listen to your formal complaints about workplace health hazards 
and inspect your workplace when necessary. Employees have a right to safety and health on the 
job without fear of punishment. 
1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
EXPOSED TO SYNTHETIC VITREOUS FIBERS? 
No tests are specific for determining whether or not you have been exposed to synthetic vitreous 
fibers. Because synthetic vitreous fibers leave the body quickly, most nonspecific tests would 
not be very useful. A chest x-ray is a common method to determine if you have certain 
conditions, such as pleural plaques, lung or pleural fibrosis, lung tumors, or mesotheliomas, but 
x-rays cannot show the presence of fibers in the lung. 
1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA).  
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
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Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or
food that are usually based on levels that affect animals; they are then adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for synthetic vitreous fibers include the 
following: 
In 1999, a Health and Safety Partnership Program was established as a voluntary workplace 
safety program for workers involved in the manufacture, fabrication, installation, and removal of 
glass wool, rock wool, and slag wool products.  The program was established as a result of 
negotiations between the OSHA, the North American Insulation Manufacturers Association, the 
National Insulation Association, and the Insulation Contractors Association of America.  The 
program established a voluntary 8-hour time-weighted average (TWA) permissible exposure 
limit (PEL) of 1 respirable fiber per cc of air.  Under this agreement, respirable fibers are 
counted as particles with length greater than 5 µm, diameter less than 3 µm, and aspect ratio 
greater than or equal to 3:1.  The agreement specifies that when the PEL is exceeded in a 
workplace (such as when insulation is blown into attics or removed), workers will wear NIOSH 
certified dust respirators. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
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ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 
may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the information and 
technical assistance toll-free number at 1-888-42ATSDR (1-888-422-8737), by email at 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 
  Division of Toxicology 
1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
For-profit organizations may request a copy of final profiles from the following: 
National Technical Information Service (NTIS) 

5285 Port Royal Road 

  Springfield, VA 22161 

  Phone: 1-800-553-6847 or 1-703-605-6000 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO SYNTHETIC VITREOUS 
FIBERS IN THE UNITED STATES  
Synthetic vitreous fibers are inorganic fibrous materials, manufactured principally from glass, rock, 
minerals, slag, and processed inorganic oxides.  Synthetic vitreous fibers are manufactured by several 
processes, all of which involve cooling of a stream of high-temperature, molten inorganic oxides.  
Commercially important synthetic vitreous fibers are primarily silica-based, but contain various amounts 
of other oxides (e.g., aluminum, boron, calcium, or iron oxides).  Synthetic vitreous fibers have 
amorphous molecular structures, while naturally occurring mineral fibers, such as asbestos, possess 
crystal structures.  In the past, synthetic vitreous fibers were classified into three categories:  fibrous glass; 
rock wool and slag wool (sometimes collectively referred to as mineral wool); and refractory ceramic 
fibers. The fibrous glass category included continuous filament glass fibers (sometimes called textile 
fibers) and glass wools. Recently, the World Health Organization (WHO) IARC classified synthetic 
vitreous fibers into two broad categories:  filaments and wools.  A schematic of this classification scheme 
is shown in Figure 2-1.  The filaments category refers to glass fibers that are produced by extrusion 
(continuous glass filaments).  IARC noted that more than 98% of currently produced continuous glass 
filaments are for electrical applications.  The wools category includes five subgroups:  glass wool, rock 
wool, slag wool, refractory ceramic fibers, and other fibers.  Included in the glass wool category are the 
subgroups, insulation wools and special purpose fibers.  The special purpose fiber group includes glass 
fibers produced by flame attenuation for special applications such as high-efficiency air filtration and 
include special fine-diameter glass fibers.  The other fibers group includes fibers such as alkaline earth 
silicate wools and high-alumina, low-silica wools that have been recently developed to be more 
biosoluble than older high-temperature synthetic vitreous fibers such as refractory ceramic fibers or rock 
wools. 
The production and use of synthetic vitreous fibers can cause their release to the environment.  Glass 
wool, rock wool, and slag wool are primarily used in insulating materials for homes, buildings, and 
appliances. Continuous filament fibers have been used to reinforce plastics, cement, papers, and roofing 
materials or woven into industrial fabrics, and currently are used mostly for electrical purposes.  
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Figure 2-1. IARC (2002) Categories of Synthetic Vitreous Fibers 
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resistance (e.g., furnace insulation).  Approximately 80% of the synthetic vitreous fibers produced and 
used in the United States are glass wool, rock wool, and slag wool.  Refractory ceramic fibers only
account for about 2% of the total amount of synthetic vitreous fibers produced.   
Synthetic vitreous fibers are persistent in the environment because they are not removed by mechanisms
that usually degrade organic compounds (e.g., biodegradation, photolysis).  Small diameter synthetic 
vitreous fibers with large surface areas can undergo dissolution in aqueous solutions, particularly at very
high or very low pH levels, but this is more important in biological systems than in the environment (see
Section 3.4 for more details regarding dissolution in physiologic fluids).  The transport and partitioning of 
synthetic vitreous fibers in the environment are largely governed by their size.  Large fibers are removed 
from air and water by gravitational settling at a rate primarily dependent on their diameter, but small 
diameter fibers may remain suspended for longer periods of time before settling down to the ground.
Inhalation exposure to airborne synthetic vitreous fibers is of public health concern because, like other 
particulate matter, fibers that get suspended in air can be inhaled and deposited in the lung.  
Measurements to determine the concentration of synthetic vitreous fibers in air samples are usually 
reported as the number of fiber(s) per cubic centimeter of air (fiber/cc).  Different studies have used 
different rules for counting fibers in air samples, but in general, a fiber is a particle that has a length 
≥5 µm and a length:diameter ratio (aspect ratio) of ≥3:1 or ≥5:1.  The WHO counts fibers as particles with 
lengths >5 µm, widths <3 µm, and aspect ratios ≥3:1. The National Institute for Occupational Safety and 
Health (NIOSH) counts fibers as particles with lengths >5 µm and aspect ratios ≥3:1. The levels of 
synthetic vitreous fibers in air are measured by phase contrast microscopy (PCM), transmission electron 
microscopy (TEM), or scanning electron microscopy (SEM) (see Chapter 7 for more details).  A human 
respirable fiber (a fiber that can be inhaled and reach the lower air-exchange portion of the respiratory 
tract) is usually defined as a fiber having a diameter <3 µm.   
When materials containing synthetic vitreous fibers are physically disturbed, fibers can become 
suspended in indoor or outdoor air.  In general, fibers with small diameters are more easily suspended and
remain suspended in air longer than larger-diameter fibers.  Among synthetic vitreous fiber types, 
continuous filament glass fibers usually have the largest average diameters, while refractory ceramic 
fibers, glass wool, rock wool, and slag wool generally have smaller average diameters (see Chapter 4 for 
more details).  Levels of synthetic vitreous fibers detected in outdoor or indoor air samples are very low, 
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fibers, reported air concentrations have mostly been reported to be <0.1–1 NIOSH fiber/cc.  Higher levels 
have been observed during the installation of insulation in a home or building (respirable airborne levels 
>1 fiber/cc have been observed); however, these levels quickly fall back to preinstallation levels within 
1 or 2 days.  The geometric mean concentration of respirable synthetic vitreous fibers ranged from 0.01 to 
3.51 fibers/cc at five construction sites where either refractory ceramic fibers, rock wool, or glass wool 
insulating materials were being installed or removed.  The greatest levels were observed during the 
removal of refractory ceramic fiber insulating material from the inside walls of industrial furnaces, and 
the lowest levels were observed during the installation of fiberglass panels around ventilation ducts at an 
industrial construction site. 
2.2 SUMMARY OF HEALTH EFFECTS  
Reversible acute irritations of the skin, eyes, and upper respiratory tract are well-known health hazards 
associated with direct dermal and inhalation exposure to refractory ceramic fibers, fibrous glass, rock 
wool, or slag wool in construction and manufacturing workplaces.  Wearing protective clothing and 
respiratory equipment has been recommended to prevent these health hazards (and possible chronic health 
hazards) when time-weighted average (TWA) airborne concentrations of fibers exceed recommended 
occupational exposure limits of 1 NIOSH fiber (length >5 µm; aspect ratio ≥3:1)/cc for continuous 
filament glass fibers, glass wool, rock wool, slag wool, and special purpose glass fibers or 0.2 NIOSH 
fibers/cc for refractory ceramic fibers. 
Although several respiratory health effects have been associated with occupational exposure to asbestos 
(pulmonary or pleural fibrosis [i.e., tissue scarring], lung cancer, and pleural or peritoneal mesothelioma), 
none of these diseases has been associated with occupational exposure during the manufacture of 
synthetic vitreous fibers.  Results from animal studies indicate that high-level inhalation exposure to any
synthetic vitreous fiber may cause reversible pulmonary inflammation, but only the most biopersistent of 
synthetic vitreous fibers have been demonstrated to produce irreversible pleural or pulmonary fibrosis, 
lung cancer, or mesothelioma. Health effects at other target organs are not expected from exposure to 
airborne synthetic vitreous fibers.   
Mechanistic and pharmacokinetic studies with asbestos and synthetic vitreous fibers indicate that greater 
potential for toxicity of inhaled inorganic fibers is associated with higher exposure concentrations, longer 
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discussed in Sections 3.4 and 3.5, fiber dimensions influence several of these key determinants of toxicity 
including: 
•	 The amount of material deposited in the alveolar region of the lung (fibers with diameters >3 µm 
do not reach this region; they are deposited in the upper respiratory tract and lung conductive 
airways, cleared by mucociliary action to the pharynx, swallowed, and eliminated via the feces); 
•	 The rate at which macrophages engulf and clear fibers deposited in the lower lung (human 
macrophages cannot fully engulf fibers with lengths longer than about 15–20 µm); and 
•	 The extent of movement of deposited fibers from the alveoli to the lung interstitium and the 
pleural cavity (fibers with diameters >0.3–0.4 µm may move less freely into the interstitium and 
pleural cavity). 
Fibers that can dissolve in physiologic fluids (i.e., that are less durable) develop weak points that can 
facilitate (1) transverse breakage by physical forces into shorter fibers and (2) faster clearance by
macrophages, compared with fibers that do not dissolve, like amphibole asbestos fibers.   
Synthetic vitreous fibers differ from asbestos in two ways that may provide at least partial explanations 
for their lower toxicity.  Because most synthetic vitreous fibers are not crystalline like asbestos, they do 
not split longitudinally to form thinner fibers.  They also generally have markedly less biopersistence in 
biological tissues than asbestos fibers because they can undergo dissolution and transverse breakage (see 
Sections 3.4 and 3.5).  
Irritation Effects.  Occupational exposure to fibrous glass materials, including glass wool insulation and 
fiberglass fabrics, has been associated with acute skin irritation (“fiberglass itch”), eye irritation, and 
symptoms of upper respiratory tract irritation such as sore throat, nasal congestion, laryngeal pain, and 
cough. The skin irritation has been associated with glass wool fibers having diameters >5 µm and 
becomes less pronounced with continued exposure.  Symptoms of irritation of the upper respiratory tract 
have been mostly associated with unusually dusty workplace conditions (concentrations >1 fiber/cc) 
involving removal of fibrous glass materials in closed spaces without respiratory protection.  The 
symptoms have been reported to disappear shortly following cessation of exposure.  Similar symptoms of 
dermal and upper respiratory irritation may also occur in workers involved in the manufacture, 
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Cancer and Nonmalignant Respiratory Disease.  Studies of workers predominantly involved in the 
manufacture of fibrous glass, rock wools, or slag wools have focused on the prevalence of respiratory
symptoms through the administration of questionnaires, pulmonary function testing, and chest x-ray
examinations.  In general, these studies reported no consistent evidence for increased prevalence of 
adverse respiratory symptoms, abnormal pulmonary functions, or chest x-ray abnormalities; however, one 
study reported altered pulmonary function (decreased forced expiratory volume in 1 second) in a group of
Danish insulation workers compared with a group of bus drivers.  Longitudinal health evaluations of 
workers involved in the manufacture of refractory ceramic fibers have not found consistent evidence of 
exposure-related changes in chest x-rays or pulmonary functions, with the exception that pleural plaques 
were found in about 3% of examined U.S. refractory ceramic fiber manufacturing workers and that 
pleural plaque prevalence showed statistically significant trends with increasing exposure categories.   
Epidemiologic studies (cohort mortality and case-control studies) of causes of mortality among groups of 
workers involved in the manufacture of fibrous glass, rock wool, or slag wool provide no consistent 
evidence for increased risks of mortality from nonmalignant respiratory disease, lung cancer, or pleural 
mesothelioma.  A number of reviews of these cohort mortality and case-control studies concur that the 
studies provide inadequate evidence for the carcinogenicity of synthetic vitreous fibers in humans.  In an 
initial report of the only available cohort mortality study of refractory ceramic fiber manufacturing 
workers, the only statistically significant excess mortality was for deaths associated with cancer of the 
urinary system.  No mesotheliomas and no excess deaths associated with respiratory cancers or 
nonmalignant respiratory disease were found.   
For all synthetic vitreous fibers tested, pulmonary inflammation has been observed in animals 
(predominately rodents) following intermediate- or chronic-duration inhalation exposure at concentrations 
more than an order of magnitude higher than 1 NIOSH fiber (length >5µm; aspect ratio ≥3:1)/cc. This 
concentration is the current occupational exposure limit for insulation wools recommended by the 
American Conference of Governmental Industrial Hygienists; for refractory ceramic fibers the limit is 
0.2 NIOSH fibers/cc. 
The most extensively studied refractory ceramic fiber, RCF1, caused minimal-to-mild pulmonary
inflammation in rats and hamsters at concentrations as low as 26 WHO fibers (length >5 µm; diameter 
<3 µm; aspect ratio ≥3:1)/cc (36 total fibers with aspect ratios ≥3:1 per cc) at 3 months.  The severity of 
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lesions did not exceed a moderate rating of “3" in most rats (on a 0–5 grade scale where 0 was “normal” 
and 5 was “severe”) even with exposure for 24 months to a concentration of 187 WHO fibers/cc.  The 
inflammation showed signs of regression after cessation of exposure.   
Other refractory ceramic fibers, RCF2, RCF3, and RCF4, caused minimal-to-mild pulmonary 
inflammation in rats at single exposure levels in the concentration range of 153–220 WHO fiber/cc.  The 
insulation glass wool MMVF10 caused pulmonary inflammation at concentrations as low as 29 WHO 
fibers/cc in hamsters and rats.  Other multiple-exposure tests in male rats have demonstrated the induction 
of minimal pulmonary inflammation from concentrations as low as 41 WHO fibers/cc of the glass wool, 
MMVF11, 34 WHO fibers/cc of the rock wool, MMVF21, and 30 WHO fibers/cc of the slag wool, 
MMVF22. Several of these studies also showed that signs of inflammation subsided to various degrees 
after cessation of exposure.   
Pulmonary inflammation has also been observed in single-concentration experiments in male rats 
following intermediate- or chronic-duration inhalation exposure to the newly developed high-temperature 
rock wool, MMVF34, at 291 WHO fibers/cc, the high-silica synthetic vitreous fiber, X607, at 180 WHO 
fibers/cc, the special-purpose 104E-glass fiber, at 1,022 WHO fibers/cc, and GB100R glass wool at 
2.2 mg/m3 (fiber counts in air samples were not measured).  Pulmonary inflammation also occurred in 

hamsters repeatedly exposed to the special-purpose durable glass fiber, MMVF33, at 310 WHO fibers/cc.  

An intermediate-duration study in male baboons reported that 1,122 NIOSH fibers/cc of 

C102/C104 blend fibrous glass induced pulmonary inflammation.  The only study to report a no­
observed-adverse-effect-level (NOAEL) for pulmonary inflammation (from chronic-duration exposure) 

exposed female Wistar rats to 252 WHO fibers/cc of Code 104/475 glass fiber for 12 months.  

Following intermediate- or chronic-duration inhalation exposure, pulmonary or pleural fibrosis has been 
observed: in rats exposed to several refractory ceramic fibers, RCF1, RCF2, RCF3, and RCF4, in the 
concentration range of 153–220 WHO fibers/cc; in hamsters exposed to the special-purpose durable glass 
fiber, MMVF33, at 310 WHO fibers/cc; in rats exposed to the insulation rock wool, MMVF21, at 
150 WHO fibers/cc; in rats exposed to the special-purpose 104E-glass fiber at 1,022 WHO fibers/cc; and 
in baboons exposed to C102/104 blend fibrous glass at 1,122  fibers/cc.  Exposure-response relationships 
for pulmonary or pleural fibrosis are best described, among these “fibrotic” synthetic vitreous fibers, for 
the refractory ceramic fiber, RCF1.  In rats exposed to RCF1 for up to 2 years, signs of irreversible 
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fibers/cc. In general, synthetic vitreous fibers that cause fibrosis are more biopersistent than those that do 
not. 
Synthetic vitreous fibers that have not induced pulmonary or pleural fibrosis in animals following 
intermediate- or chronic-duration inhalation exposure include the insulation glass wools, MMVF10 and 
MMVF11, at concentrations in the 232–339 WHO fibers/cc range, the slag wool, MMVF22, at 213 WHO 
fibers/cc, the high-temperature  rock wool, MMVF34, at 291 WHO fibers/cc, and the high-silica synthetic 
vitreous fiber, X607, at 180 WHO fibers/cc. All of these studies involved rats. 
Chronic inhalation exposure of animals to several biopersistent synthetic vitreous fibers has been shown 
to induce lung tumors or mesothelioma, whereas several less biopersistent synthetic fibers have not 
induced tumorigenic responses in animals exposed by inhalation for chronic durations.  In these 
experiments, statistically significant increases in lung tumor incidence (adenomas or carcinomas) have 
been accepted as evidence of a tumorigenic response, whereas any detection of a mesothelioma has been 
generally accepted as evidence for this relatively rare type of tumor.   
Tumorigenic responses in the lung or pleura were observed in hamsters and rats exposed to the refractory
ceramic fiber, RCF1, at concentrations as low as 75 WHO fibers/cc, in rats exposed to RCF2, RCF3, or 
RCF4 at concentrations between 153 and 220 WHO fibers/cc, in hamsters exposed to the durable glass 
fiber, MMVF33, at 310 WHO fibers/cc, and in rats exposed to the special purpose 104E-glass fiber at 
1,022 WHO fibers/cc. The carcinogenic response to 104E-glass fiber in rats was observed after only
1 year of exposure, in contrast to another special purpose glass fiber, 100/475, which did not induce 
cancer in rats exposed to 1,119 WHO fibers/cc for 1 year. 
No other synthetic vitreous fiber types have produced evidence of carcinogenicity in chronic inhalation 
animal testing.  Neither increased lung tumor incidence or the presence of mesotheliomas were found in
rats exposed for 2 years to: the insulation glass wools, MMVF10 or MMVF11 at 232 or 246 WHO 
fibers/cc; the insulation rock wool, MMVF21, at 243 WHO fibers/cc of; the slag wool, MMVF22, at 
213 WHO fibers/cc; the newly developed high-temperature rock wool, MMVF34, at 291 WHO fibers/cc; 
or the high-silica synthetic vitreous fiber, X607, at 180 WHO fibers/cc.  Additionally, evidence for 
carcinogenic responses was not found in male hamsters exposed to MMVF10a at 339 WHO fibers.  
Although no tumors were found in male baboons exposed to 1,122 NIOSH fibers/cc of C102/C104 blend 
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Increased incidences of fibrosis or tumors (e.g., lung tumors, mesotheliomas, sarcomas, or abdominal 
cavity tumors) have been observed in studies of rodents exposed to glass wool, rock wool, slag wool, or 
refractory ceramic fibers by intratracheal instillation, by intrapleural implantation or injection, and by
intraperitoneal injection. These lesions were not observed in a few studies involving intraperitoneal 
injection of continuous filament glass fibers.  Most of these studies involve a single administration 
followed by observation periods up to 2 years.  The relevance of these studies to human inhalation 
exposure is limited because of the high doses used, the bypassing of the natural defense systems of the 
nasal and upper respiratory system, and the overloading or lack (for intraperitoneal studies) of clearance 
mechanisms mediated by pulmonary macrophages. 
The U.S. Department of Health and Human Services, National Toxicology Program classified glass wool 
(respirable size) as reasonably anticipated to be a human carcinogen, based on sufficient evidence of 
carcinogenicity in experimental animals.  This assessment was originally prepared in 1993–1994 for the 
7th Report on Carcinogens, but has not been updated since then in the 8th, 9th, or 10th Reports on 
Carcinogens. Continuous filament glass, rock wool, slag wool, or refractory ceramic fibers were not 
listed or assessed for carcinogenicity in the 7th, 8th, 9th, or 10th Report on Carcinogens. 
In 2001, IARC convened a scientific working group of 19 experts from 11 countries to review a new 
monograph on “man-made vitreous fibers” that replaced the previous IARC monograph on these 
materials. The new monograph and the working group concluded that epidemiologic studies published 
since the previous IARC assessment provide no evidence of increased risks of lung cancer or of 
mesothelioma from occupational exposure during the manufacture of man-made vitreous fibers and 
inadequate evidence overall of any excess cancer risk.  IARC concluded that there was (1) sufficient 
evidence in experimental animals for the carcinogenicity of certain special purpose glass fibers and of 
refractory ceramic fibers; (2) limited evidence in experimental animals for the carcinogenicity of 
insulation glass wool, rock (stone) wool, and slag wool; and (3) inadequate evidence in experimental 
animals for the carcinogenicity of continuous glass filament and certain newly developed, less 
biopersistent fibers such as X-607 and MMVF34.  Insulation glass wool, rock (stone) wool, slag wool, 
and continuous filament glass were classified in Group 3, not classifiable as to carcinogenicity to humans
because of the inadequate evidence of carcinogenicity in humans and the relatively low biopersistence of 
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and 475 glass fibers) not used as insulating materials were classified in Group 2B, possibly carcinogenic 
to humans, because of their relatively high biopersistence.  
The U.S. EPA Integrated Risk Information System (IRIS) has not classified the potential carcinogenicity
of glass wool, continuous filament glass, rock wool, or slag wool, but assigned refractory ceramic fibers 
to Group B2, probable human carcinogen, based on no data on carcinogenicity in humans and sufficient 
evidence of carcinogenicity in animal studies.  Currently, EPA is developing a cancer assessment for 
refractory ceramic fibers based on the multiple-exposure chronic inhalation animal bioassays.  The 
assessment is considering the development of quantitative inhalation unit risk estimates for refractory
ceramic fibers based on the animal tumorigenic responses, but, as of June 2004, the assessment has not 
been released. 
2.3 MINIMAL RISK LEVELS
Inhalation MRLs 
•	 A minimal risk level (MRL) of 0.03 WHO fibers/cc has been derived for chronic-duration 
inhalation exposure to refractory ceramic fibers 
The 2-year, multiple-exposure level inhalation bioassay of the refractory ceramic fiber, RCF1, in male 
Fischer 344 rats provides the best available data describing exposure-response relationships for
nonneoplastic lesions in the lung and pleura from chronic inhalation exposure to refractory ceramic fibers 
(Mast et al. 1995a, 1995b).  The study identifies pulmonary inflammation as the critical nonneoplastic end 
point of concern and identifies other more serious effects at the higher exposure levels (pulmonary and 
pleural fibrosis and cancer of the lung and pleura).  Other studies of rats exposed to RCF1 by inhalation 
provide strong support for pulmonary inflammation as the critical end point (Bellman et al. 2001; Everitt 
et al. 1997; Gelzleichter et al. 1999; McConnell et al. 1995), as well as other animal inhalation studies of 
other refractory ceramic fibers (Mast et al. 1995a) and other synthetic vitreous fibers such as insulation 
glass wools, MMVF10 and MMVF11 (Hesterberg et al. 1993c; McConnell et al. 1999), slag wool 
MMVF22 (McConnell et al. 1994), and rock wool MMVF21 (McConnell et al. 1994).  Chronic-duration 
MRLs for the other synthetic vitreous fibers with adequate rat exposure-response data (e.g., MMVF10, 
MMVF11, MMVF21, and MMVF22) were not derived because of the lack of fully developed lung 
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The MRL was derived using a benchmark dose modeling approach and a cross-species dosimetric scaling 
factor derived from lung deposition and clearance models for RCF1 fibers in rats and humans, which 
were developed by C.P. Yu (University of Buffalo) and colleagues (Maxim et al. 2003b; Yu et al. 1995a, 
1995b, 1996, 1997, 1998a, 1998b).  There are distinct differences between laboratory animal species and 
humans in respiratory tract size and geometry, ventilation rates and pattern, and macrophage sizes that 
influence the retention (the net result of deposition and clearance) of fibers in the lung.  The lung 
retention models for RCF1 in rats and humans incorporate many of these interspecies differences, and 
significantly decrease uncertainty in extrapolating doses from rats to humans.   
The approach (described more completely in Appendix A) involved the following steps. 
(1) 	 Continuous-variable models in the EPA Benchmark Dose Software were fit to exposure-
response data for lung weight and scores for macrophage aggregation, bronchiolization, and 
collagen deposition at the bronchoalveolar junction in male Fischer 344 male rats exposed to 
RCF1 for 2 years. 
(2) 	 The best-fitting model for each end point was used to calculate a benchmark concentration 
and a lower 95% confidence limit (BMCs and BMCLs in units of total fibers/cc) associated 
with a 10% increase in lung weight, compared with controls, or a mean minimal score of 1.0 
(on a 0–5 scale) for the lesion. 
(3) 	 The point of departure for the MRL was selected as the BMCL associated with the most 
sensitive end point, the BMCL for macrophage aggregation (9 total fibers/cc). 
(4) 	 The selected rat BMCL was converted to a human equivalent concentration 
(BMCLHEC=1 WHO fibers/cc) using a cross-species scaling factor, 0.07, derived from the 
lung deposition and clearance models developed for RCF1 in rats and humans. 
(5) 	The BMCLHEC for macrophage aggregation was divided by an uncertainty factor of 30 (3 for 
interspecies extrapolation with dosimetric adjustment and 10 for human variability). 
The rat BMCL for pulmonary macrophage aggregation was selected as the point of departure for the 
MRL from the set of rat BMCLs for different pulmonary end points shown in Table 2-1.  The ATSDR 
MRL Workgroup considered an alternative MRL derivation with bronchoalveolar collagen deposition as 
the critical effect, but preferred selection of macrophage aggregation as the critical effect because this 
effect occurred at lower concentrations than the other effects, as evidenced by the values of the rat BMCs 
and BMCLs in Table 2-1. When collagen deposition was selected as the critical effect for the MRL, an 
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Table 2-1. BMCs and BMCLs for 10% Lung Weight Increase and Pulmonary
 
Lesion Scores of 1 in Rats Exposed to RCF1 for 24 Months  

Endpoint BMC (total fiber/cc) BMCL (total fiber/cc) 
Lung weight 133 79 
Pulmonary macrophage aggregation  12 9 
Bronchiolization  37 30 
Collagen deposition at the bronchoalveolar junction 37 32 
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macrophage aggregation (0.03 WHO fibers/cc).  (The alternative MRL used a rat benchmark 
concentration of 32 total fibers/cc, a cross-species scaling factor of 0.07, and a total uncertainty factor 
of 90:  3 for cross-species extrapolation, 10 for human variability, and 3 for the selection of a potentially
serious adverse effect as the critical effect; see Appendix A.)  
The rat BMCs and BMCLs shown in Table 2-1 were calculated from the best-fitting models for the 
exposure-response data for the most sensitive nonneoplastic pulmonary effects observed in Fischer 
344 rats and shown in Table 2-2.  The data in Table 2-2 show that each of these effects increased in 
severity with increasing exposure level.  The severity of each of these effects also was positively related 
with concentrations of fibers in the lungs of the rats following 24 months of exposure (see Table 2-2). 
Although the 2-year RCF1 bioassays (Mast et al. 1995a, 1995b) provide the best available exposure-
response data for refractory ceramic fibers, the presence of nonfibrous particles in the RCF1 test 
atmosphere is widely acknowledged to have added to the lung responses in rats to an undetermined 
degree (Bellmann et al. 2001; Mast et al. 2000; Maxim et al. 2003b).  Under conditions in which lung 
clearance mechanisms become overloaded, many types of nonfibrous or fibrous materials can produce 
pulmonary fibrosis or tumors in rats (Oberdörster 1994).  The ratio of total fibers:nonfibrous particles for 
the RCF1 material used in the 2-year rat bioassay has been reported to be about 3:1 by Bellmann et al. 
(2001), about 1–2:1 from data reported by Mast et al. (1995a, 1995b), and 9:1 by Maxim et al. (1997).  In 
contrast, workplace air samples showed a ratio of about 0.5:1 (Maxim et al. 1997).  The likelihood that 
the nonfibrous particles in the RCF1 material contributed, to an undetermined degree, to the lung 
responses in rat indicates that the MRL may underestimate the daily human exposure that is likely to be 
without appreciable risk of adverse noncancer health effects.  As such, the MRL is expected to be 
protective of public health.
Some evidence that the presence of the nonfibrous particles can enhance the effects on the lung was 
provided by comparing responses in rats exposed by inhalation for 3 weeks to concentrations of about 
125 fibers (with lengths >20 µm)/cc of either RCF1 or a sample of refractory ceramic fiber, called 
RCF1a, in which only 2% of the mass was accounted for by nonfibrous particles (Bellmann et al. 2001).  
Expressed as WHO fibers/cc, the mean concentrations were 481 fibers/cc for RCF1a and 679 fibers/cc for 
RCF1. Pulmonary clearance ability was markedly depressed by RCF1, but not by RCF1a, and indices of 



















26 SYNTHETIC VITREOUS FIBERS
2. RELEVANCE TO PUBLIC HEALTH 
Table 2-2. Non-neoplastic Lung Responses in F344 Rats Exposed for 
24 Months to RCF1 




lungs at 24 months 
(mean total fibers per 











0 (n=12) NR 100.0±14.0 0±0 0±0 0±0 
36 (n=6) 5.55±1.71 116.8±12.3 2.0±0 1.2±0.4 0.7±0.82 
91 (n=6) 18.80±3.59 110.9±8.1 2.5±0.6 1.8±0.4 2±0 
162 (n=6) 27.80±6.06 131.8±15.3 3.0±0 2.7±0.5 2.8±0.4 
234 (n=6) 37.00±8.01 164.7±44.2 3.2±0.4 2.7±0.5 2.2±0.4 
Source: Mast et al. 1995a, 1995b; Bernstein et al. 2001b; see Appendix A 
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The chronic MRL is expected to be appropriately applied to intermediate-duration exposure scenarios, 
based on evidence from interim sacrifice data from the Mast et al. (1995a, 1995b) bioassay that exposure-
response relationships for pulmonary inflammation and chronic exposure are similar to those for 
intermediate-duration exposure.  Scores for pulmonary inflammation progressed to only a limited degree 
with progression from intermediate to chronic duration.  For example, mean scores for macrophage 
aggregation in rats exposed to 3, 9, 16, and 30 mg/m3 at 3 months were 1.7, 2, 2, and 2, respectively. The 
respective scores were 2, 2.3, 3, and 3 at 24 months and 2, 2.5, 3, and 3.2 at 24 months.   
Exposure-response relationships for pulmonary inflammation from acute inhalation exposure to synthetic 
vitreous fibers are inadequately characterized for deriving an acute inhalation MRL for any type of 
synthetic vitreous fiber.   
Any use of the MRL for refractory ceramic fibers in assessing likely health hazards from the insulation 
wools should acknowledge the evidence that many of the insulation wools are markedly less durable and 
less potent than refractory ceramic fibers (Bernstein et al. 2001a, 2001b; Eastes and Hadley 1996; Eastes 
et al. 2000; Hesterberg et al. 1998a).  There are data from multiple-exposure-level 2-year rat inhalation 
bioassays on the glass wools, MMVF10 and MMVF11 (Hesterberg et al. 1993c; McConnell et al. 1999), 
the slag wool, MMVF22 (McConnell et al. 1994), and the rock wool, MMVF21 (McConnell et al. 1994) 
that adequately describe exposure-response relationships for nonneoplastic pulmonary effects (i.e., 
pulmonary inflammation) from intermediate- and chronic-duration exposure to these materials.  However, 
lung deposition and clearance models for these synthetic vitreous fibers (such as the ones developed by
C.P. Yu and colleagues for RCF1) are not yet fully developed to carry out physiologically based 
dosimetric calculations of human equivalent concentrations. 
There are no adequate data (from multiple-exposure level studies) for deriving inhalation MRLs for the 
other types of synthetic vitreous fibers (special applications glass fibers or continuous filament glass 
fibers that are woven). 
Oral MRLs 
No MRLs were derived for oral exposure to any synthetic vitreous fibers for any duration of exposure.  
No studies were located regarding noncancer health effects in humans or animals orally exposed to 
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health concern, given the low probability of exposure by this route.  Supporting the lack of concern, 
results from an extensive series of lifetime studies of asbestos fibers in the diet of rats and hamsters found 
no consistent evidence for increased nonneoplastic lesions in exposed compared with control animals (see
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of synthetic vitreous 
fibers. It contains descriptions and evaluations of toxicological studies and epidemiological 
investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic 
data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
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"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have been 
made for synthetic vitreous fibers.  An MRL is defined as an estimate of daily human exposure to a 
substance that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a 
specified duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the 
target organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route 
of exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic 
effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and 
oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
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3.2.1 Inhalation Exposure 
3.2.1.1 Death 
No studies were located in which acute- or intermediate-duration inhalation exposure to synthetic vitreous 
fibers caused mortality in humans.  As discussed in Sections 3.2.1.2 and 3.2.1.7, cohort mortality studies 
of workers involved in the manufacture of fiberglass, rock wool, slag wool, and refractory ceramic fibers
have not found consistently increased risk of mortality associated with nonmalignant or malignant 
respiratory disease. 
None of the animal studies described below observed increased risk of death after inhalation exposure to 
synthetic vitreous fibers. 
3.2.1.2 Systemic Effects  
No studies were located regarding hematological, musculoskeletal, endocrine, dermal, ocular, or body
weight effects in humans or animals after inhalation exposure to synthetic vitreous fibers.  The principal 
target organ of inhaled synthetic vitreous fibers is the respiratory system. 
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects from
inhalation exposure to synthetic vitreous fibers are summarized in Table 3-1 and plotted in Figure 3-1. 
Although there are epidemiological studies of workers involved in the manufacture of synthetic vitreous 
fibers such as refractory ceramic fibers, the results do not characterize exposure-response relationships for 
potential health effects in humans. In contrast, animal inhalation studies identify several types of 
respiratory effects from various types of synthetic vitreous fibers and provide information on exposure-
response relationships.  Thus, data in Table 3-1 and Figure 3-1 are restricted to reliable NOAEL and 
LOAEL values from animal inhalation toxicity studies.  Units of exposure in animal studies include 
gravimetric measurements (mg/m3), which include the weight of nonfibrous particles present in air 
samples, and fiber count measurements (# fibers/cc), which rely on microscopically aided counting of 
fiber numbers in air samples.  The most frequently reported unit of exposure among the available animal 

















Key to Species Frequency NOAEL Less Serious Serious Reference 
(Specific Route)figure (Strain)	 System (WHO fibers/cc) (WHO fibers/cc) (WHO fibers/cc) Chemical Form 
ACUTE EXPOSURE 
Systemic 
1 Rat 5 d b Everitt et al. 1994 
6 hr/d Resp 1700 M (pulmonary and pleural (Fischer- 344)	 RCF1inflammation; increased lung
(nose only) and diaphragm mesothelial cell 
proliferation) 
2 Rat 5 d Gelzleichter et al. 1996a, 1996c
Resp 2645 M (pulmonary and pleural 
(Fischer- 344) 6 hr/d inflammation)	 RCF1 
3 Hamster	 5 d b Everitt et al. 1994 
6 hr/d Resp 1700 M (pulmonary and pleural (Golden	 RCF1inflammation; increased lung
Syrian) (nose only) mesothelial cell proliferation) 
INTERMEDIATE EXPOSURE 
Systemic 
4 Rat 3 wk Bellman et al. 2001 
Resp	 679 F (very slight interstitial fibrosis, 6 hr/day(Wistar)	 RCF1pulmonary inflammation,5 d/wk 
reduced alveolar clearance)
(nose only) 
5 Rat	 3 wk Bellman et al. 2001 



























Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
Exposure/ LOAEL 
Duration/ 
a Frequency Reference Key to Species NOAEL Less Serious Serious 
(Specific Route) figure (Strain) System (WHO fibers/cc) (WHO fibers/cc) (WHO fibers/cc) Chemical Form 
6 Rat 1 yr Cullen et al. 2000 
7 hr/d Resp 1119 M (pulmonary inflammation) (Wistar) 100/475 special purpose 5 d/wk 1119 glass fiber 
1021
7 Rat 1 yr Cullen et al. 2000 
Resp 1022 M (advanced pulmonary fibrosis; 7 hr/d (Wistar) pulmonary inflammation) 104 E-glass special purpose 5 d/wk 
1022 glass fiber 
4
8 Rat 4 wk Everitt et al. 1997 
Resp 4 hr/d 300 M (pulmonary and pleural (Fischer- 344) RCF1 5 d/wk inflammation; incr. lung and 
diaphragm mesothelial cell 
(nose only) proliferation) 
300
32
9 Rat 12 wk Everitt et al. 1997 
Resp 4 hr/d 300 M (pulmonary and pleural (Fischer- 344) RCF1 5 d/wk inflammation; incr. lung and 
diaphragm mesothelial cell 
(nose only) proliferation) 
300
39
10 Rat 12 wk Gelzleichter et al. 1999 








































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
a


























































29 M (minimal-to-mild pulmonary 
inflammation) 
29 M (minimal-to-mild pulmonary 
inflammation) 
































































Key to Species Frequency 
figure (Strain) (Specific Route) 
15 Rat	 6 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
16 Rat	 12 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
17 Rat	 3 mo 






















41 M (minimal-to-mild pulmonary 
inflammation) 
41 M (minimal-to-mild pulmonary 
inflammation) 






Hesterberg et al. 1993 
MMVF11 glass wool 
Hesterberg et al. 1993 
MMVF11 glass wool 
















































System (WHO fibers/cc) 







180 M Hepatic 
180 M Renal 
180 M Bd Wt 







180 M Hepatic 
180 M Renal 







180 M (pulmonary inflammation) 
Hesterberg et al. 1998b 
X607 
180 M (pulmonary inflammation) 





























































Resp 291 M (minimal pulmonary 
inflammation) 
Kamstrup et al. 2001 
MMVF34 rock wool 
Bd Wt 291 M 






Resp 291 M (minimal-to-slight pulmonary 
inflammation; bronchoalveolar 
collagen deposition without 
fibrosis) 
Kamstrup et al. 2001 
MMVF34 rock wool 
Bd Wt 291 M 






Resp 291 M (minimal-to-slight pulmonary 
inflammation) 
Kamstrup et al. 2001 
MMVF34 rock wool 










































Key to Species Frequency 
figure (Strain) (Specific Route) 
23 Rat	 3 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
24 Rat	 6 mo 






















220 M (minimal-to-mild pulmonary 
inflammation) 






220 M (minimal-to-mild pulmonary 
inflammation) 















































Key to Species Frequency 
figure (Strain) (Specific Route) 
25 Rat	 9 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
26 Rat	 12 mo 






















220 M (minimal-to-mild interstitial 
fibrosis, minimal pleural fibrosis, 
pulmonary inflammation) 






220 M (mild interstitial fibrosis, 
pulmonary inflammation) 




































































Resp 182 M (minimal-to-mild pulmonary 
inflammation) 
Mast et al. 1995a 
RCF3 





Bd Wt 182 M 






Resp 182 M (minimal-to-mild interstitial 
fibrosis, pulmonary 
inflammation) 
Mast et al. 1995a 
RCF3 















































Key to Species Frequency 
figure (Strain) (Specific Route) 
29 Rat	 9 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
30 Rat	 12 mo 















(WHO fibers/cc) (WHO fibers/cc) 
Serious Reference 
Chemical Form(WHO fibers/cc) 
182 M (mild interstitial fibrosis, 
minimal-to-mild pleural fibrosis, 
pulmonary inflammation) 






182 M (mild-to-moderate interstitial 
fibrosis, minimal-to-mild pleural 
fibrosis, pulmonary 
inflammation) 















































Key to Species Frequency 
figure (Strain) (Specific Route) 
31 Rat	 3 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
32 Rat	 6 mo 






















153 M (minimal-to-mild pulmonary 
inflammation) 






153 M (minimal-to-mild pulmonary 
inflammation) 




































































Resp 153 M (minimal-to-mild pulmonary 
inflammation) 
Mast et al. 1995a 
RCF4 





Bd Wt 153 M 






Resp 153 M (minimal-to-mild interstitial 
fibrosis, pulmonary 
inflammation) 
Mast et al. 1995a 
RCF4 





































































Resp 26 M (minimal-to-mild pulmonary 
inflammation) 
Mast et al. 1995a, 1995b 
RCF1 





Bd Wt 187 M 






Resp 26 M (minimal-to-mild pulmonary 
inflammation) 
187 M (minimal-to-mild interstitial 
fibrosis, pulmonary 
inflammation) 
Mast et al. 1995a, 1995b 
RCF1 




































































Resp 36 M (minimal-to-mild pulmonary 
inflammation) 
91 M (minimal-to-mild interstitial 
fibrosis) 
Mast et al. 1995a, 1995b 
RCF1 
Cardio 234 M 
Hepatic 234 M 
Renal 234 M 
Bd Wt 234 M 






Resp 34 M (pulmonary inflammation) 
McConnell et al. 1994 
MMVF21 rock wool 
Cardio 243 M 
Hepatic 243 M 
Renal 243 M 










































Key to Species Frequency 
figure (Strain) (Specific Route) 
39 Rat	 6 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
40 Rat	 12 mo 






















34 M (pulmonary inflammation) 
McConnell et al. 1994 





34 M (pulmonary inflammation) 
McConnell et al. 1994 














































Key to Species Frequency 
figure (Strain) (Specific Route) 
41 Rat	 3 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
42 Rat	 6 mo 






















30 M (pulmonary inflammation) 
McConnell et al. 1994 





30 M (pulmonary inflammation) 
McConnell et al. 1994 








































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation	 (continued) 
a


























Resp 30 M (pulmonary inflammation) 
McConnell et al. 1994 
MMVF22 slag wool 
Cardio 213 M 
Hepatic 213 M 
Renal 213 M 






Muhle et al. 1987 






Resp 300 M (pulmonary and pleural 
inflammation; incr. lung and 
diaphragm mesothelial cell 
proliferation) 



































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
a































Resp 300 M (pulmonary and pleural 
inflammation; incr. lung and 
diaphragm mesothelial cell 
proliferation; early signs of 
pleural fibrosis) 





Resp 296 M (pulmonary and pleural 
inflammation) 






Resp 316 M (pulmonary inflammation) 
Hesterberg et al. 1999 





Resp 36 M (pulmonary inflammation) 
Hesterberg et al. 1999 






































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
a






























































McConnell et al. 1995 
RCF1 
McConnell et al. 1999 
MMVF10a glass wool 
McConnell et al. 1999 



































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
a












































339 M (minimal-to-mild pulmonary 
inflammation) 




310 M (minimal to mild pulmonary and 




McConnell et al. 1999 
MMVF10a glass wool 
McConnell et al. 1999 
MMVF33 special purpose glass 
McConnell et al. 1999 



































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
a





























Resp 310 M (mild pulmonary and pleural 
fibrosis, pulmonary 
inflammation) 
McConnell et al. 1999 
MMVF33 special purpose glass 





Resp 1122 M (pulmonary inflammation, scant 
ferruginous bodies) 
b Goldstein et al. 1983 




1022 M (CEL: pleural mesotheliomas, 
lung adenomas and 
carcinomas) 
Cullen et al. 2000 






215 M (CEL: pleural mesotheliomas) 



































































29 M (minimal-to-mild pulmonary 
inflammation) 
29 M (minimal-to-mild pulmonary 
inflammation) 
41 M (minimal-to-mild pulmonary 
inflammation) 



































































































System (WHO fibers/cc) 







180 M Hepatic 
180 M Renal 
180 M Bd Wt 







180 M Hepatic 
180 M Renal 







180 M (pulmonary inflammation) 
Hesterberg et al. 1998b 
X607 
180 M (pulmonary inflammation) 







































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
a


























































220 M (mild interstitial fibrosis, 




Kamstrup et al. 2001 
MMVF34 rock wool 
Kamstrup et al. 2001 
MMVF34 rock wool 
































































Resp 220 M (mild interstitial fibrosis, minimal 
pleural fibrosis, pulmonary 
inflammation) 
















Resp 220 M (mild-to-moderate interstitial 
fibrosis, minimal-to-mild pleural 
fibrosis, pulmonary 
inflammation) 



















































Key to Species Frequency 
figure (Strain) (Specific Route) 
71 Rat	 15 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
72 Rat	 18 mo 















(WHO fibers/cc) (WHO fibers/cc) 
Serious Reference 
Chemical Form(WHO fibers/cc) 
182 M (mild interstitial fibrosis, 
minimal-to-mild pleural fibrosis, 
pulmonary inflammation) 






182 M (mild interstitial fibrosis, 
minimal-to-mild pleural fibrosis, 
pulmonary inflammation) 




































































Resp 182 M (mild-to-moderate interstitial 
fibrosis, minimal pleural fibrosis, 
pulmonary inflammation) 
Mast et al. 1995a 
RCF3 





Bd Wt 182 M 






Resp 153 M (minimal-to-mild interstitial 
fibrosis, pulmonary 
inflammation) 
Mast et al. 1995a 
RCF4 




































































Resp 153 M (minimal-to-mild interstitial 
fibrosis, minimal pleural fibrosis, 
pulmonary inflammation) 
Mast et al. 1995a 
RCF4 





Bd Wt 153 M 






Resp 153 M (minimal-to-mild interstitial 
fibrosis, pulmonary 
inflammation) 
Mast et al. 1995a 
RCF4 





































































Resp 26 M (minimal-to-mild pulmonary 
inflammation) 
75 M (minimal-to-mild interstitial 
fibrosis) 
Mast et al. 1995a, 1995b 
RCF1 





Bd Wt 187 M 






Resp 26 M (minimal-to-mild pulmonary 
inflammation) 
c 
75 M (minimal-to-mild interstitial 
fibrosis, pulmonary 
inflammation) 
Mast et al. 1995a, 1995b 
RCF1 

















































Key to Species Frequency 
figure (Strain) (Specific Route) 
79 Rat	 18 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
80 Rat	 2 yr 






















34 M (pulmonary inflammation) 150 M (mild pulmonary fibrosis, 
pulmonary inflammation) 
McConnell et al. 1994 





34 M (pulmonary inflammation) 150 M (mild pulmonary fibrosis, 
pulmonary inflammation) 
McConnell et al. 1994 














































Key to Species Frequency 
figure (Strain) (Specific Route) 
81 Rat	 18 mo 
6 hr/d(Fischer- 344) 5 d/wk 
(nose only) 
82 Rat	 24 mo 






















30 M (pulmonary inflammation) 
McConnell et al. 1994 





30 M (pulmonary inflammation) 
McConnell et al. 1994 







































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation (continued) 
LOAEL 
a




















NOAEL Less Serious 
System (WHO fibers/cc) (WHO fibers/cc) 
Resp 
Cardio 215 M 
Hepatic 215 M 
Renal 215 M 
Bd Wt 215 M 
Resp 339 M (minimal-to-mild pulmonary 
inflammation) 
Bd Wt 339 M 
ReferenceSerious 
(WHO fibers/cc) Chemical Form 
McConnell et al. 1995










McConnell et al. 1999 





































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation	 (continued) 
a



























Resp 310 M (mild pleural and interstitial 
fibrosis; mesothelial 
hyperplasia) 





















182 M (CEL: pulmonary adenomas 






153 M (CEL: pleural mesothelioma) 
Reference 
Chemical Form 
McConnell et al. 1999 
MMVF33 special purpose glass 
Goldstein et al. 1983 
C102-C104 blend glass wool 
Goldstein et al. 1983 
C102-C104 blend glass wool 
Mast et al. 1995a 
RCF3 





































Table 3-1 Levels of Significant Exposure to Synthetic Vitreous Fibers - Inhalation	 (continued) 
a































220 M (CEL: pulmonary carcinomas, 
pleural mesotheliomas) 






187 M (CEL: pulmonary adenomas 
and carcinomas) 






75 M (CEL: pleural mesothelioma) 






215 M (CEL: pleural mesotheliomas) 






310 M (CEL: pleural mesothelioma) 
McConnell et al. 1999 







































System (WHO fibers/cc) (WHO fibers/cc) 
LOAEL 
Serious Reference 








200 (CEL: pleural mesothelioma) 
Smith et al. 1987 
RCF 
a The number corresponds to entries in Figure 3-1.
 
Doses are reported as WHO fibers/cc; (WHO fibers = particles with length >5µm, diameter <3 µm, and a length:width ratio =3:1)
 
b Dose reported as NIOSH fibers/cc; (NIOSH fibers = particles with length >5µm and a length:width ratio =3:1)
 
c Used to derive a chronic inhalation minimal risk level (MRL) of 0.03 WHO fibers/cc for refractory ceramic fibers, as described in detail in Appendix A.  The MRL was derived using a
 
benchmark dose modeling approach and a cross-species dosimetric scaling factor derived from lung deposition and clearance models for RCF1 fibers in rats and humans.
 
Continuous-variable models in the EPA Benchmark Dose Software were fit to data for macrophage aggregation, bronchiolization, collagen deposition at the bronchoalveolar junction,
 
and lung weight in F344 male rats exposed to RCF1 for 2 years. The best-fitting model for each endpoint was used to calculate benchmark concentrations and their lower 95%
 
confidence limits (BMCs and BMCLs in units of total fibers/cc) associated with 10% increase in lung weight, compared with controls, or a mean minimal score of 1.0 (on a 0-5 scale)
 
for the lesions. The point of departure for the MRL was selected as the BMCL associated with the most sensitive endpoint, the BMCL for macrophage aggregation - 9 total fibers/cc.
 
The selected rat BMCL was converted to a human equivalent concentration (BMCLHEC =1 WHO fibers/cc) using a cross-species scaling factor of 0.07.  The BMCLHEC for
 
macrophage aggregation was divided by an uncertainty factor of 30 (3 for interspecies extrapolation with dosimetric adjustment and 10 for human variability).
 
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; G = gavage; Gastro = gastrointestinal; gd =
 
gestational day; Gn pig = guinea pig; hemato = hematological; hr = hour(s); LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); MMVF = man-made vitreous
 
fiber; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; occup = occupational; NS = not specified; RCF = refractory ceramic fiber; Resp =
 
































Figure 3-1. Levels of Significant Exposure to Synthetic Vitreous Fibers- Inhalation 







































Figure 3-1. Levels of Significant Exposure to Synthetic Vitreous Fibers- Inhalation (Continued) 
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Figure 3-1. Levels of Significant Exposure to Synthetic Vitreous Fibers- Inhalation (Continued) 
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Figure 3-1. Levels of Significant Exposure to Synthetic Vitreous Fibers- Inhalation (Continued) 





















































































Figure 3-1. Levels of Significant Exposure to Synthetic Vitreous Fibers- Inhalation (Continued) 














































Figure 3-1. Levels of Significant Exposure to Synthetic Vitreous Fibers- Inhalation (Continued) 














*Doses represent the lowest dose tested per study that produced a tumorigenic 
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>5 µm, diameter <3 µm, and aspect ratio ≥3:1). To facilitate comparison of effects across studies, this 
exposure unit is cited in Table 3-1 and Figure 3-1, except for a few studies (Everitt et al. 1994; Goldstein 
et al. 1983) in which fiber counting measurements were reported only in units using the NIOSH fiber 
counting rules (i.e., length >5 µm; aspect ratio ≥3:1). 
Respiratory Effects. 
Human Studies. 
Refractory Ceramic Fibers.  Research into the health effects of refractory ceramic fibers has been limited 
by the relatively short time since manufacture began (50 years), small numbers of exposed workers, and 
confounding exposures (e.g., smoking and asbestos).   
Information regarding the effects of acute inhalation exposure to refractory ceramic fibers in humans is 
limited to a case-report that provided suggestive evidence of respiratory symptoms (cough, eye and throat 
irritation, wheezing, shortness of breath, and bronchospasm) that required medical treatment following 
1 hour of exposure to high levels (“like a snow storm”) of refractory ceramic fibers without respiratory 
protection (Forrester 1997). 
No human inhalation studies of intermediate duration (2 weeks–1 year) were located for refractory
ceramic fibers. 
A low prevalence of pleural plaques (about 3%) has been the most biologically significant effect found in
retrospective and longitudinal evaluations of the health of workers involved in the manufacture of 
refractory ceramic fibers in the United States (LeMasters et al. 1994; Lentz et al. 2003; Lockey et al. 
1996, 2002) and Europe (Cowie et al. 2001).  However, consistent statistically significant associations 
with exposure to refractory ceramic fibers were only found in the U.S. cohort (Lentz et al. 2003; Lockey
et al. 1996, 2002).  Although diffuse pleural thickening and circumscribed pleural plaques have been 
associated with impairment of respiratory functions, localized pleural plaques are not thought to be a 
significant health hazard and have not been mechanistically linked to increased risks of lung fibrosis, lung 
cancer, or mesothelioma (Agency for Toxic Substances and Disease Registry 2001).  Symptoms of dry
cough, runny nose, wheezing, and breathlessness also have been reported in European manufacturing 
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Additionally, some studies have observed decreased pulmonary function, usually in exposed workers with 
histories of smoking (Cowie et al. 2001; LeMasters et al. 1998; Lockey et al. 1998; Trethowan et al. 
1995).  No fibrosis or other serious health effects have been demonstrated.  Although participation rates 
are high, these studies have been limited by small cohort sizes and relatively short exposure durations.  In
the only cohort mortality study of refractory ceramic fiber manufacturing workers, there were no
statistically significant excesses of death associated with any nonmalignant disease, including 
nonmalignant respiratory disease (LeMasters et al. 2003).  
A U.S. study of 627 current and 220 former refractory ceramic fiber production workers identified pleural 
changes in 23 men (LeMasters et al. 1994).  The pleural changes were classified as plaques for 21 of the 
cases and thickening for the other 2 cases.  Even after adjusting for potential asbestos exposure, a 
significant association remained between time since first employment and pleural plaques. 
A retrospective cohort study of radiographically detected chest changes in 652 workers from five U.S. 
refractory ceramic fiber plants initially detected 20 cases of pleural plaques (Lockey et al. 1996).  In a 
later report of the survey of radiographic chest changes in U.S. refractory ceramic fiber workers 
(625 current workers at five plants and 383 former workers at two of the five plants), pleural changes 
were detected in 27 workers (2.7%) (Lockey et al. 2002).  Twenty-two of the cases showed pleural 
plaques (86% of which were bilateral).  In logistic regression analyses that adjusted for asbestos exposure 
and age, three exposure metrics (duration, time since first employment, and cumulative exposure) showed 
statistically significant trends for increasing odds ratios with increasing exposure.  For example,
respective odds ratios (ORs) for pleural changes were OR=2.2 (95% confidence interval (CI) 0.5–11.8),
OR=5.6 (95% CI 1.5–28.1), and OR=6.0 (95% CI 1.4–31.0) for the following categories of increasing 
cumulative exposure (measured in units of fibers-month/cm3): >15–45, >45–135, and >135.  In a similar 
logistic regression analysis of data collected from the same cohort, odds ratios for pleural plaques showed 
statistically significant trends with increasing exposure categories for three different cumulative exposure 
metrics: cumulative exposure; cumulative pulmonary dose of all fibers; and cumulative pulmonary dose 
of fibers with diameters <0.4 µm and length <10 µm (Lentz et al. 2003).  Pulmonary doses for each 
worker were estimated using air monitoring data from the plants, job histories, and a lung deposition 
model.   
A prospective study of 361 current male U.S. refractory ceramic fiber production workers found a 
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workers employed for >7 years at initial testing in 1987 compared to unexposed workers (OR not 
reported) (Lockey et al. 1998).  However, these effects did not remain statistically significant in 
longitudinal analyses conducted until 1994. 
In an initial report of a cohort mortality study of male workers employed at two U.S. refractory ceramic
fiber manufacturing plants between 1952 and 2000, no statistically significant excesses were found for
deaths by any cause or deaths associated with nonmalignant diseases (LeMasters et al. 2003).  A total of 
87 deaths were recorded among the 942 men included in the study (9% of the cohort).  Eight deaths 
associated with nonmalignant respiratory disease were recorded, compared with an expected 7.49 deaths 
based on U.S. mortality rates (standardized mortality ratios [SMR]=107; 95% CI 46–211). 
A cross-sectional study of workers from seven European refractory ceramic fiber manufacturing plants 
showed an association between nasal, skin, and eye symptoms and worker exposure (Burge et al. 1995; 
Rossiter et al. 1994; Trethowan et al. 1995).  A total of 628 employees participated in the study (91% 
were men).  Workplace air monitoring data were available for inspirable dust mass and respirable fibers. 
In a multiple logistic regression analysis of exposure to inspirable dust and respirable fibers, significantly
increased odds ratios for dry cough, dyspnea (grade 2), stuffy nose, eye irritation, and skin irritation were 
noted for the highest exposure group compared with the lowest exposure group (Burge et al. 1995).  No
relationships were noted for wheeze or chronic bronchitis with increasing exposure (Burge et al. 1995).  
When the effects of exposure to inspirable dust mass or respirable fibers were examined as independent 
variables, the odds ratio was significantly increased only for skin irritation for respirable fibers and for 
wheeze, dyspnea, and eye irritation for inspirable mass (Burge et al. 1995).  A multiple linear regression 
analysis (which adjusted for confounders such as age) showed that lung function variables in current 
smokers (forced expiratory volume in 1 second [FEV1] and forced midexpiratory flow, [FEF25-75])
decreased with increasing cumulative exposure to respirable fibers (Trethowan et al. 1995).  Chest x-rays
did not show any effects related to exposure to respirable fibers (Trethowan et al. 1995).   
In a subsequent cross-sectional morbidity study of 774 ceramic fiber production workers from six 
European refractory ceramic fiber manufacturing plants, the prevalence of radiographic pleural changes 
was more strongly related to age and any previous occupational exposure to asbestos than to exposure 
metrics for refractory ceramic fibers (Cowie et al. 2001).  Pleural plaques or pleural changes were noted 
in 9 or 32 workers, respectively, among the 355 workers without some occupational exposure to asbestos 
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for pleural plaques or pleural changes were calculated for refractory ceramic workers without asbestos 
exposure and with >10 years since first exposure to refractory ceramic fibers:  OR=2.03 (95% CI 0.78– 
5.25) for pleural plaques and OR=2.22 (95% CI 1.17–4.24) for pleural changes.  Exposure-related 
changes in pulmonary function variables were restricted to the finding that FEV1 and FVC in workers 
who smoked showed decreasing values with increasing measures of exposure. 
Glass Wool, Rock and Slag Wool, and Continuous Filament Glass Fibers.  In people, acute exposures 
to fibrous glass materials including continuous glass filament (e.g., fiberglass fabrics), glass wool 
insulation, and rock and slag wool have been associated with symptoms of upper respiratory tract 
irritation such as nasal itching and congestion, nosebleed, sore throat, cough, and laryngeal and 
pharyngeal pain (Horvath 1995; Milby and Wolf 1969; Nasr et al. 1971; Newball and Brahim 1976; 
Petersen and Sabroe 1991; Thriene et al. 1996).  These symptoms have been reported to disappear shortly
following cessation of exposure. Upper respiratory tract irritation has been associated mostly with 
unusually dusty workplace conditions (concentrations >1 fiber/cc) involving removal of fibrous glass 
materials in closed spaces without respiratory protection (ACGIH 2001; EPA 1980), and similar 
symptoms of upper respiratory irritation may also occur in workers involved in the manufacture, 
application, or removal of insulation materials made from rock wool or slag wool (ACGIH 2001).  
Reliable data regarding the effects of intermediate (2 weeks–1 year) inhalation exposure of people to 
continuous glass fibers, glass wool, and rock and slag wool are limited because cross-sectional studies 
have been limited to workers with longer exposures and cohort studies have frequently been confounded 
by strong healthy worker effects (Boffetta et al. 1997, 1998, 1999; Lea et al. 1999; Marsh et al. 2001a; 
Sali et al. 1999; Shannon et al. 1987, 1990). 
The possible effects of chronic exposure to continuous glass fibers, glass wool, and rock and slag wool 
have been investigated in cross-sectional health evaluation studies, cohort mortality studies, and case-
control studies.  Respiratory symptoms similar to those seen in acute studies (decreased pulmonary
function, coughing, bronchitis) have been reported (Albin et al. 1998; Clausen et al. 1993; Engholm and 
von Schmalensee 1982; Kilburn et al. 1992).  Attempts to determine whether or not exposure to 
continuous glass filament, glass wool, and rock and slag wool induced pleural plaques have been 
inconclusive or negative (Hughes et al. 1993; Kilburn and Warshaw 1991; Kilburn et al. 1992; Sanden 
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association between exposure and increased risk for mortality from nonmalignant respiratory disease 
(Hunting and Welch 1993; Marsh et al. 2001a; Sali et al. 1999; Shannon et al. 1987, 1990). 
Cross-sectional studies of populations working with fibrous glass have focused on the prevalence of 
respiratory symptoms through the administration of questionnaires, pulmonary function testing, and chest 
x-ray examinations (Clausen et al. 1993; Ernst et al. 1987; Gross 1976; Hansen et al. 1999; Hill et al. 
1973; Hughes et al. 1993; Kilburn et al. 1992; Moulin et al. 1988; Nasr et al. 1971; Sanden and Jarvholm, 
1986; Weill et al. 1983; Wright 1968).  In general, these studies reported no consistent evidence for 
increased prevalences of adverse respiratory symptoms, abnormal pulmonary functions, or chest x-ray
abnormalities (e.g., pneumonia, bronchitis, emphysema, pleural effusion and thickening, solid lesions, 
and abnormal heart and aorta).  However, increased incidences of coughing (Albin et al. 1998) and 
bronchitis (Engholm and von Schmalensee 1982) among Swedish construction workers exposed to glass 
and rock wool as well as decreased pulmonary function (forced expiratory volume in 1 second) among 
Danish construction workers exposed to glass and rock wool (Clausen et al. 1993) and U.S. appliance 
assembly workers exposed to glass wool (Kilburn et al. 1992) have been observed.  These studies did not 
have data regarding symptoms following cessation of exposure, so the persistence of these symptoms is 
unknown. In addition, information of exposure levels experienced by these workers was unavailable. 
Because occupational exposure to inhaled asbestos has been associated with changes in the pleural 
membrane (such as plaques, thickening, and fibrosis) (Agency for Toxic Substances and Disease Registry
2001), several cross-sectional studies analyzed chest x-rays of workers exposed to synthetic vitreous 
fibers but did not find consistent evidence for an association between pleural changes and exposure to 
fibrous glass, rockwool, or slag wool. No increased incidence of pleural plaques or radiographic densities 
were seen in a study of 1,401 continuous glass filament and glass wool production workers (Wright 1968)
or in a study of 788 male and 145 female rock wool production workers (Jarvholm et al. 1995).  An initial 
cross-sectional study performed in 1979–1980 of U.S. fiberglass and mineral wool workers detected a low 
prevalence of small lung opacities of low profusion that correlated significantly with duration of 
employment at two of the seven plants studied (Weill et al. 1983). However, in a follow-up study that 
used prevalences of opacities in a local population as a control, no excesses of opacities were identified in 
the exposed workers that were related to fiber exposure (Hughes et al. 1993). Two other studies observed 
opacities in groups of workers, but did not report data for reference populations, so the results are 
inconclusive (Kilburn and Warshaw 1992; Kilburn et al. 1992).  Lung radiographic abnormalities were 
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137 workers exposed to both asbestos and fiberglass (Kilburn and Warshaw 1992).  A separate study of 
appliance assembly workers exposed to glass wool observed radiographic abnormalities in 43 of 
284 workers (Kilburn et al. 1992).  Although 36 of these cases were attributed to fiberglass exposure, the 
adjustments made for self-reported asbestos exposure and smoking data were unclear (Bender 1993).  
Other studies observed pleural plaques and cough with phlegm only among fibrous glass workers with 
reported or suspected co-exposure to asbestos (Sanden and Jarvholm 1986; Scansetti et al. 1993).  
Data for mortality from nonmalignant respiratory diseases were analyzed for three major groups of 
workers involved in the manufacture of workers exposed to filament glass fibers, glass wool, rock wool, 
or slag wool in the United States (Bayliss et al. 1976; Chiazze et al. 1997, 2002; Enterline and Henderson 
1975; Enterline et al. 1983; Marsh et al. 1990, 2001a; Robinson et al. 1982; Wong et al. 1991; Watkins et 
al. 1997), Europe (Claude and Frentzel-Beyme 1984, 1986; Gustavsson et al. 1992; Lea et al. 1999; Sali 
et al. 1999; Simonato et al. 1986a; Teppo and Kojonen 1986), and Canada (Shannon et al. 1984, 1987, 
1990). These cohort studies (and their associated case-control studies) have the strengths of large sample 
sizes, long follow-up periods, low losses in follow-up, and use of existing employment records to assess 
exposure, but have the limitations of imprecise estimations of actual exposure levels and the inability to 
adjust for confounding from tobacco smoke and concomitant exposure to other hazardous agents in the 
workplace. (These cohort studies are also discussed in Section 3.2.1.7, Cancer.) 
The available cohort studies observed no increased risk of mortality from nonmalignant respiratory
diseases in U.S., European, or Canadian workers.  Significantly decreased risks of mortality from
nonmalignant respiratory disease compared with national rates reported in the U.S. fiberglass cohort 
(Marsh et al. 2001a) and in the Canadian studies on glass wool (Shannon et al. 1984, 1987) and glass 
filament (Shannon et al. 1990) workers are consistent with a possible healthy worker effect, but the 
European cohort study did not find decreased risks (Sali et al. 1999).  Categories of nonmalignant 
respiratory disease considered by these major studies were divided by organ (larynx, bronchus, trachea, 
and lung) and health effect (including asthma, bronchitis, emphysema, influenza, and pneumonia).  
Similarly, a cohort of 333 U.S. sheet metal workers investigating obstructive lung disease did not 
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Animal Studies. 
Although many animal studies administering various synthetic vitreous fibers by injection or implantation 
into the intrapleural or intraperitoneal cavities have reported the development of administration site 
nonneoplastic and neoplastic lesions (see Section 2.2.4, Other Routes of Exposure), these results are of 
limited usefulness for predicting health hazards in humans exposed by inhalation.  Studies that exposed 
animals by inhalation to well-measured levels of respirable fibers are considered more appropriate for 
assessing potential risk to human health. 
Studies in rats (Bellmann et al. 2001; Brown et al. 2000; Cullen et al. 2000; Everitt et al. 1997; 
Gelzleichter et al. 1996a, 1996b, 1996c, 1999; Haratake et al. 1995; Hesterberg et al. 1993c, 1998b, 1999;
Johnson and Wagner 1980; Kamstrup et al. 1998, 2001; Le Bouffant et al. 1987; Lee et al. 1981b; Mast et 
al. 1995a, 1995b; McConnell et al. 1994, 1999; Muhle et al. 1987; Smith et al. 1987; Yokosakai et al. 
1991), hamsters (Everitt et al. 1997; Gelzleichter et al. 1996a, 1996b, 1996c, 1999; Hesterberg et al. 1999;
Lee et al. 1981b; McConnell et al. 1995; Smith et al. 1987), guinea pigs (Lee et al. 1981b), and baboons 
(Goldstein et al. 1983) have observed consistent, dose-related responses to the inhalation of synthetic 
vitreous fibers; and only one study reported a NOAEL for respiratory effects (Muhle et al. 1987; see 
Figure 3-1). In the lungs, an immediate inflammatory response has been observed in rats and mice at the 
lowest exposure-levels tested, approximately 30–40 WHO fibers/cc of glass wool (Hesterberg et al. 
1993c, 1999), rock wool (McConnell et al. 1994), slag wool (McConnell et al. 1994), and refractory
ceramic fibers (Mast et al. 1995a, 1995b).  End points used to measure lung inflammation include 
infiltration of macrophages (which accumulate fibrous and nonfibrous inhaled particles), microgranuloma 
formation (nonneoplastic focal accumulations of macrophages), increases in other immune cells, and 
increases in biochemical markers (lactate dehydrogenase, gamma-glutamyl transferase, N-acetylglucose­
aminidase, glutathione, fibronectin, and total protein).  Although the intensity of inflammatory changes 
increased with increasing exposure, these effects have subsided rapidly after cessation of exposure and 
are therefore not considered serious in the absence of other lesions.  The reversible pulmonary
inflammatory effects observed following repeated inhalation exposure to synthetic vitreous fibers are 
typical of the lung’s response to other relatively water-insoluble particles, both non-fibrous and fibrous 
particles (Churg et al. 2000; Driscoll 1996; Hesterberg and Hart 2001; Kane 1996; Mossman and Churg 
1998).  In animal studies where exposure atmospheres included nonfibrous particles (e.g., the studies of 
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particles are expected to have contributed to the observed inflammatory responses to some undetermined 
degree (Maxim et al. 2003b).  
With repeated exposure scenarios to higher concentrations, more serious effects have been seen.  
Epithelial hyperplasia and alveolar bronchiolization, an epithelial cell transition from flat to cuboidal 
morphology, have been seen following chronic exposure to concentrations as low as about 180– 
240 WHO fibers/cc for several types of synthetic vitreous fibers including insulation glass wools 
(MMVF10, MMVF11; Hesterberg et al. 1993c), refractory ceramic fibers (RCF1, RCF2, RCF 3, RCF4; 
Mast et al. 1995a, 1995b), and rock and slag wools (MMVF21, MMVF22; McConnell et al. 1994).  For 
some fibers (e.g., refractory ceramic fibers, MMVF21, MMVF33, C102/C104 blend fibrous glass), signs 
of minimal-to-moderate fibrosis following repeat exposure have been observed (Bellman et al. 2001; 
Goldstein et al. 1983; Mast et al. 1995a, 1995b; McConnell et al. 1994, 1995, 1999).  Severe fibrosis was 
reported by only one study, with 104E-glass, a specialty continuous glass filament (Cullen et al. 2000).  
Because no regression has been observed following cessation of exposure, fibrosis is considered a serious 
respiratory lesion. 
Refractory Ceramic Fibers.  The nonneoplastic respiratory effects of inhalation exposure to refractory
ceramic fibers have been studied in conjunction with carcinogenicity studies (see Section 3.2.1.7, 
Cancer). In addition to intermediate and chronic studies in both rats and hamsters demonstrating 
reversible inflammation and irreversible fibrosis (Bellmann et al. 2001; Brown et al. 2000; Everitt et al. 
1994, 1997; Gelzleichter et al. 1996a, 1996b, 1996c, 1999; Hesterberg et al. 1998b; Mast et al. 1995a, 
1995b; McConnell et al. 1995; Smith et al. 1987; Yokosakai et al. 1991), acute- and intermediate-duration 
studies have found increased pleural mesothelial cell proliferation following acute and intermediate 
exposure in both hamsters and rats (Everitt et al. 1994, 1997; Gelzleichter et al. 1999). 
Although early rodent inhalation studies provided only limited information regarding the refractory
ceramic fiber tested (Smith et al. 1987; Yokosakai et al. 1991), subsequent studies have identified specific 
types of refractory ceramic fibers: RCF1 is a kaolin-based refractory ceramic fiber (55–75% fiber), 
RCF1a is a fiber-enriched preparation of RCF1 containing 98% fiber, RCF2 is an aluminum zirconia­
based fiber, RCF3 is a high-purity kaolin, and RCF4 is an “after-service” kaolin-based fiber previously
exposed to high temperatures.  Most studies have focused on RCF1, which is comparable to RCF3 (Mast 
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Acute studies are only available for RCF1, and have observed pulmonary and pleural inflammation 
(Everitt et al. 1994; Gelzleichter et al. 1996a, 1996b, 1996c).  In both Fischer 344 rats and male Syrian 
Golden hamsters exposed nose-only to 1,700 NIOSH fibers/cc of RCF1 (6,900 total particles/cc) for 
5 days, end points demonstrating inflammation included increased relative numbers of pulmonary
neutrophils (without changing total numbers of lavaged cells in the bronchoalveolar lavage fluid) and 
increased lung mesothelial cell proliferation; pleural neutrophil frequency was increased only in hamsters 
(Everitt et al. 1994).  Similarly, male Fischer 344 rats exposed to 2,645 WHO fibers/cc of RCF1 (55% 
fiber; 89 mg/m3) exhibited pulmonary and pleural inflammation following 5 days of exposure or at 
4 weeks postexposure (Gelzleichter et al. 1996a, 1996b).  The pulmonary inflammation consisted of a 
dramatic and transient increase in bronchoalveolar levels of neutrophils, a delayed increase in pleural 
monocyte and eosinophil numbers, and a sustained (for 4 weeks) increase in bronchoalveolar markers for 
inflammation (lactate dehydrogenase, N-acetyl glucosaminidase, alkaline phosphatase, total protein, 
albumin, soluble fibronectin, and leukocyte fibronectin secretion).  Pleural inflammation was more
limited, and was measured with biochemical markers (increased N-acetyl glucosaminidase and leukocyte
fibronectin secretion only immediately after exposure and increased total protein, albumin, and soluble 
fibronectin only at 4 weeks postexposure). 
Intermediate-duration nose-only inhalation experiments with refractory ceramic fibers in male Fischer 
344 rats (Mast et al. 1995a, 1995b), female Wistar rats (Bellmann et al. 2001; Brown et al. 2000), and 
male Syrian Golden hamsters (Everitt et al. 1997; Gelzleichter et al. 1999; McConnell et al. 1995) have 
verified the observations of pulmonary and pleural inflammation, and have also shown signs of 
progressive fibrosis. 
In male Fischer 344 rats, concentrations of RCF1 as low as 26 WHO fibers/cc (3 mg/m3) for 3 months 
have caused pulmonary inflammation (statistically significant increases in relative lung weight, 
macrophage infiltration, and microgranuloma [nonneoplastic focal accumulation of macrophages]
formation) (Mast et al. 1995a, 1995b). Exposure for the same duration to at least 75 WHO fibers/cc 
(9 mg/m3) caused another sign of inflammation, alveolar bronchiolization.  Alveolar bronchiolization is a 
pathologic response in which cells lining the alveoli become cuboidal (i.e., resembling cells lining the 
bronchioles).  No fibrosis was seen in rats exposed to 26 WHO fibers/cc of RCF1; 75 WHO fibers/cc 
caused minimal-to-mild interstitial fibrosis by 12 months, and 187 WHO fibers/cc of RCF1 caused 
minimal-to-mild pleural fibrosis by 9 months (Mast et al. 1995a, 1995b).  Following cessation of 
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nor regressed. Other studies in male Fischer 344 rats with RCF1 have also reported pulmonary
inflammation (statistically significant increases in pleural neutrophil, eosinophil and lymphocyte 
numbers, and biochemical markers of inflammation [pleural lactate dehydrogenase, N-acetylglucos­
aminidase, total protein, and fibronectin]) as well as pleural mesothelial cell proliferation following at 
least 4 weeks of exposure to 300 WHO fibers/cc (45.6 mg/m3) (Everitt et al. 1997; Gelzleichter et al. 
1999).
Exposure of male Fischer 344 rats to single exposure levels of RCF2, RCF3, or RCF4 (220, 182, or 
153 WHO fibers/cc, respectively, equivalent to 30 mg/m3 for each) for at least 3 months caused 
pulmonary inflammation (macrophage infiltration and microgranuloma formation, bronchiolization of 
proximal alveoli) (Mast et al. 1995a).  Minimal-to-mild focal pleural fibrosis was induced by RCF2 and
RCF3 in as little as 6 months and by RCF4 within 9 months (Mast et al. 1995a).
Pulmonary inflammation and slight interstitial fibrosis were also seen in female Wistar rats exposed to 
679 WHO fibers/cc of RCF1 (51.2 mg/m3) or 481 WHO fibers/cc of RCF1a (25.8 mg/m3) for 3 weeks 
(Bellmann et al. 2001; Brown et al. 2000).  RCF1a was a preparation of the same material cerused to 
prepare RCF1, but was prepared so that aerosols made from it contained less nonfibrous particles than 
RCF1 aerosols. Approximately 25% of the mass of RCF1 was accounted for by nonfibrous particles 
compared to about 2% in RCF1a.  Inflammation consisted of statistically significantly increased relative 
and absolute lung weight, biochemical markers of bronchoalveolar inflammation (lactic dehydrogenase, 
gamma-glutamyl transferase, total protein, and glutathione), and bronchoalveolar infiltration by both 
macrophages and lymphocytes.  Histopathological analyses observed slight interstitial fibrosis, bronchio­
alveolar hyperplasia, and alveolar histiocytosis.  Bronchioalveolar inflammation and hyperplasia subsided 
within 3 months postexposure, but neither interstitial fibrosis nor alveolar histiocytosis decreased within 
the 1-year postexposure observation period.  Exposure to RCF1 caused a severe retardation of alveolar 
clearance, but RCF1a did not, suggesting that the effect may have been a nonspecific response to total 
lung burden. 
Intermediate-duration studies with RCF1 in male Syrian Golden hamsters also demonstrated pulmonary
inflammation and both interstitial and pleural fibrosis (Everitt et al. 1997; Gelzleichter et al. 1999; 
McConnell et al. 1995).  In hamsters, concentrations as low as 215 WHO fibers/cc (30 mg/m3) of RCF1 
induced a dramatic bronchioalveolar infiltration by macrophages accompanied by the appearance of 
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punctate pleural foci, and collagen deposition) from 3 months onward (McConnell et al. 1995).  In the 
recovery animals (treatment stopped at 3, 6, 9, or 12 months) examined at 18 months, no progression or 
regression of fibrosis was observed versus comparably-exposed interim sacrifices, although macrophage 
levels quickly reverted to normal.  Male Syrian hamsters exposed to approximately 300 WHO fibers/cc of 
RCF1 (46 mg/m3) for as short a duration as 4 weeks also exhibited statistically significant increases in 
pleural neutrophil, eosinophil, and lymphocyte numbers; biochemical markers of inflammation (pleural 
lactate dehydrogenase, N-acetylglucosaminidase, total protein, and fibronectin); pleural mesothelial cell 
proliferation; and visceral pleural collagen levels (Everitt et al. 1997; Gelzleichter et al. 1999). 
Chronic studies have observed similar respiratory effects in rats (Hesterberg et al. 1998b; Mast et al. 
1995a, 1995b) and hamsters (McConnell et al. 1995; Smith et al. 1987).  Male Fischer 344 rats exposed to 
at least 26 WHO fibers/cc of RCF1 (3 mg/m3) for 18 or 24 months showed increased lung weight, 
macrophage infiltration with microgranuloma formation, alveolar bronchiolization, and pleural and 
interstitial fibrosis (Mast et al. 1995b). Exposure of male Fischer 344 rats to RCF2, RCF3, or RCF4 (220, 
182, or 153 WHO fibers/cc, respectively, equivalent to 30 mg/m3 for each) for 18 or 24 months caused 
pulmonary inflammation (macrophage infiltration and microgranuloma formation, bronchiolization of 
proximal alveoli) and minimal-to-moderate interstitial fibrosis and focal pleural fibrosis (Mast et al. 
1995a). Exposure to RCF1, RCF2, or RCF3 (but not RCF4) also caused bronchiolar-alveolar hyperplasia 
No nonmalignant respiratory effects were reported for male Syrian hamsters or female Osborne-Mendel 
rats exposed to 200 fibers/cc (12 mg/m3) of an unspecified refractory ceramic fiber (diameter 1.8 µm) for 
2 years, but these results are inconclusive due to data reporting limitations (Smith et al. 1987; this 
NOAEL is not in Table 3-1 or Figure 3-1).  Male Syrian Golden hamsters exposed for 15 or 18 months to 
215 WHO fibers/cc (30 mg/m3) of RCF1 exhibited dramatic pulmonary inflammation (bronchioalveolar 
infiltration of macrophages, accompanied by the appearance of microgranulomas, alveolar 
bronchiolization), as well as mild-to-moderate interstitial and pleural fibrosis (McConnell et al. 1995).  
Glass Wool (Insulation Glass Wools and Special Purpose Glass Fibers).  No acute-duration glass wool 
inhalation studies in animals were identified.   
All but one (Tempstran 475, Code 104 fiber, a special purpose glass fiber) of the glass wools induced 
pulmonary inflammation in animals following intermediate- or chronic-duration inhalation exposure 
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glass (with chronic- but not intermediate-duration exposure) (Goldstein et al. 1983), and two special 
purpose glass fibers (with intermediate- and chronic-duration exposures):  MMVF33 (McConnell et al. 
1999) and 104E-glass (Cullen et al. 2000). 
The glass wools best characterized in animal inhalation studies are MMVF10, MMVF11, and MMVF33 
(Hesterberg et al. 1993c, 1999; McConnell et al. 1999).  MMVF10 and MMVF11 are standard building
insulation glass wools, whereas MMVF33 is a more durable special purpose glass fiber.  Short-duration 
multiple-exposure-level studies with MMVF10 in male Syrian Golden hamsters observed minimal 
pulmonary inflammation (macrophage infiltration and microgranuloma formation) at levels as low as 
36 WHO fibers/cc after 13 weeks and 316 WHO fibers/cc after 7 weeks (3.2 and 30.5 mg/m3, 
respectively) (Hesterberg et al. 1999).  At 13 weeks, additional signs of inflammation were seen at the 
next-lowest concentration (increased numbers of pleural and pulmonary neutrophils and lymphocytes at 
concentrations as low as 206 WHO fibers/cc [16.5 mg/m3]) (Hesterberg et al. 1999).  These results are 
consistent with observations of pulmonary inflammation (macrophage infiltration and microgranuloma 
formation) in male Wistar rats exposed to the same approximate gravimetric concentration (2.2 mg/m3; 
fiber/cc counts not reported) of GB100R glass wool (Haratake et al. 1995) and in male Fischer rats 
exposed to 29 and 41 WHO fibers/cc (3.1 and 4.8 mg/m3) of either MMVF10 or MMVF11, respectively
(Hesterberg et al. 1993c).  No differences between MMVF10 and MMVF11 were observed in the latter 
experiment; no fibrosis was induced at the highest concentrations tested, 232 and 246 WHO fibers/cc 
(27.8 and 28.3 mg/m3), and no progression of effects was seen in animals sacrificed at 18 or 24 months 
compared to those sacrificed at 12 months.  
The other rodent experiment, which included both intermediate and chronic timepoints, tested MMVF10a 
(a low fluorine preparation of MMVF10) and MMVF33 (a durable special applications glass fiber) for 
18 months in male Syrian Golden hamsters at concentrations of 339 or 310 WHO fibers/cc, respectively
(29.6 or 37 mg/m3) (McConnell et al. 1999).  Pulmonary inflammation was seen as early as 13 weeks 
(macrophage infiltration and microgranuloma formation).  MMVF10a did not induce fibrosis, but 
MMVF33 induced mild-to-moderate interstitial and pleural fibrosis as well as other markers of 
inflammation (increased absolute lung weight; neutrophil, eosinophil, and lymphocyte infiltration; 
elevated lactate dehydrogenase, beta-glucuronidase, and total protein levels; alveolar bronchiolization), 
beginning at 13 weeks.  Both glass fibers induced mesothelial (but not bronchoalveolar) hyperplasia at 
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In male Wistar rats exposed whole-body at 1,022 WHO fibers/cc to 104E-glass or 1,019 WHO fibers/cc 
of 100/475 glass (two special-purpose glass fibers) for 1 year, both fiber types caused “considerable” 
pulmonary inflammation (macrophage infiltration associated with alveolar wall thickening), but only 
104E-glass produced considerable fibrosis (Cullen et al. 2000).  Rats exposed for 1 year to 104E-glass 
and allowed to recover for an additional year exhibited bronchoalveolar hyperplasia and fibrosis more 
advanced than in animals sacrificed immediately after exposure.  In nine rats exposed to 104E-glass that 
survived during the “recovery” period, advanced alveolar fibrosis and bronchoalveolar hyperplasia 
covered an average 8% of lung parenchyma area.  In contrast, this lesion covered only 0.2 and 0.08% of 
lung parenchyma in 100/475-exposed rats and control rats, respectively.   
The other intermediate (Goldstein et al. 1983; Johnson and Wagner 1980; Lee et al. 1981b; Muhle et al. 
1987) and chronic (Goldstein et al. 1983; Le Bouffant et al. 1987; Smith et al. 1987) studies of other glass 
wools reported minimal respiratory effects (pulmonary inflammation), but no serious nonneoplastic health 
effects (such as fibrosis). 
The only experiment with glass wool performed in a nonrodent species used baboons (Papio ursinus) and 
was applicable to both intermediate and chronic exposure (Goldstein et al. 1983).  A group of 10 male 
baboons were exposed to 1,122 fibers (with lengths >5 µm)/cc of a C102–C104 blend of fibrous glass 
(7.54 mg/m3; 5.80 mg/m3 respirable) for 35 months with periodic lung biopsies.  Pulmonary inflammation 
was seen at 8 months (pulmonary infiltration by histiocytes, fibroblasts, and giant cells, respiratory
bronchiole wall thickening, and occurrences of ferruginous bodies).  By 18 months, focal peribronchiolar 
fibrosis was detected. These results are inconclusive because data were not provided regarding lung fiber 
burdens and the frequency with which lesions were observed in the exposed and control groups. 
No significant respiratory effects were observed in female Wistar rats exposed nose-only to 252 WHO 
fibers/cc of Tempstran 475 (Code 104) glass fiber for 1 year (Muhle et al. 1987).  This study represents 
the only animal inhalation NOAEL reported for a synthetic vitreous fiber. 
Two intermediate studies with unspecified types of glass wool reported cell lysis, suggesting that 
clearance mechanisms may have been overloaded (Johnson and Wagner 1980; Lee et al. 1981b).  
Exposure of Fischer rats to 10 mg/m3 of a glass wool for 50 weeks caused focal fibrosis and pulmonary
inflammation (localized bronchiolar and alveolar degeneration and hyperplasia, and lysis of debris-filled 
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(7% fiber) glass wool for 3 months exhibited pulmonary inflammation (hyperplasia and lysis of dust-
filled lung cells [presumably macrophages], and a very slight increase in the incidence of ferruginous 
bodies [iron deposits]) that subsided within 6 months (Lee et al. 1981b).  Apparently, no inflammation 
occurred in similarly exposed hamsters, but conclusions could not be drawn from the study due to limited 
reporting. 
A 2-year assay of four types of glass wool in female Osborne-Mendel rats and male Syrian Golden 
hamsters did not report any signs of nonmalignant respiratory effects (Smith et al. 1987).  The results of 
this study are inconclusive, because reporting of study details was very limited.  As such, NOAELs and 
LOAELs from this study are not included in Table 3-1 or Figure 3-1.  The concentrations were 300 or 
3,000 fibers/cc of a 0.45 µm diameter glass (0.3 or 3.0 mg/m3), 100 fibers/cc of a 3.1 µm diameter glass 
(10 mg/m3), 10 or 100 fibers/cc of a 5.4 µm diameter glass (1.2 or 12 mg/m3), and 25 fibers/cc of 6.1 µm
diameter glass (9 mg/m3). 
In Wistar rats exposed for 2 years to a glass wool (concentration not specified), the reported signs were 
“simple alveolar macrophage reactions” and fibrosis (Le Bouffant et al. 1987).  These effects were 
reported for all of the fibers tested (asbestos, glass wool, and rock wool). 
Rock Wool. No acute-duration rock wool inhalation studies in animals were identified.  
Two parallel studies, with intermediate and chronic timepoints, provide the most reliable information for 
the respiratory effects of MMVF21 and MMVF34/HT rock wool (Kamstrup et al. 1998, 2001; McConnell 
et al. 1994). MMVF21 is a traditional basalt-based, rock (stone) wool.  MMVF34/HT is a more recently
developed rock wool characterized as having a relatively high content of aluminum and low content of 
silica, compared with MMVF21.  Supporting information is provided by an intermediate (Johnson and
Wagner 1980) and a chronic (Le Bouffant et al. 1987) study.  Pulmonary inflammation was seen for all of 
the rock wools tested; fibrosis was seen for MMVF21 (and unspecified types of rock wool), but not for 
MMVF34. 
In male Fischer 344 rats exposed nose-only to MMVF21 at concentrations of 34, 150, or 243 WHO 
fibers/cc (3.1, 16.1, or 30.4 mg/m3) for up to 24 months with interim sacrifices, minimal pulmonary
inflammation (increase in pulmonary macrophages) was seen at levels as low as 34 WHO fibers/cc 
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level (Kamstrup et al. 2001; McConnell et al. 1994). For example, rats in the highest exposure group
showed mild bronchiolization, in addition to increased pulmonary macrophages, by 3 months of 
exposure. Signs of minimal fibrosis (collagen deposition at the bronchoalveolar junction) were found in
2/6 rats exposed to 264 WHO fibers/cc at 12 months of exposure.  By 18 months of exposure, all rats 
exposed to 150 or 264 WHO fibers/cc showed signs of minimal or mild fibrosis (rats with mild fibrosis 
showed some interlobular linking), but the fibrosis was not more pronounced at these exposure levels 
after 24 months.  
In male Fischer 344 rats exposed nose-only to 291 WHO fibers/cc (30.1 mg/m3) of MMVF34/HT, for up 
to 2 years, inflammation (increased absolute and relative lung weight, macrophage infiltration and 
microgranuloma formation, alveolar bronchiolization) was seen as early as 3 months (Kamstrup et al. 
1998, 2001).  Minimal bronchoalveolar collagen deposition (a sign of fibrosis) was seen in a few rats at 
6 and 18 months, but was not observed in rats exposed for 12 or 24 months.  As such, no clear and 
consistent signs of pulmonary fibrosis were found in rats exposed to 291 WHO fibers/cc of MMVF34/HT 
for up to 24 months.  The results indicate that the newly developed rock wool, MMVF34/HT, is a less 
potent respiratory toxicant than the traditional rock wool, MMVF21.  
Exposure of Fischer rats to 10 mg/m3 of an unspecified rock wool for 50 weeks reportedly caused focal 
fibrosis, localized bronchiolar and alveolar degeneration and hyperplasia, and lysis of debris-filled 
macrophages (Johnson and Wagner 1980).   
In Wistar rats exposed for 2 years to a rock wool (concentration not specified), the reported signs were 
“simple alveolar macrophage reactions” and fibrosis (Le Bouffant et al. 1987).  These effects were 
reported for several fibers tested (asbestos, glass wool, and rock wool) in this study.
Slag Wool. No acute-duration slag wool inhalation studies in animals were identified.  Pulmonary
inflammation, but no fibrosis, has been reported for slag wool. 
Male Fischer 344 rats exposed nose-only for 2 years to levels as low as 33 fibers/cc of MMVF22, a blast-
furnace slag wool (30 WHO fibers/cc; 3.1 mg/m3) exhibited minimal pulmonary inflammation by
3 months (macrophage infiltration, microgranuloma development, and bronchiolization) (McConnell et 
al. 1994).  The severity of these effects increased with increasing concentration and with longer exposure 
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Another study reported no fibrosis or bronchoalveolar metaplasia in female Osborne-Mendel rats or male 
Syrian Golden hamsters exposed for 2 years to 200 fibers/cc of a 2.7 µm diameter slag wool (10 mg/m3) 
(Smith et al. 1987).  This apparent NOAEL was not included in Table 3-1 or Figure 3-1 due to limiting 
reporting of experimental details and results for this study. 
Continuous Filament Glass.  No inhalation studies in animals with continuous glass filaments were 
identified. Because this type of synthetic vitreous fiber most frequently has large diameters that render 
the fibers nonrespirable (ACGIH 2001; Lee et al. 1995), studies have focused on other routes of exposure 
(see Section 3.2.4). 
Other Fibers.  Exposure of male Fischer 344 rats to high-silica synthetic vitreous fiber, X607, at a 
concentration of 180 WHO fibers/cc (equivalent to 30 mg/m3), caused pulmonary inflammation 
(macrophage aggregation by 13 weeks, alveolar bronchiolization by 39 weeks, and macrophage 
microgranulation as early as 52 weeks), but no evidence of bronchioalveolar or pleural fibrosis even after 
2 years of exposure (Hesterberg et al. 1998b).  X607 is a high-silica synthetic vitreous fiber with glass-
like characteristics, which is produced using processes similar to those used for rock wool, slag wool, and 
refractory ceramic fibers.  It has temperature resistance properties that are intermediate between those of 
insulation glass wools and refractory ceramic fibers (Hesterberg et al. 1998b). 
The highest reliable NOAEL values and all reliable LOAEL values for respiratory effects (and other 
systemic effects) in animals exposed by inhalation to synthetic vitreous fibers are summarized in 
Table 3-1 and plotted in Figure 3-1. 
Cardiovascular Effects. Analysis of cause-of-death information for 2,758 male workers (from a 
cohort of 11,373 men) included in the European cohort study found a statistically significant increase in 
mortality from ischemic heart disease among continuous filament workers (51 of 172 total deaths, 
standardized mortality ratio (SMR) of 1.22 with a 95% CI=1.06–1.88), but not among workers exposed to 
glass or rock and slag wool (mean SMRs of 1.05, and 0.97, respectively) (Sali et al. 1999).  Among rock 
and slag wool workers, the trend for increased risk of mortality from ischemic heart disease correlated 
significantly with age.  No elevations of risk for mortality from diseases of the circulatory system or 
cerebrovascular disease were observed (SMR ranged from 0.99 to 1.22 and from 0.95 to 1.21, 
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death from ischemic heart disease and occupational exposure during the manufacture of continuous 
filament glass, due to the lack of measures of confounding influences on ischemic heart disease such as 
heat, other chemical exposures in the workplace such as carbon monoxide, and physical strain. 
The risk of death from cardiovascular diseases related to occupational exposure to continuous glass fibers, 
glass wool, and rock and slag wool were not increased significantly in either the U.S. cohort study (Marsh 
et al. 2001a) or the Canadian studies (Shannon et al. 1987, 1990). 
Some intermediate- and chronic-duration animal studies conducted routine heart histopathology, but did 
not find any adverse effects (see Table 3-1). 
Gastrointestinal Effects.    The majority of synthetic vitreous fibers that are deposited in the 
respiratory tract during inhalation exposure are transported by mucociliary action to the pharynx, where 
they are swallowed (see Section 3.4).  Consequently, the gastrointestinal epithelium is also directly
exposed to fibers as a result of inhalation exposure.  
Despite this exposure, inhalation exposure to continuous glass filament, glass wool, and rock and slag 
wool were not associated with increased risk of mortality from diseases of the digestive tract in the death 
records of 9,060 workers (from a cohort of 32,110) in the U.S. study (Marsh et al. 2001a), 2,758 male 
workers (from a cohort of 11,373 men) in the IARC study (Sali et al. 1999), 157 insulating glass wool 
workers (from a cohort of 2,557) in Sarnia, Canada (Shannon et al. 1984, 1987), 96 continuous glass 
filament workers (from a cohort of 1,465) in Guelph, Canada (Shannon et al. 1990), or 554 prefabricated 
houses builders (from a cohort of 1,068) in Sweden with glass and rock wool exposure (Gustavsson et al. 
1992).
Some intermediate- and chronic-duration animal studies did not find any adverse histopathologic changes 
in the gastrointestinal tracts (see Table 3-1). 
Hepatic Effects.    The European cohort study reported that mortality from cirrhosis of the liver was 
significantly increased among continuous filament workers (12 of 172 total deaths, SMR=2.12, 95%
CI=1.10–3.71), but not among workers exposed to glass or rock and slag wool (mean SMRs of 0.99 and 
1.10, respectively) (Sali et al. 1999).  The cause for this slight increase is unclear, but may be related to 
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11,373 men) was analyzed.  In contrast, the number of mortalities caused by liver cirrhosis was 
significantly decreased among the total U.S. cohort compared to national (but not local county) rates 
(SMRs of 0.68 and 0.88, respectively) (Marsh et al. 2001a).  A smaller study analyzing 554 deaths from a 
cohort of 1,068 prefabricated house builders found no correlation between liver cirrhosis and exposure to 
glass and rock wool (Gustavsson et al. 1992).   
Some intermediate- and chronic-duration animal studies conducted routine liver histopathology but did 
not report any adverse effects (see Table 3-1). 
Renal Effects.    No relationship between occupational exposure to rock and slag wool, glass wool, or 
continuous filament and mortality from nonmalignant renal disease has been detected in occupational 
cohort studies in the United States (Marsh et al. 2001a), European (Sali et al. 1999), or Swedish 
(Gustavsson et al. 1992) cohorts.  Data for mortality from nonmalignant renal disease were not reported 
for the Canadian cohorts (Shannon et al. 1987, 1990). 
Some intermediate- and chronic-duration animal studies conducted routine kidney histopathology, but did 
not find any adverse effects (see Table 3-1). 
No reliable studies were located regarding the following effects in humans or animals after inhalation 
exposure to synthetic vitreous fibers: 
3.2.1.3 Immunological and Lymphoreticular Effects  
3.2.1.4 Neurological Effects 
3.2.1.5 Reproductive Effects  
3.2.1.6 Developmental Effects 
3.2.1.7 Cancer 
The principal target organs of concern for cancer are the lungs (bronchoalveolar adenoma and carcinoma) 
and the pleura (mesothelioma).  Single layers of mesothelial cells compose the pleura, the delicate serous 
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as the peritoneum, the membrane lining the abdominal walls and viscera.  Mesotheliomas are rare 
malignant tumors of mesothelial cells; their incidence in the general human population is low, and pleural 
mesotheliomas have not been observed in control animals.  
Available epidemiological results provide inadequate evidence of the carcinogenicity of synthetic vitreous 
fibers in humans (see below).  Animal studies have detected elevated incidences of lung tumors and the 
formation of mesotheliomas following exposure to refractory ceramic fibers and two other fiber types 
(e.g., special-purpose glass microfiber 104E-glass and MMVF33, a durable special purpose glass fiber), 
but not for other synthetic vitreous fibers, such as traditional building insulation glass wools, that are less 
biopersistent (see below and Section 3.5). 
Intermediate-duration (1-year) exposure of male Wistar rats to special purpose 104E-glass fibers was 
associated with a statistically significant increase in the combined (but not individual) incidence of lung 
adenomas and carcinomas (Cullen et al. 2000).  Chronic exposure of male Fischer 344 rats to refractory
ceramic fibers, RCF1 or RCF3, was associated with statistically significant elevations in lung adenoma 
and carcinoma incidence, and exposure to RCF2 was associated with increased lung carcinoma (but not
adenoma) incidence (Mast et al. 1995a).  In contrast, RCF1 did not induce lung tumors in male Syrian 
Golden hamsters (McConnell et al. 1995).  The discrepancy between the two studies may be related to 
species specificity or differences in exposure duration (24 months for rats, 18 months for hamsters).  No 
increased lung tumor incidence was reported in intermediate-duration studies with 100/475 special-
purpose glass microfiber (Cullen et al. 2000), Code 104/475 special purpose glass fiber (Muhle et al. 
1987), or GB100R glass wool (Haratake et al. 1995) in rodents or in chronic-duration studies with 
MMVF10, MMVF11 (Hesterberg et al. 1993c), MMVF21, MMVF22 (McConnell et al. 1994), MMVF33
(McConnell et al. 1999), MMVF34 (Kamstrup et al. 2001), or X607 fiber (Hesterberg et al. 1998b) in 
rodents or with C102/C104 blend fibrous glass in baboons (Goldstein et al. 1983). 
Only one study has observed a statistically significant increase in pleural mesotheliomas, in male Syrian 
Golden hamsters exposed to 215 WHO fibers/cc of RCF1 for 18 months (42/102 versus 0/106 for 
controls) (McConnell et al. 1995); mesotheliomas were first seen at 40 weeks.  Other studies have 
detected one or two mesotheliomas per treatment group among rats exposed to 1,022 WHO fibers/cc of 
104E-glass for 1 year (Cullen et al. 2000), rats exposed for 2 years to 75 or 220 (but not 120) WHO 
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(Mast et al. 1995a, 1995b), and hamsters exposed to 310 WHO fibers/cc of MMVF33, a durable special 
purpose glass fiber, for 18 months (McConnell et al. 1999).   
Human Studies.  
Refractory Ceramic Fibers.  In a recent initial report of a cohort mortality study of male workers 
employed at two U.S. refractory ceramic fiber manufacturing plants between 1952 and 2000 (LeMasters 
et al. 2003), the only statistically significant excess mortality was deaths associated with cancer of the 
urinary system.  As of December 31, 2000, a total of 87 deaths were recorded among the 942 men 
(average age=51 years) included in the study (about 9% of the cohort).  Observed number of deaths and 
SMRs for selected cancer-related deaths were as follows (with 95% CI noted in parentheses):  all cancers, 
29 deaths, SMR=94.2 (63–135); malignancies of the respiratory system, 9 deaths, SMR=78.8 (36–150);
and malignancies of the urinary system, 5 deaths, SMR=344.8 (112–806).  No mesotheliomas were 
identified among the cohort to date, based on careful review of death certificates, medical records, and 
lung tissue analysis.  LeMasters et al. (2003) noted that the finding for excess urinary cancer deaths may
be a chance finding given the wide confidence interval for the SMR, the large number of statistical tests 
that were conducted (n=46), and the lack of a plausible mechanistic explanation of how fibers may
increase the risk for urinary cancer mortality.  Continued monitoring of the mortality experience of this 
cohort is planned. 
Glass Wool, Rock and Slag Wool, and Continuous Filament Glass Fibers.  Major cohort mortality and 
nested case-control studies of groups of workers engaged in the production of filament glass fibers, glass 
wool, rock wool and slag wool are ongoing in the United States (Bayliss et al. 1976; Buchanich et al. 
2001; Chiazze et al. 1992, 1993, 1995, 1997, 2002; Enterline and Henderson 1975; Marsh et al. 1990, 
2001a, 2001b, 2001c; Morgan 1981; Quinn et al. 2001; Robinson et al. 1982; Smith et al. 2001; Stone et 
al. 2001; Watkins et al. 1997; Wong et al. 1991; Youk et al. 2001) and Europe (Andersen and Langmark 
1986; Bertazzi et al. 1986; Boffetta et al. 1997, 1999; Claude and Frentzel-Beyme 1984, 1986; Khaerheim
et al. 2002; Lea et al. 1999; Olsen and Jensen 1984; Olsen et al. 1986; Plato et al. 1995c; Sali et al. 1999; 
Saracci et al. 1984; Simonato et al. 1986a, 1987; Teppo and Kojonen 1986; Westerholm and Bolander 
1986).  Smaller studies have been conducted in Canada (Shannon et al. 1984, 1987, 1990), Sweden 
(Gustavsson et al. 1992; Plato et al. 1997), and the United States (Bayliss et al. 1976; Enterline and 
Henderson 1975; Morgan 1981; Robinson et al. 1982).  These studies provide inadequate evidence of 
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elevations in respiratory system cancer risk were detected, the lack of sufficient data regarding potential 
confounding factors prevents a conclusive determination that the increased risks were due to these 
synthetic vitreous fibers (see below). 
Early studies of U.S. fibrous glass production workers did not associate exposure to fibrous glass or rock 
and slag wool with increased risk of respiratory or other cancers (Bayliss et al. 1976; Enterline and 
Henderson 1975; Morgan 1981; Robinson et al. 1982), but lacked statistical power due to their small size 
(cohorts of <1,500 men and cause-of-death information obtained for <400 workers).  A larger study
analyzed mortality statistics for workers from 17 U.S. plants manufacturing either fiberglass (glass wool 
or continuous filament glass) or rock wool and slag wool from the 1940s to the 1980s; it was conducted 
by the University of Pittsburgh under the sponsorship of the Thermal Insulation Manufacturers 
Association (TIMA), analyzing mortality statistics from the 1940s to the 1980s (Chiazze et al. 1992, 
1993, 1995, 1997, 2002; Enterline 1990; Enterline et al. 1983, 1987; Marsh et al. 1990; Watkins et al. 
1997; Wong et al. 1991); the results found either none or small and occasionally statistically significant 
elevations in the risk for respiratory system cancer among glass wool and rock and slag wool workers, but 
observed no correlation between length of exposure and increased risk.  To overcome limitations in these 
initial studies, a comprehensive surveillance of the U.S. cohort was performed by the University of 
Pittsburgh under the sponsorship of the North American Insulation Manufacturer’s Association (NAIMA) 
(Buchanich et al. 2001; Marsh et al. 2001a, 2001b, 2001c; Quinn et al. 2001; Smith et al. 2001; Stone et 
al. 2001; Youk et al. 2001).  Mortality data collected until 1992 for 9,060 workers from a cohort of 
32,110 workers in the 10 largest and longest-operating factories were analyzed (Marsh et al. 2001a).  The 
mean exposure to respirable fibers was estimated at 0.073 fibers/cc.  A small, but statistically significant, 
increase in the SMR for respiratory system cancer was limited to workers employed <5 years (SMR=1.12, 
95% CI=1.01–1.24), suggesting an exposure-independent “healthy worker” effect.  No patterns or 
statistically significant trends associated increasing risk for respiratory system cancer mortality with 
increasing measures of exposure (years of employment or estimated cumulative exposure).  A nested-case 
control analysis (632 cases, 572 controls) did not observe any relationship between respiratory system
cancer risk and exposure indices (Marsh et al. 2001a; Youk et al. 2001).   
The IARC began a large international cohort study of European workers involved in the manufacture of 
synthetic vitreous fibers in 1976.  The study includes 13 factories that produced glass wool, continuous 
glass filament, or rock and slag wool in Denmark, Finland, Norway, Sweden, the United Kingdom, 
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Langmark 1986; Bertazzi et al. 1986; Claude and Frentzel-Beyme 1984, 1986; Olsen and Jensen 1984; 
Olsen et al. 1986; Plato et al. 1995c; Teppo and Kojonen 1986; Westerholm and Bolander 1986) going 
back as far as the 1930s. The ongoing European study has incorporated these data and has published 
follow-up reports for data collected through the 1980s (Boffetta et al. 1992; Gardner et al. 1986, 1988; 
Saracci et al. 1984; Simonato et al. 1986a, 1987) and early 1990s (Lea et al. 1999; Sali et al. 1999), with 
the most recent reports considering data up to 1995 (Boffetta et al. 1997, 1999).  Most recently, cause-of­
death information for 4,521 workers (191 continuous filament workers from two factories, 1,679 glass 
wool workers from five factories, and 1,281 rock and slag wool workers from seven factories) was 
analyzed from a cohort of 22,002 individuals (Boffetta et al. 1997).  No increased risk of cancer incidence 
was clearly related to exposure, and none were related to duration of employment or time since first 
employment.  Among glass wool workers, a statistically significant overall increase (SMR=1.27, 95% 
CI=1.07–1.50) in mortality from cancers of the trachea, bronchus, and lung did not persist either when 
local mortality rates were used or when workers with <1 year of employment were excluded (a national 
healthy worker effect). The increase of mortality from lung cancer among continuous filament workers 
(SMR=1.11, 95% CI=0.61–1.86) was not significant overall and was attributed to one factory in Italy.  
Potential exposure to asbestos was associated with a significant increase (SMR=1.69, 95% CI=1.22–2.29) 
in the risk of lung cancer among all workers.  A statistically significant increase (SMR=1.34, 95%
CI=1.08–1.63) in the SMR for risk of death from cancers of the trachea, bronchus, and lung for all rock 
and slag wool workers was attributed to one factory in Germany where exposure to asbestos was reported.  
After exclusion of that factory, no significant elevation in risk remained (SMR=1.16, 95% CI=0.87–1.51) 
for rock and slag wool workers.  The authors concluded that “these results are not sufficient” to conclude 
that exposure to synthetic vitreous fibers increased the risk of lung or other cancer types.  
Because cancer incidence may be a more sensitive tool than mortality incidence for the detection of 
adverse health effects, a cancer incidence study of the European cohort was conducted (Bofetta et al. 
1999).  Data were obtained from the national cancer registrations of Denmark, Finland, Norway, and 
Sweden for 3,685 rock and slag wool workers and 2,611 glass wool workers who had been employed for 
at least 1 year in one of nine factories in between 1933 and 1995.  Although the elevation for cancers of 
the oral cavity and pharynx was statistically significant (27 cases, standard incidence ratio [SIR]=1.84, 
95% CI=1.22–2.68) for slag wool workers, the combined incidence of cancers of the oral cavity, pharynx, 
and larynx combined was not significant (31 cases, SIR=1.46, 95% CI=0.99–2.07).  Among glass wool 
workers, these incidences were not significantly elevated (11 cases, SIR=1.31, 95% CI=0.65–2.34 and 
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employment working with glass wool and increased incidences of oral, pharyngeal, and laryngeal cancers 
was statistically significant.  The authors concluded that these data were inadequate evidence of 
carcinogenicity because potential effects from confounding factors such as smoking had not been 
included. 
In a nested case-control study of 133 lung cancer cases and 513 matched controls among men who 
worked in seven rock and slag wool manufacturing plants in Denmark, Norway, Sweden, or Germany, no 
statistically significant associations with exposure were found (Kjaerheim et al. 2002).  Occupational 
exposure was assessed on the basis of interview data and exposure information from the manufacturing 
plants; cases and controls were placed in quartile categories of exposure.  Smoking-adjusted odds ratios 
for workers with at least 15 years since first exposure showed no evidence of increasing odds ratio with 
increasing category of cumulative exposure; odds ratios for the second, third, and fourth quartiles of 
cumulative exposure (with 95%CI noted in parentheses) were 1.3 (0.7–2.3), 1.0 (0.5–1.9), and 0.7 (0.3– 
1.3), respectively. Similar results were obtained with other exposure metrics and after controlling for 
other potential confounders. 
Two mortality studies were conducted in Canada, using mortality data collected from the national Vital 
Statistics and Disease Registry.  An initial (Shannon et al. 1984) and follow-up (Shannon et al. 1987) 
study obtained information for 157 male workers employed between 1955 and 1977 for at least 90 days at 
an insulating glass wool manufacturing plant in Sarnia, Ontario, Canada.  In 1978, the mean concentration 
of glass wool fibers with diameters <3.5 µm in the plant was 0.1 fiber/cc, but the authors believed that 
earlier concentrations had been higher.  A statistically significant increase (SMR=1.99, 95% CI=1.28– 
3.11) for mortality from lung cancer was detected among exposed employees based on an observed 
19 deaths versus 9.5 expected.  However, four of these deaths occurred in men with <1 year of exposure, 
and cancer risk was not elevated in people with at least 5 years of exposure.  Because increasing length of 
exposure did not correlate with increasing risk or decreased latency, the authors considered the results 
inconclusive.  The other mortality study identified 96 deaths from a cohort of workers who had been 
employed for at least 1 year between 1951 and 1986 at a glass filament plant in Guelph, Ontario, Canada 
(Shannon et al. 1990).  The mean number of fibers in dust samples collected at that plant between 
1979 and 1987 reportedly ranged from 0.02 to 0.5 fibers/cc with values as high as 0.91 fibers/cc, but the 
proportion of glass fibers was not determined.  No significant difference in lung cancer mortality was 
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cancers combined, cancer of the digestive system and peritoneum, cancer of the genito-urinary organs, 
lymphatic and hepatopoietic malignancies), and data were not adjusted for smoking habits. 
European case-control studies of lung cancer, multiple myeloma, mesothelioma, and cancers of the larynx 
and hypopharynx conducted separately from the European cohort mortality study have been inconclusive 
due to relatively few cases exposed to synthetic vitreous fibers without confounding exposures (Brueski-
Hohlfeld et al. 2000; Lee et al. 2003; Marchand et al. 2000; Pohlabeln et al. 2000; Rodelsperger et al. 
2001).  Exposure was estimated by employment information collected from questionnaires, and the 
potential for co-exposure to asbestos was a confounding factor.  An analysis of pooled lung cancer 
incidence data collected in Germany (1988–1993 and 1990–1996) identified only 51 cases and 
28 matched controls (identified from a national mandatory registry of residents) who had been exposed to 
glass wool or mineral wool (as insulators in the construction industry) without asbestos co-exposure 
(Brueski-Hohlfeld et al. 2000; Pohlabeln et al. 2000); after adjustment for smoking, this difference was 
not statistically significant (OR=1.56, 95% CI=0.92–2.65). No statistically significant association 
between occupational exposure to mineral wool and multiple myeloma was found in a case-control study
of 446 cases of multiple myeloma among Swedish construction workers (Lee et al. 2003).  A German 
case-control study for mesothelioma was inconclusive because only two cases of diffuse malignant 
mesothelioma and two controls (matched from a national mandatory registry of residents) who had been 
exposed to synthetic mineral fibers, but not asbestos, were identified from a total of 125 cases and 
125 controls (Rodelsperger et al. 2001). A French case-control study for squamous cell carcinoma of the 
larynx or hypopharynx did not associate exposure to exposures to mineral wool (OR=1.33, 95% CI=0.91– 
1.95 and OR=1.55, 95% CI=0.99–2.41), glass filaments (OR=0.44, 95% CI=0.15–1.31 and OR=0.91, 
95% CI=0.30–2.76), or ceramic fibers (OR=1.28, 95% CI=0.51–3.22 and OR=0.78, 95% CI=0.26–2.38) 
to increased risks of these cancers in 528 cases and 205 controls (hospital patients with nonmalignant 
respiratory disease) (Marchand et al. 2000).   
Small studies of exposure in other occupations have also been inconclusive.  A cohort study of 
1,342 unexposed workers and 1,068 workers exposed to glass and rock wool in the production of 
prefabricated houses in 11 Swedish plants did not detect any statistically significant elevation in risk of 
mortality from any type of cancer (Gustavsson et al. 1992).  The study assigned three categories of 
exposure: the mean for 478 men was 0.11 fibers/cc (range 0.05–0.17 fibers/cc), for 375 men was 
0.09 fibers/cc (range 0.05–0.13 fibers/cc), and for 215 men was 0.06 fibers/cc (range 0.02–0.08 fibers/cc).  
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in the Swedish prefabricated house industry observed no increased risk of lung cancer (for the general 
cohort, SMR=0.56, 95% CI=0.45–1.44; for insulators, SMR=0.85, 95% CI=0.01–3.01) associated with 
exposure to synthetic vitreous fibers (not specified, presumably glass wool) (Plato et al. 1997).  The mean 
exposure to synthetic vitreous fibers (not specified, presumably glass wool) was 0.14 fibers/cc; insulators, 
as high as 0.18 fibers/cc (Plato et al. 1997). 
In summary, studies of workers involved in the manufacture of continuous glass filament, glass wool, and 
rock and slag wool provide inadequate evidence for carcinogenicity in humans.  A number of reviews of 
the fibrous glass cohort mortality and case-control studies concur with this conclusion (ACGIH 2001; 
Hesterberg and Hart 2001; IARC 1988, 2002; Lee et al. 1995; NIOSH 1977; NRC Subcommittee on 
Manufactured Vitreous Fibers 2000; Wilson et al. 1999).  No evidence has associated inhalation exposure 
to these materials with nonrespiratory cancers.  
Animal Studies. 
Refractory Ceramic Fibers.  Studies conducted in rats and hamsters have associated inhalation exposure 
to refractory ceramic fibers with mesothelioma formation and increased incidences of lung adenomas and 
carcinomas (Davis et al. 1984; Hesterberg et al. 1998b; Mast et al. 1995a, 1995b; McConnell et al. 1995; 
Smith et al. 1987). 
Two studies relevant to intermediate-duration exposure were identified.  Exposure of Wistar rats to 
95 WHO fibers/cc of a ceramic aluminum silicate glass for 12 months followed by a 20-month 
observation period was associated with a statistically significant increase in the combined incidence of 
respiratory tumors (one adenoma, three carcinomas, and four malignant histiocytomas in a group of 
48 rats) compared to controls (no observed tumors in 40 rats) (Davis et al. 1984).  Additionally, one 
peritoneal mesothelioma was identified; the relevance of this tumor outside the pleural cavity is unclear, 
but it might represent a metastasis of an occult lesion.  A chronic study that exposed male Syrian Golden 
hamsters exposed to 215 WHO fibers/cc (30 mg/m3) of RCF1 for up to 18 months detected meso­
theliomas in animals that reportedly died from other (noncancer) causes:  2 at 40 weeks, 1 at 45 weeks, 
and 1 at 47 weeks (McConnell et al. 1995).  Additionally, a mesothelioma (1/3) was observed in the 
interim-sacrifice group euthanized at 12 months (McConnell et al. 1995).  At study termination, no lung 
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incidences of mesothelial cell hypertrophy (0/106 versus 33/102) and pleural mesothelioma (0/106 versus 
42/102) were significantly increased.   
Other chronic studies have also found evidence of carcinogenicity.  No lung tumors were seen in male 
Fischer 344 rats exposed nose-only to RCF1 at concentrations as high as 120 WHO fibers/cc (17 mg/m3) 
for 2 years, although a single mesothelioma was seen at 75 WHO fibers/cc (Mast et al. 1995b).  A 
companion 2-year study exposed male Fischer 344 rats nose-only to single concentrations of RCF1, 
RCF2, RCF3, or RCF4 (187, 220, 182, or 153 WHO fibers/cc; 30 mg/m3 for each) (Mast et al. 1995a).  
The first three concentrations induced statistically significant increases in the incidences of bronchiolar­
alveolar hyperplasia (control 5/130; 17/123, 15/121, 15/121, and 8/118 for RCF1, RCF2, RCF3, and 
RCF4, respectively) and pulmonary carcinoma (control 0/130; 8/123, 5/121, 9/121, and 2/118 for RCF1, 
RCF2, RCF3, and RCF4, respectively).  Only RCF1 and RCF3 significantly induced pulmonary 
adenomas (control 2/130; 8/123, 5/121, 9/121, and 2/118 for RCF1, RCF2, RCF3, and RCF4, 
respectively).  Although the incidences were not statistically significant, mesotheliomas were detected for 
RCF1, RCF2, and RCF3 (but not RCF4) (control 0/130; 2/120, 3/123, 2/121, 0/118 for RCF1, RCF2, 
RCF3, and RCF4, respectively).  Data from the 2-year bioassays with male Fischer 344 rats exposed to 
RCF1 (Mast et al. 1995a, 1995b) provide the best available data describing exposure-response 
relationships for cancer and chronic exposure to refractory ceramic fibers; however, the presence of non-
fibrous particles in the RCF1 test atmosphere is widely acknowledged to have added to the noncancer and 
cancer responses to an undetermined degree (Bellmann et al. 2001; Mast et al. 2000; Maxim et al. 2003b). 
Under conditions in which lung clearance mechanisms become overloaded, many types of nonfibrous or
fibrous materials can produce pulmonary fibrosis or tumors in rats (Oberdörster 1994). 
A mesothelioma was also found in male Syrian Golden hamsters exposed to 200 fibers/cc (12 mg/m3) of 
an unspecified type of refractory ceramic fiber for 2 years (Smith et al. 1987).  No lung tumors were 
observed in these hamsters, or in similarly-treated female Osborne-Mendel rats.  The study was 
inconclusive because the positive control (crocidolite asbestos) failed to induce lung tumors and reporting 
of experimental details was limited. 
In summary, different samples of refractory ceramic fibers induced lung tumors in rats and meso­
theliomas in both hamsters and rats.  These results have demonstrated the carcinogenicity of refractory
ceramic fibers in animals following inhalation exposure, and indicate that fiber type and exposure levels 
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particles in RCF1 may have contributed to the carcinogenic responses in RCF1-exposed rats (Mast et al. 
1995a, 1995b) is undetermined.   
Glass Wool (Insulation Glass Wools and Special Purpose Glass Fibers).  Mesothelioma formation has 
been found in one chronic rat study with MMVF33, a durable special purpose glass fiber (Hesterberg et 
al. 1999) and another rat study involving 1-year exposures to special purpose 104E-glass fiber (Cullen et 
al. 2000).  No mesotheliomas were found in rats exposed to the insulation glass wools, MMVF10 or 
MMVF11 (Hesterberg et al. 1993), or in hamsters exposed to MMVF10a (McConnell et al. 1999).  
Exposure to special purpose 104E-glass fiber also induced increased incidences of lung tumors in rats 
(Cullen et al. 2000). In contrast, inhalation studies with MMVF33 and the insulation glass wools, 
MMVF10, MMVF11, and C102/C104 fibrous glass blend, did not find exposure-related increases in lung 
tumor incidence (Goldstein et al. 1983; Haratake et al. 1995; Johnson and Wagner 1980; Kamstrup et al. 
1998, 2001; McConnell et al. 1994, 1999; Muhle et al. 1987; Smith et al. 1987). 
Intermediate-duration experiments did not provide evidence of carcinogenicity.  No increased lung tumor 
incidence was found in female Wistar rats exposed nose-only to 252 fibers/cc (3 mg/m3) of Code 104/475 
special purpose glass fiber for 1 year (Muhle et al. 1987) or in small experiments (<16 animals/exposure 
group) with male Wistar rats exposed to 2.2 mg/m3 of a glass wool (fiber counts not reported) for 1 year 
(Haratake et al. 1995), or rats, hamsters, and guinea pigs exposed to 70 fibers/cc of a ball-milled 
fiberglass (7% fiber) for 3 months (Lee et al. 1981b), with post-exposure periods up to 1 year. 
In male Wistar rats exposed whole-body to 1,022 WHO fibers/cc of special purpose 104E-glass fiber for 
1 year followed by a 1-year recovery period, the combined lung tumor incidence was statistically
significantly different from controls (3/43 versus 1/38 adenomas and 7/42 versus 1/38 carcinomas, 
respectively) (Cullen et al. 2000); additionally, one mesothelioma was induced (1/43 versus 0/38 for 
controls). Exposure of rats to 1,119 WHO fibers/cc of special purpose glass fiber code 100/475 using the 
same protocol did not induce any mesotheliomas or statistically significantly increased incidences of lung 
tumors (Cullen et al. 2000).
One pleural mesothelioma (1/83 versus 0/83 for controls) and no lung tumors were observed in male 
Syrian Golden hamsters exposed to 310 WHO fibers/cc (37 mg/m3) of MMVF33, a durable special 
applications glass fiber for 18 months (Hesterberg et al. 1999).  No lung tumors or mesotheliomas were 
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glass wool (a low fluorine preparation of MMVF10) for 18 months (McConnell et al. 1999).  No lung 
tumors and no increased incidences of bronchoalveolar metaplasia were seen in male Syrian Golden 
hamsters or female Osborne-Mendel rats exposed for 2 years to 300 or 3,000 fibers/cc of a 0.45 µm
diameter glass wool (0.3 or 3.0 mg/m3), 100 fibers/cc of a 3.1 µm diameter glass wool (10 mg/m3), 10 or 
100 fibers/cc of 5.4 µm diameter glass wool (1.2 or 12 mg/m3), 25 fibers/cc of 6.1 µm diameter glass 
wool (9 mg/m3), or 200 fibers/cc of a 2.7 µm diameter slag wool (10 mg/m3) (Smith et al. 1987). 
Similarly, tumor incidence was not elevated in male Fischer 344 rats exposed nose-only to three 
concentrations of MMVF10 or MMVF11 glass wool for 2 years (Hesterberg et al. 1993c).  MMVF10 was 
tested at 29, 145, and 232 WHO fibers/cc (3.1, 17.1, and 27.8 mg/m3) and MMVF11 was tested at 41, 
153, and 246 WHO fibers/cc (4.8, 15.8, and 28.3 mg/m3). 
No tumors were seen in biopsies collected at 8, 18, and 30 months (2/animals per time point) from a 
group of 10 male baboons (Papio ursinus) exposed to 1,122 NIOSH fibers (lengths >5 µm)/cc of a blend 
of C102 and C104 fibrous glass wools (7.54 mg/m3; 5.80 mg/m3 respirable) for 35 months (Goldstein et 
al. 1983).  The study was inconclusive because of the small numbers used and the small amount of tissue 
available for analysis.  
Slag Wool. The limited animal inhalation studies identified for slag wool did not provide any evidence of 
carcinogenicity. 
No lung tumors and no increased incidences of bronchoalveolar metaplasia were seen in male Syrian 
Golden hamsters or female Osborne-Mendel rats exposed for 2 years to 200 fibers/cc of a 2.7 µm
diameter slag wool (10 mg/m3) (Smith et al. 1987). 
In male Fischer 344 rats exposed nose-only for 24 months to 30, 131, or 213 WHO fibers/cc (3.1, 16.1, or 
29.9 mg/m3) of MMVF22, a blast-furnace slag wool, no significant increases were seen in the individual 
or combined incidences of pulmonary adenoma or pulmonary carcinoma (McConnell et al. 1994). 
Rock Wool. The limited animal studies identified for rock wool did not provide any evidence of
carcinogenicity. 
No tumors were reported in Fischer rats exposed to 10 mg/m3 of rock wool (fiber count not reported) for 
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In male Fischer 344 rats exposed nose-only for 24 months to 34, 150, or 243 WHO fiber/cc (3.1, 16.1, or 
30.4 mg/m3) of MMVF21, a traditional basalt-based rock (stone) wool, no significant increases were seen 
in the individual or combined incidences of pulmonary adenoma or pulmonary carcinoma (McConnell et 
al. 1994).  Similarly, in male Fischer 344 rats exposed nose-only to 291 WHO fibers/cc (30.1 mg/m3) of 
MMVF34/HT, a newly developed high-temperature rock wool, for 2 years (6 hours/day, 5 days/week), 
lung tumor incidence was not significantly increased (Kamstrup et al. 1998, 2001). 
Continuous Filament Glass.  No inhalation cancer studies in animals with continuous glass filaments 
were identified. Because these fibers are not normally respirable (ACGIH 2001; Lee et al. 1995), studies 
have been limited to injection and implantation (see Section 3.2.4, Other Routes of Exposure). 
Other Fibers.  No mesotheliomas or increased incidences of lung adenomas (1/121 versus 2/130 for 
controls or lung carcinomas (1/121 versus 0/130 for controls) were seen in male Fischer 344 rats exposed 
to 180 WHO fibers/cc (30 mg/m3) of X-607 (Hesterberg et al. 1998b). 
3.2.2 Oral Exposure  
3.2.2.1 Death 
No studies were located regarding death in humans or animals after oral exposure to synthetic vitreous 
fibers. 
3.2.2.2 Systemic Effects  
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, musculo­
skeletal, hepatic, renal, endocrine, dermal, ocular, body weight, or metabolic effects in humans or animals 
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No studies were located regarding the following effects in humans or animals after oral exposure to 
synthetic vitreous fibers: 
3.2.2.3 Immunological and Lymphoreticular Effects  
3.2.2.4 Neurological Effects 
3.2.2.5 Reproductive Effects  
3.2.2.6 Developmental Effects 
3.2.2.7 Cancer 
3.2.3 Dermal Exposure  
3.2.3.1 Death 
No studies were located regarding death in humans or animals after dermal exposure to synthetic vitreous 
fibers. 
3.2.3.2 Systemic Effects  
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, endocrine, or body weight effects in humans or animals after dermal 
exposure to synthetic vitreous fibers.  
Dermal Effects.    Strong itching and contact dermatitis (with erythema, maculae, papules, and other 
eczematous symptoms) have been associated with occupational exposure to synthetic vitreous materials, 
including glass wool insulation and fiberglass fabrics (Bendsoe et al. 1987; Bjornberg 1985; Bjornberg et 
al. 1979a, 1979b, 1979c; Fisher 1982; Fisher and Warkentin 1969; Heisel and Hunt 1968; Koh and Khoo, 
1995; Longely and Jones 1966; Minamoto et al. 2002; Possick et al. 1970; Stam-Westerveld et al. 1994; 
Tarvainen et al. 1993), rock wool (Bjornberg and Lowhagen 1977; Eun et al. 1991; Fisher 1982; Kiec-
Swierczynska and Szymczk 1995; Peterson and Sabroe 1991; Thriene et al. 1996), and refractory ceramic 
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having diameters >5 µm and becomes less pronounced with continued exposure, a “hardening” of the skin 
(ACGIH 2001; Heisel and Hunt 1968; Stam-Westerveld et al. 1994).  
No studies were located regarding the dermal effects of synthetic vitreous fibers in animals after dermal 
exposure. 
Ocular Effects.    Occupational exposure to fibrous glass materials, including glass wool insulation and 
fiberglass fabrics, has been associated with acute eye irritation (Longley and Jones 1966; Petersen and 
Sabroe 1991; Stokholm et al. 1982). 
No studies were located regarding the ocular effects of synthetic vitreous fibers in animals after dermal 
exposure. 
No studies were located regarding the following effects in humans or animals after dermal exposure to 
synthetic vitreous fibers: 
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.2.4 Other Routes of Exposure 
No studies were located regarding adverse health effects in humans after exposure by other routes to 
synthetic vitreous fibers. 
Intratracheal instillation, interpleural implantation, and intraperitoneal injection studies with synthetic 
vitreous fibers have been performed.  Most have been acute-duration studies (single administration 
followed by observation periods up to 2 years).  The relevance of these studies to human inhalation 
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defense systems of the nasal and upper respiratory system, and the overloading or lack (for intraperitoneal 
studies) of pulmonary clearance mechanisms
Continuous Filament Glass Fibers. Neither intrapleural implantation (Stanton et al. 1972, 1977) nor 
intraperitoneal injection of continuous glass filaments into rats was carcinogenic (Pott et al. 1987). 
Glass Wool. Studies in which glass wool was instilled into the trachea of animals were equivocal; some
(but not all) demonstrated pulmonary fibrosis (Feron et al. 1985; Mohr et al. 1984; Pickrell et al. 1983; 
Renne et al. 1985; Smith et al. 1987; Wright and Kuschner 1977).  Only two of these studies reported 
tumor induction in rats and hamsters (Mohr et al. 1984; Smith et al. 1987). 
Rock Wool. Intratracheal instillation of rock wool did not cause tumor formation in female Syrian 
Golden hamsters (Adachi et al. 1991). 
Slag Wool. No studies were located regarding the adverse health effects of slag wool in animals 
following other routes of exposure. 
Refractory Ceramic Fibers.  Intratracheal instillation of a refractory ceramic fiber caused lung cancer in 
male Syrian Golden hamsters, but not in female Osborne-Mendel rats (Smith et al. 1987).  Intraperitoneal 
injection of ceramic aluminum silicate fibers in rats and hamsters induced cancer (Davis et al. 1984; 
Smith et al. 1987).  Refractory alumina and zirconia fibers injected intraperitoneally did not induce 
fibrosis in rats (Pigott and Tshmael 1981). 
3.3 GENOTOXICITY  
No evidence for genotoxic activity of several synthetic vitreous fibers was found in bacterial mutation 
assays (Chamberlain and Tarmy 1977) or sister chromatid exchange assays in cultured human cells 
(Casey 1983).  However, several cytogenetic effects have been observed in other in vitro assays.  Notably 
absent are data on genotoxic end points following in vivo exposure of animal or humans to synthetic 
vitreous fibers. Results from short-term in vitro genotoxicity assays are of limited applicability to in vivo
exposure scenarios because of evidence that long-term residence of synthetic vitreous fibers in the 
principal toxicity target, the lung, can lead to changes (dissolution, breakage into shorter fibers) that can 
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Synthetic vitreous fibers induced: chromosomal aberrations in cultured Chinese hamster cells (Brown et 
al. 1979a, 1979b); morphological transformations in Syrian hamster embryo cells (Hesterberg and Barrett 
1984; Hesterberg et al. 1985; Oshimura et al. 1984) and BALB/c-3T3 cells (Gao et al. 1995; Whong et al. 
1999); micronuclei and multinuclei in Chinese hamster ovary cells (Hart et al. 1992), Chinese hamster 
lung fibroblasts (Ong et al. 1997; Zhong et al. 1997), Syrian hamster epithelial lung cells (Peraud and 
Riebe-Imre 1994), Syrian hamster embryo fibroblasts (Dopp and Schiffmann 1998), and human amniotic 
fluid cells (Dopp and Schiffmann 1998; Dopp et al. 1997); polyploidy in Chinese hamster lung cells 
(Koshi et al. 1991; Sincock et al. 1982); and deoxyribose nucleic acid (DNA) strand breaks and DNA­
DNA interstrand crosslinks in human lung epithelial A549 cells (Wang et al. 1999b).  In addition, several 
synthetic vitreous fiber types have been demonstrated to damage isolated DNA (Donaldson et al. 1995c) 
and to hydroxylate 2-deoxyguanosine to 8-hydroxydeoxyguanosine, presumably via hydroxyl radicals 
(Leanderson et al. 1988, 1989).   
There is evidence that fiber dimensions can influence in vitro cytogenetic activities (Hesterberg and 
Barrett 1984; Hesterberg et al. 1985; Ong et al. 1997) and that synthetic vitreous fibers are often less 
active than asbestos fibers (e.g., Donaldson et al. 1995c; Leanderson et al. 1988, 1989; Peraud and Rieve-
Imre 1994; Wang et al. 1999b).  For example, thin glass fibers (diameters 0.1–0.2 µm, lengths >10 µm) 
were very active in transforming Syrian hamster embryo cells, whereas thick glass fibers (diameter about 
0.8 µm) were much less potent (Hesterberg and Barrett 1984).  Milling of the thin glass fibers to reduce 
the length to <1 µm diminished the transforming activity. 
Gene amplification of several proto-oncogenes, H-ras, K-ras, c-myc, and c-fos, has been reported in 
several transformed BALB/C-3T3 cell lines that were induced by a glass fiber (AAA-10 microfiber) 
(Whong et al. 1999). Point mutations, detected by sequencing analysis of DNA from several of the 
transformed cell lines, were also found in the proto-oncogene K-ras, and in the p53 tumor suppressor 
gene (Whong et al. 1999).  Induction of c-fos and c-jun proto-oncogenes by crocidolite asbestos was 
demonstrated in cultured hamster tracheal epithelial cells and rat pleural mesothelial cells, but induction 
activities of a glass wool (MMVF10) and a refractory ceramic fiber (RCF1) were much less in this test 
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3.4 TOXICOKINETICS 
3.4.1 Absorption
Absorption of synthetic vitreous fibers across the epithelial layers of the respiratory tract, the gastro­
intestinal tract, and the skin is expected to be low to negligible due to the relatively large physical 
dimensions of these elongated particles (see Chapter 4).  However, deposition of inhaled fibers on the 
surface of the epithelial layers of the respiratory tract is an initial process that has been well studied and, 
along with the process of lung clearance, plays an important role in determining toxicity (especially the 
deposition and clearance of fibers in the alveolar region of the respiratory tract).  An overview of the 
deposition of inhaled synthetic vitreous fibers in the respiratory tract is presented in the next section 
(Section 3.4.1.1).  The deposition of inhaled fibers has been reviewed in more detail in other published 
sources (Dai and Yu 1998; Jones 1993; Lippmann 1990; Morgan 1995; Oberdörster 1994, 2000; Stober 
1972; Stober and McClellan 1997; Timbrell 1965; Yu et al. 1995a).
3.4.1.1 Inhalation Exposure 
Very limited amounts of inhaled synthetic vitreous fibers are expected to be absorbed in humans or 
animals.  Consistent with the expectation of limited, if any, absorption are findings from a study in which 
rats were given single intratracheally-instilled doses (1 mg/rat, equivalent to 3.5x106 fibers/rat) of a saline 
suspension of radiolabeled (24Na) glass fibers (Morgan et al. 1993).  The fibers were produced as a 
continuous filament with an approximate uniform diameter of 2 µm.  The fibers in the instilled material 
had a log-normal distribution of lengths, with a median of 16 µm and geometric standard deviation of 1.8.  
Radioactivity measured in urine collected for 24 hours after dose administration accounted for <1% of 
administered radioactivity, and no radioactivity was detected in 24- to 48-hour urine samples.  
Radioactivity in feces collected for 48 hours and in the gastrointestinal tracts and lungs accounted for 
>96% of administered radioactivity in 4/8 rats sacrificed 48 hours after dose administration.  The average 
total recovery of administered radioactivity in feces, gastrointestinal tract, and lungs of all eight rats 
was 93%. The average individual percentages of administered radioactivity in the feces, gastrointestinal 
tract, and lungs were 30, 2, and 61%.  (In these experiments, radioactivity detected in the gastrointestinal 
tract and feces represents fibers deposited in the respiratory tract, removed by mucous flow to the gastro­
intestinal tract, and eliminated with the feces—see Sections 3.4.2 and 3.4.4). Morgan et al. (1993) 
reported that, during dose administration, occasional losses of small volumes of the fiber suspension 
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for the small differences between the calculated administered doses of radioactivity and the total 
radioactivity recovered in the feces, gastrointestinal tract, and lungs. 
There is evidence to suggest that a small amount of inhaled synthetic vitreous fibers may enter the body 
via the lymph nodes.  For example, in hamsters exposed for 78 weeks to MMVF10a or MMVF33, 
elevated concentrations of fibers (# fibers/mg dry tissue) were measured in mediastinal tissue containing 
lymph nodes, the diaphragm, and the thoracic wall (Hesterberg et al. 1999).  
The fraction of inhaled synthetic vitreous fibers deposited on the epithelial surface of the respiratory tract 
and the region where deposition occurs are determined by fiber dimensions, fiber density, ventilation 
parameters, and the structure and airway size of the respiratory tract (Dai and Yu 1998; Lippmann 1990; 
Morgan 1995; Yu et al. 1995a).  In general, relatively thick inhaled fibers are deposited in the upper 
airways (i.e., the nasopharyngeal region and tracheobronchial regions), and only relatively thin fibers are 
carried to distal regions of the respiratory tract (i.e., the terminal bronchiole and alveolar regions).  In the 
large conducting airway regions of the lung and in the nonciliated bronchoalveolar regions, fiber 
deposition is particularly enhanced at branching points (Brody and Roe 1983; Lippmann 1990; Myojo 
1987).
In published studies of animals exposed by inhalation to different types of fibers, estimates of the fraction 
of inhaled fibers deposited in the lung have ranged from about 1–23% (Okabe et al. 1997).  Given the 
complexity of factors influencing apparent lung deposition (e.g., fiber dimensions, exposure duration and 
concentration, ventilation parameters, and airways size and geometry) and the differences in experimental 
conditions and techniques used in these studies, the wide range is not surprising. However, studies that 
restricted periods of exposure to glass wool fibers to 30 minutes (Morgan 1995) or 10 minutes (Okabe et 
al. 1997) to minimize clearance by mucociliary action (see Section 3.4.2) reported values in the upper end 
of the range (15–23%). 
Major mechanisms involved in the deposition of nonelectrostatically charged fibers in the respiratory tract 
include impaction (under high velocity airflows experienced in the larger airways of the respiratory tract), 
gravitational sedimentation (under low velocity airflows), interception, and diffusion.  Impaction and 
sedimentation are influenced by the aerodynamic diameter of the particle, whereas interception is 
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where p=particle density; d=actual diameter; and L=length (Hesterberg and Hart 2001; Stober 1972).  For 
glass fibers of uniform particle density, aerodynamic diameters are described by the following formula: 
2 2. β 
DA = 66d  2 + 4 β 
where β=length:diameter ratio (Gross 1981).  Calculated values of aerodynamic diameters of fibers of a 
uniform density range from about 2.5–4 times that of the actual diameter (Gross 1981; Timbrell 1965).  
More complicated mathematical expressions for aerodynamic diameters of fibers have been derived to 
account for changing orientation of fibers with respect to direction of airflow (Dai and Yu 1998).  Fibers 
or particles with aerodynamic diameters >3–5 µm are expected to be predominantly deposited in the 
upper airways and have less probability of traveling to the lower lung than particles or fibers with smaller 
aerodynamic diameters (Morgan et al. 1980; Oberdörster 1994).  Based on a review of the literature on 
particle deposition in the human lung, ACGIH (2001) published an algorithm predicting the collection 
efficiency of particles of varying aerodynamic diameters.  The algorithm predicts that inhalation exposure 
to particles of uniform aerodynamic diameters of 1, 5, 6, or 10 µm would lead to the following mass 
percentages being deposited in the alveolar or gas-exchange region: 97, 30, 17, or 1%. 
More specific mathematical models to predict the deposition of inhaled fibers in rodents and humans have 
been developed and are discussed in more detail by Yu et al. (1995a) and Dai and Yu (1998), and in 
Section 3.4.5, Physiologically Based Pharmacokinetic/Pharmacodynamic Models.  The fraction of inhaled 
fibers that is deposited in the alveolar region is of particular toxicologic interest because fibers deposited 
in this region are more slowly removed than fibers deposited in the nasopharyngeal or tracheobronchial 
regions. Models that predict alveolar deposition fraction for refractory ceramic fibers in rats, hamsters, 
and humans have been used to examine the influence of differences in ventilation parameters, airway size, 
and fiber characteristics on this important parameter (Dai and Yu 1998).  The human model predicts that 
increasing workload reduces alveolar deposition fraction and switching from nose-breathing to mouth-
breathing increases alveolar deposition fraction.  The models predict that alveolar deposition of fibers 
with aerodynamic fibers >3.5 µm and length:diameter ratios >10 is insignificant in rats and hamsters, 
whereas in humans, considerable alveolar deposition occurs with fibers having aerodynamic diameters as
large as 5–6 µm.  For example, for exposure to fibers with 30 µm length, 1.5 µm diameter, and 3.26 µm
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(expressed as percentage of inhaled fibers) were 0.04% for rats, 0.27% for hamsters, and 6.82% for 
humans (Dai and Yu 1998). 
3.4.1.2 Oral Exposure  
No studies were located examining the possible absorption of ingested synthetic vitreous fibers in humans 
or animals.  
3.4.1.3 Dermal Exposure  
No studies were located examining the possible absorption of synthetic vitreous fibers across the skin of 
humans or animals. 
3.4.2 Distribution  
3.4.2.1 Inhalation Exposure 
Fibers deposited on the epithelial surfaces of the nasal passages and the tracheobronchial tree, which are 
lined with ciliated cells and coated with a mucous layer, are quickly removed by the flow of mucous to 
the pharynx and swallowed into the gastrointestinal tract.  This mechanical distribution is generally
thought to be completed within about 24–48 hours (Jones 1993; Lippmann 1990; Morgan and Holmes 
1980; Oberdörster 1994).  A small fraction of fibers deposited in the trachea can be retained within the 
epithelium, as demonstrated in rats intratracheally instilled with suspensions of glass fibers (Morgan 
1995; Morgan et al. 1994a).   
The removal and clearance of fibers deposited on epithelial surfaces of the lower lung, which are lined 
with nonciliated cells without a mucous layer, is comparatively slow.  Clearance from this region is 
accomplished by several mechanisms:  engulfment by macrophages (phagocytosis) and movement to the 
mucociliary escalator (sometimes referred to as mechanical macrophage-mediated clearance); dissolution 
(either in near neutral [pH 7.4–7.5] extracellular pulmonary fluid or in presumably acidic [pH 4.5–5]
phagolysosomes of macrophages); and translocation of fibers to the interstitium, the lymphatic 
circulation, and the pleural cavity.  These mechanisms influence the biopersistence of inhaled fibers, 
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pathogenesis. Some data illustrating these distribution mechanisms are discussed in this section.  For 
more comprehensive reviews, the reader is referred to recent papers by Bernstein et al. (2001a, 2001b), 
Hesterberg and Hart (2000, 2001), and Oberdörster (2000) and other earlier papers (Bellmann et al. 
1994a, 1994b; Bernstein et al. 1995; Muhle and Bellmann 1995, 1997; Musselman et al. 1994; 
Oberdörster 1994). 
Macrophages are motile cells found in the lung interstitium, on the surface of epithelial cells lining the 
alveoli, and on the surface of ciliated epithelial cells (Carpenter and Wilson 1999; Valberg and Blanchard 
1991).  They are capable of engulfing foreign materials in the conducting airways, the alveoli, and the 
interstitium and moving onto the mucociliary escalator.  Macrophages facilitate a major clearance 
mechanism for the lower respiratory tract.  Macrophage engulfment, however, is limited to fibers with 
lengths less than the diameter of the macrophage. Alveolar macrophage diameters range from about 10– 
13 µm in rats and 14–21 µm in humans (Hesterberg and Hart 2001; Oberdörster 2000).  Fibers longer than 
about 20 µm are not expected to be cleared by macrophages unless they undergo transverse breakage 
(Eastes et al. 2000; Hesterberg and Hart 2001; Hesterberg et al. 1998a; Oberdörster 2000). 
Results from early studies of lung clearance of intratracheally-instilled glass wool fibers of varying 
lengths in rats provided evidence of the inability of macrophages to engulf and clear long fibers, the 
dissolution and transverse breakage of synthetic vitreous fibers in the lung, and the limited degree to 
which fibers may be translocated to the lymph nodes (Morgan et al. 1982).  In these studies, rats were 
given single intratracheal instillations of sized glass wool fibers with median diameters of about 1.5 µm
and median lengths of 5, 10, 30, or 60 µm. 
Long Fibers are Poorly Cleared by Macrophages.  For the 5- and 10-µm length fibers, the number of 
fibers remaining in lungs declined smoothly with time after administration (Morgan et al. 1982).  At 
1 year, 90 and 80% of the injected 5- and 10-µm length fibers, respectively, had been cleared. In contrast, 
the number of fibers in lungs of rats exposed to 30- or 60-µm length fibers did not decline over a 9-month 
period after administration, indicating no discernible clearance.  The fibers recovered at 9 and 18 months 
from the lungs of rats exposed to 60-µm length fibers showed evidence of transverse breakage of the 
fibers. The respective median lengths of recovered fibers at these times were 40 and 25 µm.  The number 
of fibers in lungs at 9 months was 20–30% greater than the number in lungs of similarly exposed rats at 
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that transverse breakage would influence recovered fiber number more than any possible clearance 
mechanism).
Glass Fibers Dissolve at pH 7.4–7.5.  Fibers recovered at 18 months also showed decreased diameters 
indicating dissolution within the lung (Morgan et al. 1982).  Median diameters of recovered fibers at 
18 months in the groups exposed to 5-, 10-, 30-, and 60-µm length fibers were decreased by 12, 28, >50, 
and >50%, respectively, of the original 1.5-µm diameters, indicating faster dissolution of longer fibers 
than shorter fibers.  This result is consistent with the faster in vitro dissolution of glass fibers at pH 7.4– 
7.5 (the pH of extracellular fluid in the lung) than at acidic pHs (4.5–5) found within the phagolysosomes 
of macrophages (Oberdörster 2000).  However, not all types of synthetic vitreous fibers show faster in 
vitro dissolution at pH 7.4–7.5 than at acidic pHs.  For example, MMVF34, a stone wool, has been shown 
to be very biosoluble in the rat lung, poorly soluble in vitro at pH 7.4–7.5, and soluble in vitro at pH 4.5 
(Hesterberg and Hart 2001).  
Limited Translocation of Fibers to the Lymphatic Circulation may Occur.  One year after 
administration, the fibers detected in hilar lymph nodes of rats exposed to 5-µm long glass fibers 
accounted for only 4% of the total lung fiber number (Morgan et al. 1982).  The hilar lymph nodes 
contained smaller proportions of recovered fibers in rats exposed to the 10- and 30-µm length fibers.  At 
the same time period, no fibers were detected in the hilar lymph nodes of rats exposed to 60-µm length 
fibers. The results indicate that only limited numbers of glass fibers were translocated to the lymph nodes 
under these experimental conditions. 
Other studies with rats, hamsters, or guinea pigs indicate that considerable translocation of inhaled fibers 
to lymph nodes and the pleural cavity can occur under conditions that overload the mucociliary clearance 
mechanism (Lee et al. 1981a).  In these studies, animals were exposed by inhalation to high 
concentrations (2,900, 13,500, or 41,800 fibers/cc) of potassium octatitanate fibers (average length of 
6.7 µm and diameter of 0.2 µm) for 3 months.  Numerous dust-laden macrophages were observed in 
tracheobronchial and mediastinal lymph nodes and in mediastinal adipose tissue adjacent to the lymph 
nodes when the animals were sacrificed 15 months after exposure ceased.  Dust-laden macrophages also 
accumulated in the pleural cavity.  Exposed animals showed fibrosis in the respiratory bronchiolar region 
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Evidence of rapid translocation of small numbers of short and thin fibers to pleural tissue has been 
observed in rats and hamsters after inhalation exposure to a refractory ceramic fiber, RCF1 (Everitt et al. 
1997; Gelzleichter et al. 1996a, 1996c, 1999).  In an acute exposure study, rats were exposed (nose-only) 
to concentrations of 2,645 WHO respirable fibers/cc (length:diameter ≥3:1, length >5 µm, diameter 
<3 µm) 6 hours/day for 5 days (Gelzleichter et al. 1996a, 1996c).  The aerosol concentration of total 
fibers (length:diameter ratio ≥3:1) was 6,206 fibers/cc.  Rats were sacrificed immediately after and 
32 days after exposure.  Fiber concentrations and dimensions in lung and pleural tissue samples were 
measured using scanning electron microscopy.  At both sampling dates, lung fiber concentrations were 
about 1,000-fold greater than pleural fiber concentrations, indicating that relatively small numbers of 
fibers were translocated from the lung to the pleura.  Average pleural fiber concentrations declined from
25,000 fibers/pleura at day 5 to 15,700 fibers/pleura at day 32, indicating some clearance of pleural fibers 
after exposure ceased. All fibers found in pleural tissues had lengths <5 µm and diameters <0.35 µm.  
Fibers detected in the pleural samples had geometric mean lengths of 1.4 and 1.5 µm, and geometric mean 
diameters of 0.87 and 0.10 µm, at days 5 and 32, respectively.  In contrast, geometric mean lengths and 
diameters of fibers detected in lung tissue were notably larger than pleural fibers and were similar to the 
values for the exposure aerosol (geometric mean length, 4.54 µm [range: 0.7–111 µm] and geometric 
mean diameter, 0.56 µm).  In subsequent studies in which rats or hamsters were exposed to about 
300 WHO fibers/cc of RCF1, 4 hours/day, 5 days/week for up to 12 weeks, fibers detected in pleural 
tissue (sampled at 4 or 12 weeks or 12 weeks after exposure ceased) also displayed shorter mean lengths 
and thinner mean diameters than the fibers in the exposure aerosol (Everitt et al. 1997; Gelzleichter et al. 
1999). In lung tissues in both species at all time points, fibers longer than 5 µm accounted for 
approximately 67% of detected fibers, whereas in pleural tissue, fibers longer than 5 µm accounted for 
12% in hamsters and 4% in rats (Gelzleichter et al. 1999). 
The biopersistence of fibers in lungs has been examined in several studies of rodents following acute 
(5-day) inhalation exposures to a number of glass wools, continuous filament glass, rock and slag wools, 
and a refractory ceramic fiber, as well as amosite or crocidolite asbestos (Bernstein et al. 1996; Eastes and 
Hadley 1995; Hesterberg et al. 1996, 1998a, 1998b). Lung tissues were sampled at several times after 
exposure from 1 hour up to 1 year, and concentrations and dimensions of fibers in the tissues were 
measured using scanning electron microscopy.  These studies focused on the clearance of fibers with 
lengths >20 µm, which is thought to be mediated mainly by dissolution and subsequent transverse 
breakage, rather than direct mechanical macrophage-mediated clearance.  One- and two-compartment 
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most fiber types, the two-compartment model provided a better fit than the one-compartment model.  
From the two models, two measures of lung clearance were used to compare the biopersistence of fiber 
types—a weighted clearance half-time that incorporated the half-times from the slow and fast 
compartment of the two-compartment model (WT1/2: Bernstein et al. 1996) or the days required for 
clearance of 90% of the fibers with lengths >20 µm that were present in the lung 1 day after cessation of 
exposure. For fiber types for which a two-compartment model did not provide an improved fit over a 
one-compartment model, clearance half-time (T1/2) was compared with WT1/2 for the other fibers.   
Using either measure of lung biopersistence (WT1/2 or T-90 for fibers with lengths >20), synthetic 
vitreous fibers showed a considerable range of values, but all were markedly less biopersistent than 
amosite and crocidolite asbestos (Table 3-2).  Amosite and crocidolite asbestos showed high WT1/2 values 
(418 and 817 days, respectively), several durable synthetic vitreous fibers showed moderately high WT1/2 
values between 37 and 91 days, and several glass wools, a slag wool, and newly developed rock wools 
showed WT1/2 values below 13 days (Table 3-2).  
The dissolution of a variety of synthetic vitreous fibers has been extensively studied in vitro in simulated
physiological fluids (Bernstein et al. 1996; Christensen et al. 1994; Eastes and Hadley 1995; Knudsen et 
al. 1996; Mattson 1994; Potter and Mattson 1991; Scholze and Conradt 1987).  These studies are often 
conducted at pH 7.4 to simulate acellular dissolution and pH 4.5 to simulate dissolution in the acidic 
phagolysosomes of macrophages.  The following equation is fit to in vitro data for changing fiber 
diameter (D) with time (t) to provide estimates of Kdis, the dissolution rate coefficient, for different fiber 
types: 
D t( )  = D0 − 2 K dist / ρ 
where ρ is the density of the fiber, and Kdis is usually in units of ng/cm2-hour. A larger coefficient 
indicates faster dissolution.  Amphibole asbestos fibers, such as crocidolite or amosite, essentially do not 
dissolve at pH 7.4 and have Kdis values <1 (Table 3-2). In contrast, synthetic vitreous fibers dissolve, but 
show variance among fiber types in rates of dissolution.  Kdis values for synthetic vitreous fibers in 
Table 3-2 range from 3 to >500 ng/cm2-hour. In vitro dissolution rates are correlated with rates of lung 
clearance, but several exceptions indicate that dissolution at pH 7.4 is not the only determinant of lung
biopersistence (Table 3-2). For example, MMVF34 (HT rock wool) has a moderately low in vitro pH 
7.4 Kdis (59 ng/cm2-hour), but displays very fast lung clearance (WT1/2=6 days).  In contrast, MMVF10 
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Table 3-2. Lung Clearance of Fibers with Lengths >20 µm in F344 Male Rats 

Following Nose-only Inhalation Exposure (6 Hours/Day for 5 Days) to 

19 Different Synthetic Vitreous Fibers or Two Types of Asbestos 

Fiber Weighted half-time 90% clearance In vitro Kdis, 
name Type (WT1/2, days) (T-90, days) pH 7.4a 
Amosite Asbestos 418 2,095 <1 
Crocidolite Asbestos 817b 2,270 <1 
MMVF32 Special application continuous filament 79 371 9 
glass 
MMVF21 Rock (stone) wool 67 (91)c 264 (206)c 21 
RCF1a Refractory ceramic fiber  55 227 3 
MMVF33 Durable special applications glass 49 240 12 
L Traditional rock wool 45 186 20 
MMVF10 Insulation glass wool 37b 123 300 
H New rock wool 13 49 270 
MMVF11 Insulation glass wool 9 (13)c 38 (40)c 100 
MMVF22 Slag wool 9 37 400 
J Experimental 10 18 170 
9bF New rock wool 28 160 
MMVF34 New rock wool (HT fiber, soluble in 6 19 59 
acid) 
6bO Rock wool 20 >500 
6bP Glass wool 19 >500 
5bM Glass wool 18 >500 
5bG New rock wool 18 210 
A New glass wool  4 9 250 
C New glass wool 4 14 >500
B B-01/09 (glass wool) 2 8 >500 
aKdis is the empirically derived coefficient (in ng/cm2-hour) for in vitro dissolution in a flowing physiological saline 

solution at pH 7.4.  A larger coefficient indicates faster dissolution. 





cValues in parentheses are from a second experiment. 
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(WT1/2=37 days) compared with other synthetic vitreous fibers.  Short-term in vivo lung clearance tests 
and in vitro dissolution tests have been proposed as preliminary screening tools to predict lung 
biopersistence and subsequent toxicity of untested fibers (Davis et al. 1996; Eastes et al. 2000; Zoitos et 
al. 1997).  
Results from short-term in vivo lung clearance tests reflect the accumulation and biopersistence of fibers 
in the lungs of animals exposed for chronic durations.  For example, lung elimination half-times for fibers 
with lengths >20 µm after 5 days of inhalation exposure of rats to comparable concentrations of rock 
wools MMVF21 or MMVF 34 (HT rock wool) were 92 days and 5 days, respectively, reflecting 
moderate and low biopersistence of the two rock wools (Kamstrup et al. 1998). This difference in 
biopersistence was reflected in lung concentrations in rats exposed (nose-only, 6 hours/day, 5 days/week) 
to comparable concentrations of the two rock wools for up to 18 months.  Rats exposed to 
MMVF34 showed lung concentrations for fibers with lengths >20 µm of 8, 11, 10, and 11 fibers per mg
dry lung x103 at respective sampling times of 3, 6, 12, and 18 months.  These findings are consistent with 
early attainment of a balance between continued exposure and fast dissolution (i.e., low biopersistence) of 
this fiber. In contrast, concentrations in rats exposed to the moderately biopersistent fiber, MMVF21, 
were higher and showed evidence of accumulation with time at the same sampling times: 18, 23, 55, and 
62 fibers per mg lung x103. 
3.4.2.2 Oral Exposure  
No studies were located examining distribution of ingested synthetic vitreous fibers in humans or animals. 
3.4.2.3 Dermal Exposure  
No studies were located examining distribution of dermally applied synthetic vitreous fibers in humans or 
animals. 
3.4.2.4 Other Routes of Exposure 
The clearance kinetics of a variety of synthetic vitreous fibers from the respiratory tract following 
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rats, hamsters, and sheep (Bellmann et al. 1994a, 1994b, 1995; Dufresne et al. 1999; Eastes et al. 1995; 
Morgan et al. 1982, 1994a; Morris et al. 1995; Searl et al. 1999).  Intratracheal instillation offers the 
advantage of being less expensive than inhalation experiments, and results from these studies are 
supportive of results from clearance studies following inhalation.  For example, the intratracheal 
instillation study by Morgan et al. (1982) discussed in the previous section provided evidence of the 
inability of macrophages to engulf and clear long fibers, the dissolution and transverse breakage of 
synthetic vitreous fibers in the lung, and the limited degree to which fibers may be translocated to the 
lymph nodes.  However, this mode of administration has a few disadvantages, relative to inhalation 
exposure, including the increased potential to form clumps of fibers and the induction of inflammatory
responses to high bolus doses (Oberdörster 2000). Because clumping and inflammation may influence 
fiber dissolution and clearance, the results from clearance studies following intratracheal instillations are 
not discussed further in this section. 
3.4.3 Metabolism 
3.4.3.1 Inhalation Exposure 
Synthetic vitreous fibers are not metabolized via typical enzyme-mediated processes, but undergo 
dissolution at varying rates depending on fiber composition, manufacturing processes under which the 
fibers were formed, and physical and chemical conditions in which the fiber may exist (Hesterberg and 
Hart 2001; Zoitos et al. 1997).  In general, the dissolution of vitreous fibers in physiological fluids is 
thought to occur via reactions in which a water molecule (or some part thereof) replaces a cation in the 
matrix of the fiber (Eastes et al. 2000). In the simplest model for dissolution, all components in the 
matrix are assumed to dissolve at approximately the same rate.  This model is used in the traditional 
determinations of Kdis, the in vitro dissolution rate coefficient, for various fibers. However, for many
synthetic vitreous fibers, certain components dissolve more rapidly than others.  Vitreous fibers with high 
alumina and silica contents favor a uniform rate of dissolution of all components, whereas fibers with a 
lower proportion of alumina and silica (<63 mole%) show nonuniform dissolution rates in which oxides 
of calcium, magnesium, and potassium dissolve quickly, leaving a weakened silica matrix (Hesterberg 
and Hart 2001).  At points where the matrix is weakened, applied physical stress can lead to transverse 
breakage of the fiber. More complicated models to predict fiber dissolution without assuming uniform
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Synthetic vitreous fibers have amorphous molecular structures that do not have planes of cleavage such as 
those in the crystal structure of chrysotile asbestos.  The longitudinal cleavage of asbestos fibers can form
thinner fibers that may more readily move into the interstitium or the pleura cavity (Agency for Toxic 
Substances and Disease Registry 2001).  This property is not expected with synthetic vitreous fibers and 
may contribute to the difference in potency between asbestos and synthetic vitreous fibers.  In addition, 
asbestos fibers, especially amphibole fibers, undergo very little, if any, dissolution in in vitro pH 7.4 tests 
(see Table 3-2).  The relatively high persistence of long amphibole asbestos fibers in lungs is 
demonstrated by long clearance half-times of amphibole asbestos in rats (as shown in Table 3-2).  
Chrysotile asbestos, the least persistent asbestos type, is also expected to be more persistent in lungs than 
most synthetic vitreous fibers.  For example, in rats following 10-day inhalation exposure to similar 
concentrations of chrysotile or a special purpose Code 100/475 glass fiber, the lung clearance half-time 
for long (>15 µm) chrysotile fibers was 46.2 weeks, whereas the half-time for long Code 100/475 glass 
fibers was 6.6 weeks (Searl 1997). 
3.4.3.2 Oral Exposure  
No studies were located regarding compositional or structural changes in synthetic vitreous fibers in the 
gastrointestinal tract. 
3.4.3.3 Dermal Exposure  
No studies were located regarding compositional or structural changes in synthetic vitreous fiber after 
dermal exposure. 
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
As discussed in Section 3.4.2.1, the principal pathways by which synthetic vitreous fibers are removed 
from the respiratory tract involve (1) mechanical mucociliary translocation to the pharynx, swallowing 
into the gastrointestinal tract, and elimination in the feces, (2) dissolution, and (3) transverse breakage of 
long fibers into shorter fibers.  Mechanical translocation is mediated directly with fibers deposited on the 
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the nonciliated epithelial region in the lower respiratory tract.  After fibers or fiber-laden macrophages are 
on the mucociliary escalator, mechanical translocation is thought to be complete within about 24– 
48 hours (Jones 1993; Lippmann 1990; Morgan and Holmes 1980; Oberdörster 1994).  Clearance of 
synthetic vitreous fibers from the lower airways is slower but shows variance with fiber types and 
dimensions. For example, clearance half-times for fibers longer than 20 µm in the lungs of rats have been 
reported to range from 2 to 79 days for 19 different synthetic vitreous fibers (Hesterberg et al. 1998a; see 
Table 3-2). For asbestos fibers in rats, more rapid clearance of shorter (<5 µm) fibers than of longer 
(>10 or 20 µm) fibers has been observed.  This is explained as a result of the relative difficulty with 
which longer fibers are engulfed by macrophages.  In contrast, many synthetic vitreous fibers show a 
more rapid clearance rate for long fibers compared with short fibers.  This difference is consistent with 
the inability of macrophages to engulf long fibers, the relatively rapid dissolution of many synthetic 
vitreous fibers in the near-neutral pH solution of the intracellular spaces in the lung, and the subsequent 
transverse breakage of long vitreous fibers into shorter fibers.  For example, lung clearance half-times in 
rats for long (>20 µm) fibers were 44, 6, and 986 days for MMVF10, MMVF11, and crodidolite asbestos, 
respectively; for short (<5 µm) fibers, the respective half-times were 111, 46, and 44 days (Hesterberg et 
al. 1996). 
3.4.4.2 Oral Exposure  
No studies were located regarding excretion of synthetic vitreous fibers after oral exposure.  Most, if not 
all, synthetic vitreous fibers that are ingested are expected to be excreted in the feces.  Fecal elimination 
of a single oral dose of asbestos fibers has been demonstrated to be essentially complete within 48 hours 
(Gross and Stanton 1974). 
3.4.4.3 Dermal Exposure  
No studies were located regarding excretion of synthetic vitreous fibers following dermal exposure, but it 
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3.4.4.4 Other Routes of Exposure 
As with inhaled fibers, intratracheally-instilled synthetic vitreous fibers are cleared by mucociliary
translocation, dissolution, and transverse breakage (Bellmann et al. 1994a, 1994b, 1995; Dufresne et al. 
1999; Eastes et al. 1995; Morgan et al. 1982, 1994a; Morris et al. 1995; Searl et al. 1999).  Fibers 
swallowed into the gastrointestinal are efficiently excreted in the feces. 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
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numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.   
PBPK models for insoluble or slowly soluble inhaled materials, such as synthetic vitreous fibers, focus on 
the retention of the inhaled materials in the alveolar region of the lung (Stober and McClellan 1997).  The 
models recognize that alveolar retention (the net result of the deposition and clearance processes in the 
alveolar region) is also dependent on deposition and clearance of particles in the upstream regions of the 
respiratory tract.  The models divide the respiratory system into a number of connected compartments 
(most often into the nasopharyngeal, tracheobronchial, and alveolar regions) with each compartment 
having a distinct set of deposition and clearance parameters.  As reviewed below, alveolar retention 
models for refractory ceramic fibers have been developed for rats, hamsters, and humans; the rat model 
has recently been extended to other synthetic vitreous fibers such as glass, rock, and slag wools (Yu et al. 
1994, 1995b, 1996, 1998a, 1998b). 
Models for alveolar retention of refractory ceramic fibers in rats and hamsters have been developed based 
on: (1) theoretical and empirical understanding of deposition processes (e.g., sedimentation and 
impaction) in various regions of the respiratory tract as they are influenced by particle dimensions, 
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mechanical mucociliary clearance, macrophage-mediated mucociliary clearance, dissolution, and 
transverse breakage of long fibers into shorter fibers; and (3) data for lung concentrations and size 
distributions of fibers in animals exposed chronically to accurately measured inhaled concentrations of 
refractory ceramic fiber (RCF1) aerosols (Yu et al. 1994, 1995b, 1996).  The rat model for refractory
ceramic fibers was also extended to a more general model to apply to other synthetic vitreous fiber 
including glass wools and rock wools (Yu et al. 1998a, 1998b).  
The most recent of the retention models developed by Yu and colleagues include mathematical 
descriptions of alveolar deposition rates with the following explanatory variables: tidal volume, breathing 
frequency, air concentrations of fibers of specific lengths and diameters, and alveolar deposition fraction 
of fibers with specific diameter and length.  The deposition models account for the dependence of the 
fraction of inhaled fibers depositing in the alveolar region not only on the deposition efficiency of the 
alveolar region itself (i.e., the amount deposited divided by the amount entered), but also on deposition 
efficiencies in the nasopharyngeal and tracheobronchial regions.  The clearance models describe removal 
of fibers from lungs by three simultaneous processes:  alveolar macrophage-mediated clearance (as a 
function of fiber length and alveolar macrophage volume); dissolution (decrease in fiber diameter with 
time at a constant rate); and transverse breakage of long fibers into shorter fibers (Yu et al. 1996, 1997, 
1998a, 1998b).  Macrophage-mediated clearance in the model is also a function of lung burden, the total 
accumulated fiber and particle volume in the lung; the rate of clearance slows at high lung burdens.  
Model simulations of lung concentrations of fibers of various length classes (lengths <5, 5–10, 10–20, 
and >20 µm) showed good agreement with empirical lung concentrations in rats exposed (nose-only, 
6 hours/day, 5 days/week) for up to 104 weeks to RCF1 concentrations of 36, 91, 162, and 234 total 
fibers/cc (Yu et al. 1996). Good agreement was also found between model simulations and empirical 
lung concentrations in rats at various postexposure periods following exposure (nose-only, 6 hours/day
for 5 days) to each of four types of synthetic vitreous fibers (two glass wools—MMVF10, MMVF11; one 
rock wool—MMVF21; or one slag wool—MMVF22) at gravimetric concentrations of 30 mg/m3 (Yu et 
al. 1998a). Model simulations were also compared with lung concentration data for rats exposed by
inhalation for up to 104 weeks to several concentrations of the same synthetic vitreous fibers (MMVF10, 
MMVF11, MMVF21, or MMVF22) (Yu et al. 1998b).  The model simulations were reported to “compare 
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A deposition and clearance model for refractory ceramic fibers in humans was developed from the rat 
model based on anatomical and physiological differences between rats and humans (Yu et al. 1995a, 
1997). Some of the differences used in developing the human model are described in Table 3-3.  
Appropriate data to examine the accuracy of the human model are not available (i.e., lung fiber 
concentrations from autopsied lungs of exposed subjects and accurate information regarding time-
weighted average air concentrations to which the subjects were exposed and durations of exposure).  The 
model was used, however, to predict human lung concentrations following 15–20 years of occupational 
exposure to various air concentrations of refractory ceramic fibers.  These were compared with lung 
concentration data for three workers who worked in a refractory ceramic fiber manufacturing plant for 
13–17 years (Yu et al. 1997).  The comparison suggested that one subject may have been exposed to an 
average air concentration of 0.25 fibers/cc and that the other subjects may have been exposed to 0.6– 
0.7 fibers/cc. These concentrations are within the range of air concentrations measured for some 
refractory ceramic fiber manufacturing plants (Yu et al. 1997). 
For refractory ceramic fiber size ranges and concentrations encountered in workplaces, the deposition 
models predicted that:  (1) the average alveolar deposition fraction in humans is 8.4% for nose-breathing 
and 15.9% for mouth-breathing; (2) the average alveolar deposition fraction in rats and hamsters are 
3.7 and 5.7%, respectively; (3) humans have 1–2.5 times less deposited fiber per unit lung surface area 
than rats and hamsters; and (4) the geometric mean size dimensions (diameter and length) of fibers 
deposited in the lungs of rats and hamsters are smaller than those of fibers deposited in human lungs (Yu 
et al. 1995a). 
One impetus to develop rat, hamster, and human alveolar retention models for synthetic vitreous fibers is 
to use the models to facilitate animal-to-human extrapolations of dose-response relationships for adverse 
effects in rodents exposed by inhalation to synthetic vitreous fibers (see Section 3.5.3, Animal-to-Human 
Extrapolations and Appendix A). Several quantitative human cancer risk estimates have been prepared 
using the data from the RCF1 2-year rat bioassay and the lung deposition and clearance models developed 
by C.P. Yu and colleagues (Maxim et al. 2003b; Moolgavkar et al. 1999, 2000; Turim and Brown 2003; 
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Table 3-3. Comparative Human and Rat Anatomical and Physiological 

Parameters Relevant to Alveolar Retention of  

Refractory Ceramic Fibers 

Parameter Human Rat 
Body weight (kg) 70 0.3 
Lung weight (g) 1,000 1.48 
Airway volume (cm3) 3,200 6.5 
Airway surface area (cm2) 627,000 5,500 
Number of alveolar macrophages 7x109 2.6x107 
Alveolar macrophage volume (µm3 per lung) 2,500 1,000 
Total alveolar macrophage volume (mm3) 17,500 26 
Tidal volume (cm3) 500 2.74 
Breathing frequency (minute-1) 14 98 
Minute ventilation (cm3/minute) 7,000 268 
Life span (years) 70 2 
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3.5 MECHANISMS OF ACTION  
The mechanisms by which inhaled fibers and particles, including synthetic vitreous fibers, induce adverse 
effects on the lung and pleural membrane are incompletely understood, but extensive research over the 
past few decades with asbestos fibers, silica, and synthetic vitreous fibers of various types has led to a 
complex working hypothesis that includes pharmacokinetic mechanisms influencing the dose of fibers to 
the lung and toxicity mechanisms involving the responses of lung cells and tissues to retained fibers.  
Evidence has accumulated that these mechanisms are influenced to varying degrees by fiber dimensions, 
dose to the lung, and fiber durability; surface area and chemical composition not related to durability may
also play roles in the mechanisms.  This section provides a brief overview of mechanisms involved in 
fiber-induced effects on the lung (inflammation, cytotoxicity, genotoxicity, cell proliferation, fibrosis, and 
lung tumors) and the pleural membrane (pleural plaques, pleural thickening and pleural mesothelioma).  
More detailed and comprehensive information on this area of research can be found in reviews by Churg 
et al. (2000), Driscoll (1996), Hart et al. (1994), Hesterberg and Hart (2001), Hesterberg et al. (1993c), 
Kane (1996), and Mossman and Churg (1998). 
3.5.1 Pharmacokinetic Mechanisms 
The amount of fibers deposited in the alveolar region of the lung is a key determinant of the potential 
development of adverse effects in the interstitium of the lung and in the pleural membrane.  The 
aerodynamic diameter of fibers, along with ventilation parameters and geometry and size of airways, 
strongly influence alveolar deposition (Dai and Yu 1998; Oberdörster 2000).  Fibers with aerodynamic 
diameters >3–4 µm are mostly excluded from the alveolar region due to deposition in upstream regions of 
the respiratory tract. The fraction of inhaled fibers deposited in alveoli decreases to zero with 
aerodynamic diameters of about 5 µm in rats and 10 µm in humans (Dai and Yu 1998).
The mechanisms whereby fibers deposited in the alveoli move to the interstitium, the pleural membrane, 
or the lymphatic system are unknown, although it is believed that movement into these regions is 
enhanced when rates of dissolution and macrophage-mediated clearance are overwhelmed by intakes at 
high exposure concentrations (Gross and Stanton 1973; Oberdörster 2000).  Using electron microscopy,
recent experiments have detected predominately short (<5 µm) and thin (<0.35 µm) fibers in pleural 
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RCF1 (Everitt et al. 1997; Gelzleichter et al. 1996a, 1996b, 1999). These findings suggest that rapid fiber 
movement into pleural tissues occurs and has size limitations.  Whether the movement is principally 
passive through intracellular spaces or mediated by the movement of inflammatory cells is unknown.  The 
detection of fibers in the pleural tissues in the intermediate-duration studies was accompanied by
inflammation and cell proliferative changes in pleural tissue.  Hamsters showed more severe pleural 
changes than rats, but this was not correlated with a greater total number of fibers in hamster pleural 
tissues (Everitt et al. 1997).  However, more extensive subsequent examinations of fiber size distributions 
in pleural tissues from rats and hamsters following intermediate-duration exposure to RCF1 found that 
fibers longer than 5 µm accounted for 12 and 4% of the fiber burden in hamsters and rats, respectively
(Gelzleichter et al. 1999).  The pleural surface density of these “long” fibers in hamsters (150 fibers per 
cm2) was about 2–3 times that in the rat, whereas the pleural burden of short (<5 µm) fibers in the rats 
was about 1.5–2 times that in the hamster.  The differences between hamsters and rats in intermediate-
duration pleural cell proliferative changes may be due, in part, to the differences in retained “long” fiber 
surface density, but contributions from other mechanisms, such as release of reactive oxygen species, 
cytokines, or growth factors from alveolar macrophages or other cells are also plausible (Adamson et al. 
1994). 
The dose of fibers that remains in the lower lung is a net result of the amount of fibers deposited and the 
amount of deposited fibers removed by macrophage-mediated clearance via the mucociliary escalator, 
and by the combined actions of dissolution and transverse breakage of long fibers into shorter fibers.  
Whereas fiber aerodynamic diameter is a critical factor for deposition, fiber length is a critical factor for 
macrophage engulfment.  Fibers longer than 15–20 µm are expected to be too long for human
macrophages to completely engulf and transport out of the lung.  Thus, clearance of long fibers from the 
lower lung cannot occur until the fibers either dissolve or break into shorter fibers that can be removed by
macrophages (Eastes et al. 2000; Hesterberg and Hart 2001; Hesterberg 1998a; Oberdörster 2000).   
Dissolution of fibers is influenced by their chemical composition and structure.  As discussed in 
Section 3.4, synthetic vitreous fibers of various types show a range of in vitro dissolution rates (that are 
correlated with in vivo lung clearance half-times in rats), but all synthetic vitreous fibers tested to date are 
less biopersistent than amphibole asbestos fibers, which undergo no dissolution and are very
biopersistent. Vitreous fibers with relatively high alumina and silica contents favor a relatively uniform, 
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lead to nonuniform rates of dissolution, faster breakage, and faster clearance (Eastes et al. 2000; 
Hesterberg and Hart 2001; Morgan et al. 1994b; Potter and Mattson 1991). 
When rates of fiber deposition exceed the rates of removal, fibers can accumulate in the lung leading to 
chronic and persistent inflammation and tissue damage.  For a variety of synthetic vitreous fibers and 
some amphibole asbestos fibers (amosite and crocidolite) correlations have been demonstrated among 
fiber durability in simulated pH 7.4 physiological fluids, fiber breakage rates, fiber lung clearance half­
times in rodent models, and the ability to induce prefibrotic lesions (e.g., cell proliferation or collagen 
deposition), fibrosis, or tumors in rodents following repeated inhalation exposure (Bernstein et al. 2001a, 
2001b; Eastes and Hadley 1996; Eastes et al. 2000; Hesterberg et al. 1998a).  These correlations stress the 
importance of fiber durability in determining fiber pathogenicity and are the basis of proposals for using 
in vitro dissolution tests and short-term rodent lung clearance tests as preliminary screening tools to 
assess the potential toxicity of newly developed fibers.  Measurements of in vitro dissolution rates for a 
number of synthetic vitreous fibers of varying chemical content indicate that substitution of sodium, 
potassium, boron, calcium, and magnesium in the silicate network tends to increase dissolution rate, 
whereas increasing aluminum oxide content tends to decrease dissolution rate.   
In support of the hypothesis that chemical composition, fiber durability, and fiber pathogenicity are 
linked, Wardenbach et al. (2000) demonstrated a significant correlation between the potencies of seven 
synthetic vitreous fibers to induce tumors in rats following intraperitoneal injection and their 
“carcinogenicity index”, which was defined as the summation of sodium-, potassium-, boron-, calcium-, 
magnesium-, and barium-oxide weight percentage minus 2 times the aluminum-oxide weight percentage.  
However, chemical composition is not expected to be the sole determinant of fiber biopersistence, as 
conditions in the manufacturing process, such as flame attenuation versus air attenuation, have been 
demonstrated to influence the dissolution rate of synthetic vitreous fibers (see Hesterberg and Hart 2001 
for review). 
3.5.2 Mechanisms of Toxicity
The deposition of relatively insoluble particles, such as synthetic vitreous fibers, in the lower lung of 
animals is well known to cause a complex defensive inflammatory response characterized by increased 
numbers of alveolar macrophages and other inflammatory cells.  Chronic and persistent inflammation 
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been linked for the most biopersistent synthetic vitreous fibers and asbestos to the development of cell 
injury, DNA changes, cell proliferation, deposition of collagen and other extracellular components 
leading to fibrosis (tissue scarring), and tumor development (Greim et al. 2001; IARC Expert Panel 1996;
Kane 1996; Mossman and Churg 1998).  Cellular and molecular events in these fiber-induced 
nonneoplastic and neoplastic effects are poorly understood, but several mechanistic hypothesis have been 
proposed based predominately on research with asbestos.  The following discussion highlights results 
relevant to synthetic vitreous fibers. 
The penetration or engulfment of fibers into macrophages, other inflammatory cells, epithelial cells, or 
mesothelial cells generates reactive oxygen and nitrogen species that can damage DNA, lipids, and 
proteins, lead to cytotoxicity, and stimulate release of inflammatory mediators, cytokines, and growth 
factors that may induce epithelial and mesothelial cell proliferation (Churg et al. 2000; Driscoll 1996; 
IARC Expert Panel 1996). Reactive oxygen species may also be generated by reactions on the surfaces of 
fibers, but this activity appears to be much greater with certain asbestos fibers (e.g., amosite) than with 
insulation wools (e.g., MMVF10) and refractory ceramic (e.g., RCF1) fibers (Gilmour et al. 1995, 1997).  
Experiments with cultured cells exposed to asbestos fibers have demonstrated that anti-oxidant systems 
can protect against fiber-induced cytotoxicity, providing support for the importance of reactive oxygen 
species in the development of fiber-induced disease (Mossman and Churg 1998). 
Fibers of similar size distributions, but different chemical compositions, may elicit different responses 
from macrophages.  For example, in vitro incubation of MMVF10 fibers with rat alveolar or peritoneal 
macrophages did not produce detectably increased levels of superoxide anions, but MMVF21 fibers with 
a similar distribution of fiber sizes caused increased production of superoxide anions by either type of 
macrophage (Dörger et al. 2001).  This difference was associated with the finding that significantly higher 
numbers of macrophages completely phagocytized MMVF21 compared with MMVF10 fibers.  The 
chemical or cellular basis for these differences is unknown, but may be related to lesser ability of 
MMVF10 fibers to directly elicit cytokines and proinflammatory mediators that modulate phagocytic 
functions of cells (Driscoll 1996). 
In addition to fiber-induced reactive oxygen-mediated mechanisms that may lead to cytotoxic and 
cytoproliferative or hyperplastic responses, other proposed mechanisms in which fibers may directly
induce cell proliferation include:  (1) a “healing” response secondary to direct fiber-induced cell injury; 

















134 SYNTHETIC VITREOUS FIBERS
3. HEALTH EFFECTS 
mediators that cause tissue damage and stimulate cell proliferation; and (3) a direct cell proliferative 
effect of fibers on cells (Driscoll 1996). It is likely that multiple mechanisms play variable roles in the 
cell proliferation responses to different fiber types and exposure scenarios.  Understanding of the 
interactions among the possible multiple mechanisms is too incomplete to provide reliable in depth 
explanations for observed differences in apparent potency among fiber types, although there is sufficient 
evidence to indicate that fiber durability plays a key role.  The comparative examination of cellular and 
molecular responses related to cell proliferation and inflammation from fibers with similar size
distributions, but varying pathogenic potency, is an area of intensive current research (e.g., Barchowsky et 
al. 1997; Brown et al. 1998, 1999, 2000; Donaldson et al. 1995a, 1995b; Dörger et al. 2000, 2001; 
Gilmour et al. 1997; Jensen and Watson 1999; Johnson and Jaramillo 1997; Leikauf et al. 1995; Luoto et 
al. 1997; Marks-Konczalik et al. 1998; Morimoto et al. 1999a; Tsuda et al. 1999). 
Fiber-induced cell proliferative responses that can lead to tissue scarring in the lung and pleural tissues 
are also thought to play a role in the development of lung carcinomas or mesotheliomas by enhancing the 
frequency of cells transformed by spontaneous or fiber-induced genetic changes (Driscoll 1997; Greim et 
al. 2001; IARC Expert Panel 1996; Kane 1996).  Thus, the carcinogenic responses to synthetic vitreous 
fibers observed in animals may develop via both genotoxic and non-genotoxic modes of action.  As 
discussed in Section 3.3, results from in vitro tests indicate that, like asbestos fibers, several types of 
synthetic vitreous fibers can induce cytogenetic changes and alter DNA.  Proposed mechanisms for fiber-
induced genetic changes include DNA alterations from reactive oxygen species and physical interference 
of fibers with cellular cytoskeletons and chromosomes (Kane 1996).  
3.5.3 Animal-to-Human Extrapolations 
As discussed in Section 3.4.5, there are distinct differences between animal species and humans in 
respiratory tract size and geometry, ventilation rates and patterns, and macrophage size that influence the 
retention (the net result of deposition and clearance) of fibers in the lung.  Yu and colleagues have 
developed lung retention models for refractory ceramic fibers in rats, hamsters, and humans that 
incorporate many of these interspecies differences, some of which are shown in Table 3-3 (Dai and Yu 
1998; Yu et al. 1994, 1995a, 1995b, 1996, 1997).  The models incorporate mechanisms of deposition in 
the nasopharyngeal, tracheobronchial, and alveolar regions, macrophage-mediated clearance (with shorter 
fibers preferred and impaired clearance occurring at high levels of fiber lung concentration), fiber 
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synthetic vitreous fibers, but extension of the human model to other synthetic vitreous fibers has not been 
reported (Yu et al. 1998a, 1998b).  The dosimetric models for refractory ceramic fibers predict fiber lung 
concentration as a function of time for both humans and rodents for given air concentrations of fibers with 
specified distributions of length and diameter.  The models can be used to convert exposure levels in 
animal inhalation toxicity and cancer studies to human equivalent exposure levels (Appendix A describes 
the use of these models in deriving a chronic inhalation MRL for refractory ceramic fibers).  As discussed 
in Section 3.4.5, several quantitative human cancer risk estimates have been prepared using the data from
the RCF1 2-year rat bioassay and the lung deposition and clearance models developed by C.P. Yu and 
colleagues (Maxim et al. 2003b; Moolgavkar et al. 1999, 2000; Turim and Brown 2003; Yu and 
Oberdörster 2000). 
In contrast to the relatively robust understanding of fiber pharmacokinetics in animals and humans, 
understanding of the relative sensitivity of rodents and humans to synthetic vitreous fibers or asbestos 
fibers (i.e., the relative pharmacodynamics) is poor.  For asbestos, rats appear to be a suitable qualitative
model for humans given that effects observed in groups of workers exposed to high levels of airborne 
asbestos (chronic inflammation, pulmonary fibrosis, lung cancer, and mesothelioma) have also been 
observed in rat inhalation studies (Agency for Toxic Substances and Disease Registry 2001).  However, 
similar qualitative comparisons between rodent and human responses to synthetic vitreous fibers are not 
possible. Available epidemiological studies of workers involved in the manufacture of fibrous glass, rock 
wool, or slag wool, or in the manufacture of refractory ceramic fibers have not found consistently
increased risks for nonmalignant respiratory disease, lung cancer, or mesothelioma, although pulmonary
fibrosis, lung cancer, and mesothelioma have been demonstrated in rats and hamsters exposed by 
inhalation to the most potent synthetic vitreous fibers (see Section 3.2). 
For asbestos, limited quantitative data are insufficient to conclusively determine the relative sensitivity of 
humans and rodents to fibers, although several hypotheses have been proposed on this issue.  
Rodelsperger and Woitowitz (1995) proposed that humans may be more susceptible to asbestos’s 
capability to induce mesothelioma based on a finding that lung fiber concentrations in a group of humans 
who died from asbestos-induced mesothelioma were markedly higher than concentrations in a bioassay of 
crocidolite-exposed rats. Earlier, Rowe and Springer (1986) proposed that humans and rodents may be 
equally sensitive to asbestos based on a comparison of estimated human lung cancer risks based on rodent 
inhalation bioassays and those derived in epidemiological studies of asbestos-exposed workers.  Maxim
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hamsters exposed to a series of asbestos (crocidolite, chrysotile) and synthetic vitreous fibers (rockwool 
MMVF21 and refractory ceramic fiber RCF1) and compared these with fiber concentrations in autopsied 
lungs from several studies of workers with asbestosis (i.e., pulmonary fibrosis from asbestos exposure).  
Estimated concentrations in rodents ranged from 1.7x106 to 20x106 fibers (>20 µm long) per g dry lung
compared with 1.6x106 to 30x106 fibers (>20 µm long) per g dry lung in humans.  Maxim and McConnell 
(2001) concluded, based on these and other considerations, that “there seems little reason to believe that 
humans and rats have greatly different sensitivities with respect to the development of pulmonary fibrosis 
or lung cancer.” 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the EPA 
to develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
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are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
No studies were located regarding the possible effects of synthetic vitreous fibers on the neuroendocrine 
axis in humans or animals or in in vitro systems. 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
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1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
No information was located specifically concerning health effects in children exposed to synthetic 
vitreous fibers. There was no indication from the available literature that specialized respiratory defense 
mechanisms might be less active or underdeveloped in children relative to adults.  Results from animal 
studies indicate that inflammation, fibrosis, and cancer of the lung or pleura are possible outcomes 
resulting from repeated inhalation exposure to certain synthetic vitreous fibers depending on the exposure 
dose, exposure duration, fiber dimensions, and fiber durability.  However, no studies were located that 
have compared immature and mature animals with respect to pharmacokinetics of, or susceptibility to, 
inorganic fibers of any type (including asbestos) by any route of exposure.  
No human or animal studies were located regarding the possible developmental toxicities of synthetic 
vitreous fibers by any route of exposure.  Direct effects on the developing fetus would be unexpected 
given the very small, if any, absorption of synthetic vitreous fibers by the lungs, gastrointestinal tract, or 
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was indicated in several oral administration studies with rats, mice, and hamsters (Agency for Toxic 
Substances and Disease Registry 2001). 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to synthetic vitreous fibers are discussed in 
Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
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A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10 “Populations That Are Unusually Susceptible.” 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Synthetic Vitreous Fibers  
Uncoated or coated fibers in bronchoalveolar lavage fluid samples or in autopsied or surgically resected 
lung tissue samples are the principal biomarkers of exposure to biopersistent asbestos fibers (Agency for 
Toxic Substances and Disease Registry 2001).1  However, similar biomarkers to identify or quantify
human exposure to synthetic vitreous fibers, which are less biopersistent than asbestos fibers, have not 
been developed for routine clinical use.  Nevertheless, aluminum-silicate fibers with chemical 
compositions consistent with synthetic vitreous fibers have been detected in human lung tissues 
(McDonald et al. 1990; Roggli 1989; Sébastien et al. 1994) and in bronchoalveolar lavage samples 
(Dumortier et al. 2001).   
For example, among 1,800 bronchoalveolar samples submitted to a Belgium hospital between 1992 and 
1997 for fiber analysis, pseudoasbestos bodies were detected in samples from nine patients (0.5%)
(Dumortier et al. 2001).  In samples from these nine patients (all of whom had occupational experience 
with furnaces or welding), fibers of composition consistent with refractory ceramic fiber composition 
were detected in 42% of core fibers analyzed (Dumortier et al. 2001).  Other nonasbestos fibers and 
asbestos fibers accounted for 28 and 30% of the core fibers analyzed in these samples, respectively. 
In another study, lung fiber concentrations were determined in autopsied tissue samples from a subset of 
deaths occurring between 1950 and 1979 in a cohort of U.S. workers involved in the manufacture of 
synthetic vitreous fibers (McDonald et al. 1990).  The 145 autopsied tissue samples analyzed represented 
about 3% of the deaths that occurred in the cohort during this period.  Lung fiber concentrations were 
1 Particles or fibers that are deposited in the lung and are too large to be phagocytized by alveolar macrophages may
become coated with an iron-rich protein coat.  The generic term for these structures is ferruginous bodies.  When the core fiber is
asbestos, the resultant structure is termed an asbestos body (Agency for Toxic Substances and Disease Registry 2001). 
Ferruginous bodies having the appearance of asbestos bodies under light microscopy and a nonasbestos core fiber have been
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compared with concentrations in 124 autopsied referents who had no known occupational experience with
synthetic vitreous fibers, were matched for location of death (i.e., hospital), age, and year of death, and 
died from causes other than malignant disease.  Lung fiber concentrations (lengths >5 µm and 
length:diameter ratio >3:1) determined by phase contrast microscopy were about 60% higher in workers 
than referents. Electron microscopy (coupled with energy dispersive spectrometry and selected area 
electron diffraction) showed no statistically significant excess of any particular type of fiber in the 
workers compared with the referents, although asbestos fibers were detected with greater frequency than 
synthetic vitreous fibers in both workers and referents.  Nonasbestos fibers described as “siliceous” 
displayed a strong energy dispersive signal for silicon without sodium, aluminum, potassium, calcium,
titanium, or iron signals and represented >90% of fibers identified as synthetic vitreous fibers.  However, 
lung samples from only 26% of the workers contained any synthetic vitreous fibers.  The low detection 
frequency of synthetic vitreous fibers in the worker lung samples may reflect both low exposure 
concentrations and low biopersistence of these fibers.  
In animal inhalation experiments with synthetic vitreous fibers, concentrations of fibers in the lung have 
been used to assay internal doses (e.g., Hesterberg et al. 1993c, 1999; Mast et al. 1995a, 1995b; 
McConnell et al. 1999). Based on rat experiments involving intraperitoneal injection of three different 
types of synthetic vitreous fibers, urinary levels of titanium or barium were proposed as potential 
biomarkers of exposure to synthetic vitreous fibers that contain these elements normally present in 
humans and animals in small quantities (Wastiaux et al. 1994).  Reports of further development of urinary
titatnium or barium as biomarkers of exposure to synthetic vitreous fibers were not located. 
3.8.2 Biomarkers Used to Characterize Effects Caused by Synthetic Vitreous Fibers  
Epidemiological studies of synthetic vitreous fiber manufacturing workers have not found consistent 
evidence for increased risks of malignant or nonmalignant respiratory or pleural effects, but results from
animal experiments indicate that repeated inhalation exposure to synthetic vitreous fibers may result in 
pulmonary or pleural fibrosis, lung cancer, or mesothelioma, depending on fiber dimensions, fiber 
durability in the lung, duration of exposure, and exposure levels.   
The chest x-ray is the most common means of detecting the onset of pleural or pulmonary changes that 
may precede or accompany fibrosis (i.e., irreversible scarring of lung or pleural tissue that can lead to 
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profusion of opacities in chest x-rays that includes four categories of increasing severity, each with three 
subcategories: 0 (0/-, 0/0, 0/1); 1 (1/0, 1/1, 1/2); 2 (2/1, 2/2, 2/3); and 3 (3/2, 3/3, 3/4) (ILO 1980).  The 
American Thoracic Society (1986) recommends that chest x-rays be scored for pleural and pulmonary
changes separately because of the experience with asbestos-exposed workers indicating that pleural and 
pulmonary fibrosis have differences in “epidemiology, clinical features, and prognosis.”  Computerized 
tomography (CT) and high-resolution computed tomography provide alternative techniques to the chest 
x-ray that may more sensitively detect pleural and pulmonary changes in some cases (Agency for Toxic 
Substances and Disease Registry 2001).  Lung function tests are also useful to characterize the 
development of pulmonary or pleural fibrosis; forced vital capacity is diminished with increasing severity
of pulmonary or pleural fibrosis. 
Clinical diagnostic criteria for pulmonary fibrosis include chest x-rays with small irregular opacifications 
of a profusion of 1/1 or greater, impaired forced vital capacity below the lower limit of normal, and a 
diffusing capacity below the lower limit of normal (American Thoracic Society 1986).  Pleural changes 
associated with chronic inflammation from inhaled fibers or particles include pleural plaques, pleural 
fibrosis (also referred to as thickening or calcification), and pleural effusions.  Pleural plaques are 
localized or diffuse areas of thickening of the pleura that appear as opaque, shiny, and rounded lesions in 
the chest x-ray. Pleural fibrosis represents a more pronounced thickening or scarring that, when severe, 
can make the pleura appear as a thick peel encasing the lung in chest x-rays.  Persons with pleural fibrosis 
can experience chest pain and impaired pulmonary functions, but persons with pleural plaques alone 
usually do not (American Thoracic Society 1986).  Pleural effusion is the exudation of cell-containing 
fluid from lung tissue into the pleural cavity, which is often taken as an early manifestation of exposure to 
asbestos fibers (American Thoracic Society 1986).  Pleural effusions have been reported in groups of 
people exposed occupationally to asbestos (Agency for Toxic Substances and Disease Registry 2001), but 
have not been reported in workers involved in the manufacture of synthetic vitreous fibers. 
3.9 INTERACTIONS WITH OTHER CHEMICALS  
Epidemiological and clinical studies of asbestos workers have indicated that workers who smoked 
tobacco had greater risks of developing lung cancer and pulmonary fibrosis than workers who did not 
smoke, and that smoking may increase these risks by more than risks predicted by an additive model (see 
Agency for Toxic Substance and Disease Registry 2001 for review).  In contrast, the studies provided no 
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fully understood, but there is evidence to suggest that smoking may decrease the ability of lungs to clear 
fibers or other particles.  For example, the lungs of smoking workers with heavy asbestos occupational 
exposure showed higher concentrations of chrysotile and amosite fibers compared with nonsmoking 
workers (Churg and Stevens 1995), and the clearance rate of short chrysotile fibers was decreased by 30% 
in guinea pigs after coexposure to chrysotile and cigarette smoke compared with guinea pigs exposed to 
chrysotile alone (Churg et al. 1992). 
A similar interaction between smoking and inhalation exposure to synthetic vitreous fibers in jointly
affecting lung cancer or pulmonary fibrosis is plausible, but direct evidence to support the possible 
interaction is very limited.  In a study of European refractory ceramic fiber production workers, a 
statistically significant association between indices of cumulative exposure to fibers and decreased 
pulmonary function was observed in workers who smoked, but not in nonsmokers (Cowie et al. 2001; 
Rossiter et al. 1994; Trethowan et al. 1995).  Alveolar macrophages from rats exposed to sidestream
cigarette smoke produced statistically significantly greater quantities of a cytokine involved in regulating 
cellular proliferation (tumor necrosis factor) in response to chrysotile fibers in vitro than did macrophages 
from rats not exposed to smoke (Morimoto et al. 1993).  Refractory ceramic fibers also induced tumor 
necrosis factor production by macrophages in vitro. Macrophages from smoke exposed rats produced 
more tumor necrosis factor than macrophages from nonexposed rats, but the difference was not 
statistically significant (Morimoto et al. 1993).  The only other published finding of relevance to the 
possible interactive effects smoking and exposure to synthetic vitreous fibers is the observation that in 
vitro oxidative damage to calf thymus DNA (assayed as the formation of 8-hydroxydeoxyguanosine 
residues) produced by cigarette smoke condensate and rockwool fibers together was greater than the sum
of the damage by each agent alone (Leanderson and Tagesson 1989). 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to synthetic vitreous fibers than 
will most persons exposed to the same level of synthetic vitreous fibers in the environment.  Reasons may
include genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., 
cigarette smoke).  These parameters result in reduced detoxification or excretion of synthetic vitreous 
fibers, or compromised function of organs affected by synthetic vitreous fibers.  Populations who are at 
greater risk due to their unusually high exposure to synthetic vitreous fibers are discussed in Section 6.7, 
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Persons with impaired pulmonary clearance mechanisms (e.g., due to chronic exposure to cigarette smoke 
or repeated exposure to dusty air leading to high burdens of particles in the lung) or genetically 
determined relatively poor ability to detoxify reactive oxidative molecules produced during pulmonary
disposition of fibers (e.g., reactive oxygen radicals or nitrogen oxide) may be more susceptible than others
to possible nonmalignant or malignant pulmonary or pleural disorders from chronic exposure to synthetic 
vitreous fibers. Direct evidence in support of these hypotheses, however, is lacking for synthetic vitreous 
fibers, except for the observation that cumulative exposure indices were associated with decreased 
pulmonary function in European refractory ceramic fiber workers who smoked, but not in nonsmokers 
(Cowie et al. 2001; Rossiter et al. 1994; Trethowan et al. 1995).   
In case-control studies of asbestos-exposed persons, associations have been observed between deletion of 
the gene (GSTM1) encoding one class of glutathione S-transferase (GSTµ), an enzyme that protects 
against oxidative tissue damage, and increased risks for mesothelioma, other cancers, or nonmalignant 
pulmonary disorders (Hirvonen 1997; Hirvonen et al. 1996; Kelsey et al. 1997). Increased risks for 
developing nonmalignant pulmonary disorders or mesothelioma were also observed among persons with 
histories of high-level asbestos exposure who lacked the GSTM1 gene and had a slow genotype for 
N-acetyltransferase 2 (NAT2), compared with risks in exposed subjects with the GSTM1 gene and the 
fast NAT2 genotype (Hirvonen et al. 1996).  Slow acetylation by NAT2 may lead to accumulation of 
polyamines that stimulate cell proliferation. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to synthetic vitreous fibers.  However, because some of the treatments discussed may be 
experimental and unproven, this section should not be used as a guide for treatment of exposures to 
synthetic vitreous fibers.  When specific exposures have occurred, poison control centers and medical 
toxicologists should be consulted for medical advice.  The following texts provide specific information 
about treatment following exposures to synthetic vitreous fibers:   
Standard texts of medical toxicology (e.g., Ellenhorn et al. 1997; Goldfrank et al. 1998) do not provide 
specific information about treatment of acute irritation effects or possible chronic effects from exposure to 
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synthetic vitreous fibers have been making modifications to new products in order to make them more 
biosoluble (i.e., less biopersistent) and potentially less hazardous than older products (Hesterberg and 
Hart 2001; IARC 2002). 
3.11.1 Reducing Peak Absorption Following Exposure  
Absorption of synthetic vitreous fibers is expected to be negligible following inhalation, ingestion, or
dermal exposure.  Recommendations have been made to avoid contact with the fibers by wearing 
protective clothing and using ocular and respiratory protection when working with materials containing
synthetic vitreous fibers and to minimize physical disturbance of the material and generation of dusts, in 
order to avoid the acute dermal, respiratory, or ocular irritation experienced from contact with synthetic 
vitreous fibers (e.g., “fiberglass itch”), and prevent the possible pulmonary or pleural disorders from
chronic inhalation exposure (Ellenhorn et al. 1997; Goldfrank et al. 1998; Jeffress 1999; Mentzer 1999; 
OSHA 1999). Rinsing of exposed areas with water also minimizes contact. 
3.11.2 Reducing Body Burden  
As discussed in Section 3.4, the principal pathways by which inhaled and deposited synthetic vitreous 
fibers are removed from the respiratory tract involve:  (1) direct or macrophage-mediated mechanical 
mucociliary translocation to the pharynx, swallowing into the gastrointestinal tract, and elimination in the 
feces; (2) dissolution; and (3) transverse breakage of long fibers into shorter fibers.  To date, there are no 
clinical methods to enhance or supplement these natural methods of elimination of inhaled fibers that 
deposit on the epithelial surfaces of the respiratory tract. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
The mechanisms by which repeated exposure to airborne synthetic vitreous fibers may cause pulmonary
or pleural disorders are poorly understood (see Section 3.5), and there are no tested methods of 
interference. It is plausible that repeated exposure to the more durable synthetic vitreous fibers could also 
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3.12 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of synthetic vitreous fibers is available.  Where adequate 
information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is 
required to assure the initiation of a program of research designed to determine the health effects (and 
techniques for developing methods to determine such health effects) of synthetic vitreous fibers. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Synthetic Vitreous Fibers  
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
synthetic vitreous fibers are summarized in Figure 3-2.  The purpose of this figure is to illustrate the 
existing information concerning the health effects of synthetic vitreous fibers.  Each dot in the figure 
indicates that one or more studies provide information associated with that particular effect.  The dot does 
not necessarily imply anything about the quality of the study or studies, nor should missing information in 
this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for 
Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic 
Substances and Disease Registry 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature.
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    As discussed in Section 3.2, acute occupational exposure to synthetic 
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symptoms of irritation of the upper respiratory tract (ACGIH 2001; Horvath 1995; Milby and Wolf 1969; 
Nasr et al. 1971; Newball and Brahim 1976; Petersen and Sabroe 1991; Thriene et al. 1996), the skin 
(Bendsoe et al. 1987; Bjornberg 1985; Bjornberg and Lowhagen 1977; Bjornberg et al. 1979a, 1979b, 
1979c; Eun et al. 1991 Fisher 1982; Fisher and Warkentin 1969; Heisel and Hunt 1968; Kiec-
Swierczynska and Szymczk 1995; Koh and Khoo, 1995; Longley and Jones 1966; Peterson and Sabroe 
1991; Possick et al. 1970; Stam-Westerveld et al. 1994; Tarvainen et al. 1993; Thriene et al. 1996), and 
the eyes (Longley and Jones 1966; Petersen and Sabroe 1991; Stokholm et al. 1982).  The skin irritation 
has been associated with fibers of diameter >5 µm and often becomes less pronounced with continued 
exposure (ACGIH 2001; Heisel and Hunt 1968; Stam Westerveld et al. 1994).   
The available human data adequately identify reversible skin irritation as a concern from acute dermal 
exposure. The data support occupational health and public health recommendations to limit dermal 
contact and airborne exposure by limiting the generation of dusts from materials containing synthetic 
vitreous fibers and by wearing loose protective clothing, gloves, and ocular and respiratory protection 
when handling the material.  
Acute inhalation studies in animals are limited to rodent studies with RCF1 that observed pulmonary and 
pleural inflammation (Everitt et al. 1994; Gelzleichter et al. 1996a, 1996c).  Other studies have observed 
nonneoplastic and neoplastic health effects caused by injection or implantation (e.g., single acute dosing) 
of synthetic vitreous fibers into the intraperitioneal or intrapleural cavities of animals (Adachi et al. 1991;
Davis et al. 1984; Feron et al. 1985; Mohr et al. 1984; Pickrell et al. 1983; Pigott and Ishmael 1981; Pott 
et al. 1987; Renne et al. 1985; Smith et al. 1987; Stanton and Wrench 1972; Stanton et al. 1977; Wright 
and Kuschner, 1977). Their relevance to human inhalation exposure is unclear because of the high doses 
and rapid dose rates used, the bypassing of the natural defense systems of the nasal and upper respiratory
system, and the overloading or lack (for intraperitoneal studies) of pulmonary clearance mechanisms.  No 
acute inhalation MRL was derived because data describing dose-response relationships for irritation of 
the upper respiratory tract in humans or animals are not available.   
No acute-duration oral exposure studies in humans or animals were identified.  The oral route of exposure 
is not of public health concern for synthetic vitreous fibers; therefore, no data need is identified.
Intermediate-Duration Exposure.    Epidemiologic studies involving inhalation exposure have 
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factors. In animals, multiple exposure-level experiments were conducted for RCF1, the glass wools 
MMVF10 and MMVF11, the rock wool MMVF21, and the slag wool MMVF22 (Hesterberg et al. 1999;
Mast et al. 1995b; McConnell et al. 1994), but other fiber types were tested only at single (usually high) 
concentrations. The studies were designed as chronic studies, but include interim sacrifice data 
describing dose-response relationships for effects from intermediate-duration inhalation exposure. 
Virtually all of the fibers tested caused reversible pulmonary inflammation, including the refractory
ceramic fibers RCF1, RCF2, RCF3, and RCF4, the insulation glass wools MMVF10 and MMVF11, the 
rock wool MMVF21, the slag wool MMVF22, the durable glass fiber MMVF33, the high-temperature 
rock wool MMVF 34, the high-silica synthetic vitreous fiber X607, the special-purpose 104E-glass fiber, 
GB100R glass wool, and C102/C104 blend fibrous glass (Cullen et al. 2000; Goldstein et al. 1983; 
Haratake et al. 1995; Hesterberg et al. 1993c, 1998b; Kamstrup et al. 2001; Mast et al. 1995a, 1995b; 
McConnell et al. 1994, 1999). Only one study reported a NOAEL, for Code 104 glass wool (Muhle et al. 
1987). 
Interstitial or pleural fibrosis was seen in rodents exposed to the refractory ceramic fibers RCF1, RCF2, 
RCF3, and RCF4, the durable glass fiber MMVF33, and the special purpose 104E-glass following 
intermediate-duration exposure (Cullen et al. 2000; Mast et al. 1995a, 1995b; McConnell et al. 1999), but
no increase in fibrosis was seen in animals exposed to MMVF10, MMVF11, MMVF34, or 
X607 (Hesterberg et al. 1993c, 1998b; Kamstrup et al. 2001; McConnell et al. 1999). 
The available animal data adequately identify pulmonary or pleural effects as potential health hazards 
from intermediate-duration inhalation exposure to synthetic vitreous fibers.  The data also provide 
adequate descriptions of dose-response relationships for these effects in rats from samples of glass wools, 
rock wool, slag wool, and refractory ceramic fibers.   
A chronic inhalation MRL was derived for the refractory ceramic fiber, RCF1, based on pulmonary
inflammation in rats as the critical effect (see Section 2.3 and Appendix A).  The MRL derivation used rat 
and human lung deposition and clearance models to extrapolate rat exposure levels to human equivalent 
concentrations and was based on the assumption that the responses in rats would occur in humans at the 
same dose of fibers deposited in the alveolar region of the lung.  The interim sacrifice data from the 
chronic study indicated that dose-response relationships for this effect were similar for chronic and 
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derived, the data indicate that it would be similar to the chronic MRL.  It is expected that the chronic 
MRL can be used reliably to assess effects from intermediate-duration exposures.  Additional data for 
intermediate-duration exposure to RCF1 do not appear to be needed.   
Adequate rat data are also available for intermediate and chronic inhalation exposure to MMVF10, 
MMVF11, MMVF21, and MMVF22.  However, no intermediate or chronic inhalation MRLs were 
derived because of the uncertainty in extrapolating from rats to humans in the absence of human lung 
deposition and clearance models for these synthetic vitreous fibers.  However, when such models are 
available, the rat studies will provide adequate data for deriving intermediate and chronic inhalation 
MRLs for glass wool, rock wool, and slag wool. 
No intermediate-duration oral or dermal exposure studies in humans or animals were identified.  Repeated 
exposure by the oral route is of relatively low concern for the general population; therefore, no data need 
has been identified at this time.  For dermal exposure, the available data demonstrating acute reversible 
skin irritation from direct contact with insulation materials containing synthetic vitreous is adequate to 
support public health recommendations to wear gloves and protective clothing (and other protective 
devices including eye and respiratory protection) when handling materials containing synthetic vitreous 
fibers. No data need has been identified for potential health effects from intermediate-duration dermal 
exposure. 
Chronic-Duration Exposure and Cancer.    The most biologically significant effect found in 
retrospective and longitudinal evaluations of the health of workers involved in the manufacture of 
refractory ceramic fibers in the United States (LeMasters et al. 1994; Lentz et al. 2003; Lockey et al. 
1996, 2002) and Europe (Cowie et al. 2001; Trethowan et al. 1995) is a low prevalence of pleural plaques 
(about 3%). However, consistent statistically significant associations with exposure to refractory ceramic
fibers were only found in the U.S. cohort (Lentz et al. 2003; Lockey et al. 1996, 2002).  Consistent 
exposure-related effects on pulmonary function have not been found in these cohorts (Burge et al. 1995; 
Cowie et al. 2001; Lockey et al. 1998).
Adverse findings in cross-sectional health evaluation studies of workers involved in the manufacture of 
continuous glass fibers, glass wool, or rock and slag wool are restricted to elevated prevalences of self-
reported respiratory symptoms (e.g., coughing, bronchitis) (Albin et al. 1998; Clausen et al. 1993; 
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plaques in these workers is inadequate (Hughes et al. 1993; Kilburn and Warshaw 1991; Kilburn et al. 
1992; Sanden and Jarvholm 1986; Scansetti et al. 1993; Weill et al. 1983).   
Cohort mortality and case-control studies have tracked nonneoplastic and neoplastic causes of mortality
among groups of workers involved in the manufacture of fibrous glass, rock wool, or slag wool without
finding conclusive evidence of increased risks associated with exposure (Bayliss et al. 1976; Bertazzi et 
al. 1986; Boffetta et al. 1999; Buchanich et al. 2001; Chiazze et al. 1992, 1993, 1995, 1997, 2002; 
Enterline and Henderson 1975; Kjaerheim et al. 2001; Marsh et al. 1990, 2001a, 2001b, 2001c; Morgan 
1981; Sali et al. 1999; Saracci et al. 1984; Shannon et al. 1984, 1987, 1990; Simonato et al. 1986a, 1987;
Watkins et al. 1997). Similar cohort mortality or case-control studies of workers involved in the 
manufacture of refractory ceramic fibers are restricted to a mortality study of male workers employed at 
two U.S. manufacturing plants (LeMasters et al. 2003). In an initial report of the mortality experience of 
this cohort (about 90% of which is still alive), the only statistically significant excess mortality was for 
deaths associated with cancer of the urinary system.  No mesotheliomas and no excess deaths associated 
with respiratory cancers or nonmalignant respiratory disease were found.  The excess urinary cancer 
deaths may be a chance finding given the wide confidence interval for the SMR, the large number of 
statistical tests (n=46) that were conducted, and the lack of a plausible mechanistic explanation of how 
fibers may increase the risk for urinary cancer mortality.  Continued monitoring of the mortality 
experience of this cohort is planned.   
In animals, chronic-duration inhalation studies were primarily continuations of intermediate-duration 
studies, with pulmonary inflammation observed for all fibers tested and fibrosis observed for the 
refractory ceramic fibers and MMVF 33 (see Section 3.2).  The special-purpose 104E-glass was not tested 
in a chronic-duration study.  Although C102/C104 blend fibrous glass was not fibrogenic at 8 months, 
pulmonary fibrosis was observed by 18 months (Goldstein et al. 1983).  Pleural mesotheliomas were 
observed in rodents exposed to refractory ceramic fibers (RCF1, RCF2, and RCF3), MMVF33, and
104E-glass (Cullen et al. 2000; Mast et al. 1995a; McConnell et al. 1999; Smith et al. 1987).  Lung tumor 
incidence (adenomas, carcinomas, or the combined incidence) were elevated in rodents exposed to RCF1, 
RCF2, RCF3, RCF4, or 104E-glass (Cullen et al. 2000; Mast et al. 1995a, 1995b; McConnell et al. 1995), 
but not in studies with other synthetic vitreous fibers including MMVF10, MMVF11, MMVF 21, 
MMVF22, MMVF34, Code 104 glass wool, GB100R glass wool, high-silica synthetic vitreous fiber 
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al. 1995; Hesterberg et al. 1993c, 1998b; Kamstrup et al. 2001; Mast et al. 1995a, 1995b; McConnell et 
al. 1994, 1999; Muhle et al. 1987). 
As discussed in the previous section, a chronic inhalation MRL was derived for the refractory ceramic 
fiber, RCF1, based on pulmonary inflammation in rats as the critical effect (see Section 2.3 and 
Appendix A). One area of uncertainty associated with the critical study for the chronic MRL is the 
degree to which the dose-response relationship for pulmonary inflammation is affected by the nonfibrous 
particles in the aerosols to which the rats were exposed.  Nonfibrous particles (with aspect ratios <3:1) 
have been reported to account for about 25% of the mass in RCF1 aerosols (Bellmann et al. 2001).  
Results from 3-week exposure studies with rats suggest that pulmonary responses to RCF1a, a material 
with only 2% of its mass accounted for by nonfibrous particles, are less severe than those induced by
RCF1 at similar exposure levels (Bellmann et al. 2001).  Additional research may be useful to 
quantitatively determine the effect of nonfibrous particles on the dose-response relationship for 
pulmonary inflammation from chronic exposure to refractory ceramic fibers.  
Adequate rat data are also available for intermediate and chronic inhalation exposure to the glass wools, 
MMVF10 and MMVF11, a rock wool, MMVF21, and a slag wool, MMVF22.  However, no intermediate 
or chronic inhalation MRLs were derived because of the uncertainty in extrapolating from rats to humans 
in the absence of human lung deposition and clearance models for these synthetic vitreous fibers.  When 
such models are available, the rat studies will provide adequate data for deriving intermediate and chronic 
inhalation MRLs for glass wool, rock wool, and slag wool. 
Workers involved in the installation or removal of insulation materials with synthetic vitreous fibers are 
expected to be exposed to higher airborne levels of fibers than manufacturing workers, but research that 
monitored health status and mortality patterns in groups of these types of workers is limited.  Additional 
longitudinal monitoring of the respiratory health of insulation workers (and their exposure conditions) 
may be helpful in a better assessment of the health safety of their work environment. 
No chronic-duration oral or dermal exposure studies in humans or animals were identified, although 
experimental studies with human subjects, case reports, and occupational exposure experience document 
the well-known acute, but reversible, skin irritation caused by direct dermal contact with insulation glass 
wools. Repeated exposure by these routes is not of high concern for the general public; therefore, no data 
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by oral exposure to fibrous materials, results from several studies of rats exposed for life to several types 
of asbestos found no convincing evidenc for nonmalignant disease in the exposed rats (Agency for Toxic 
Substances and Disease Registry 2001). 
Genotoxicity.    No evidence for genotoxic activity of several synthetic vitreous fibers was found in 
bacterial mutation assays (Chamberlain and Tarmy 1977) or sister chromatid exchange assays in cultured 
human cells (Casey 1983).  However, cytogenetic effects induced by synthetic vitreous fibers in 
mammalian cells in vitro include chromosomal aberrations (Brown et al. 1979a, 1979b); morphological 
transformations (Gao et al. 1995; Hesterberg and Barrett 1984; Hesterberg et al. 1985; Oshimura et al. 
1984; Whong et al. 1999); micronuclei and multinuclei (Dopp and Schiffmann 1998; Dopp et al. 1997;
Hart et al. 1992; Ong et al. 1997; Peraud and Riebe-Imre 1994; Zhong et al. 1997); polyploidy (Koshi et 
al. 1991; Sincock et al. 1982); and DNA strand breaks and DNA-DNA interstrand crosslinks (Wang et al. 
1999b). In addition, several synthetic vitreous fiber types have been demonstrated to damage isolated 
DNA (Donaldson et al. 1995c) and to hydroxylate 2-deoxyguanosine to 8-hydroxydeoxyguanosine, 
presumably via hydroxyl radicals (Leanderson et al. 1988, 1989). 
There is evidence that fiber dimensions can influence in vitro cytogenetic activities (Hesterberg and 
Barrett 1984; Hesterberg et al. 1985; Ong et al. 1997) and that synthetic vitreous fibers are often less 
genotoxically active than asbestos fibers (e.g., Donaldson et al. 1995c; Janssen et al. 1994a; Leanderson et 
al. 1988, 1989; Peraud and Rieve-Imre 1994; Wang et al. 1999b).  For example, thin glass fibers 
(diameters 0.1–0.2 µm, lengths >10 µm) were very active in transforming Syrian hamster embryo cells, 
whereas thick glass fibers (diameter about 0.8 µm) were much less potent (Hesterberg and Barrett 1984).  
Milling of the thin glass fibers to reduce the length to <1 µm diminished the transforming activity. 
The available evidence is sufficient to suggest that synthetic vitreous fibers may produce cytogenetic 
changes in in vitro systems, but data regarding in vivo genotoxicity is lacking.  In vivo data may be 
helpful to further assess the genotoxic potential of synthetic vitreous fibers. 
Reproductive Toxicity.    There are no studies in humans or animals on the potential for synthetic 
vitreous fibers to produce reproductive effects.  Given the limited degree to which synthetic vitreous 
fibers are absorbed into the body, there is no mechanistic basis to suspect that reproductive effects may be 
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Developmental Toxicity.    There are no studies in humans or animals on the potential for synthetic 
vitreous fibers to produce developmentally toxic effects.  As with reproductive toxicity, there is no 
empirical or mechanistic basis to suspect that developmental effects may be of concern from exposure to 
synthetic vitreous fibers.  No data needs have been identified at this time. 
Immunotoxicity.    There are no studies in humans or animals specifically designed to examine the 
potential for synthetic vitreous fibers to affect the immunological or lymphoreticular systems following 
inhalation, oral, or dermal exposures.  There are several reports of immune system depression in asbestos-
exposed workers who developed asbestosis or cancer (see Agency for Toxic Substance and Disease 
Registry 2001), but whether or not the depression was directly caused by asbestos or by the diseased state
is unknown. Given the lack of increased reporting of symptoms of allergy or immune system depression 
in health surveillance studies of workers involved in the manufacture of refractory ceramic fibers or 
insulation wools (Clausen et al. 1993; Cowie et al. 2001; Ernst et al. 1987; Gross 1976; Hansen et al. 
1999; Hill et al. 1973; Hughes et al. 1993; Kilburn et al. 1992; LeMasters et al. 1998; Lockey et al. 1998; 
Moulin et al. 1988; Nasr et al. 1971; Sanden and Jarvholm 1986; Trethowan et al. 1995; Weill et al. 1983; 
Wright 1968), immunological effects do not appear to be a critical public health concern from exposure to 
synthetic vitreous fibers.  No data needs have been identified at this time. 
Neurotoxicity.    There are no studies in humans or animals on the potential for synthetic vitreous fibers 
to produce neurotoxic effects.  As with reproductive and developmental toxicity, there is no empirical or 
mechanistic basis to suspect that neurotoxic effects may be of concern from exposure to synthetic vitreous 
fibers. No data needs have been identified at this time. 
Epidemiological and Human Dosimetry Studies.    Studies of workers predominately involved in 
the manufacture of fibrous glass materials have focused on the prevalence of respiratory symptoms 
through the administration of questionnaires, pulmonary function testing, and chest x-ray examinations 
(Clausen et al. 1993; Gross 1976; Hill et al. 1973; Hughes et al. 1993; Nasr et al. 1971; Weill et al. 1983; 
Wright 1968).  In general, these studies reported no consistent evidence for increased prevalence of 
adverse respiratory symptoms, abnormal pulmonary functions, or chest x-ray abnormalities; however, one 
study reported altered pulmonary function (decreased forced expiratory volume in 1 second) in a group of
Danish insulation workers compared with a group of bus drivers (Clausen et al. 1993).  Longitudinal 
health evaluations of workers involved in the manufacture of refractory ceramic fibers, fibrous glass, rock 
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pulmonary functions, with the exception that pleural plaques were found in about 3% of examined U.S. 
refractory ceramic fiber manufacturing workers and that pleural plaque prevalence showed statistically
significant trends with increasing exposure categories (LeMasters et al. 1994; Lentz et al. 2003; Lockey et 
al. 1996, 2002).   
Epidemiologic studies (cohort mortality and case-control studies) of causes of mortality among groups of 
workers involved in the manufacture of fibrous glass, rock wool, or slag wool provide no consistent 
evidence for increased risks of mortality from nonmalignant respiratory disease, lung cancer, or pleural 
mesothelioma (Bayliss et al. 1976; Bertazzi et al. 1986; Boffetta et al. 1999; Buchanich et al. 2001;
Chiazze et al. 1992, 1993, 1995, 1997, 2002; Enterline and Henderson 1975; Kjaerheim et al. 2002; 
Marsh et al. 1990, 2001a, 2001b, 2001c; Morgan 1981; Sali et al. 1999; Saracci et al. 1984; Shannon et al. 
1984, 1987, 1990; Simonato et al. 1986a, 1987; Watkins et al. 1997).  In an initial report of the only
available cohort mortality study of refractory ceramic fiber workers, the only statistically significant 
excess mortality was for deaths associated with cancer of the urinary system (LeMasters et al. 2003).  No 
mesotheliomas and no excess deaths associated with respiratory cancers or nonmalignant respiratory
disease were found.  Continued monitoring of the mortality experience of this cohort is planned. 
As discussed in the “Chronic-Duration Exposure and Cancer” section, workers involved in the installation 
or removal of insulation materials with synthetic vitreous fibers are expected to be exposed to higher 
airborne levels of fibers than manufacturing workers, but monitoring of the health status and mortality
patterns in groups of these types of workers is limited.  Additional longitudinal monitoring of the 
respiratory health of groups of insulation workers (and their exposure conditions) may be helpful in a 
better assessment of the health safety of their work environment. 
Biomarkers of Exposure and Effect.     
Exposure. The most pertinent parameter for measuring exposure to synthetic vitreous fibers would be 
retained or deposited dose of fibers in the lung, a biomarker that is invasive and impossible to determine 
without autopsy or resection.  The detection and chemical identification of fibers in bronchoalveolar 
lavage or sputum samples has been proposed as less invasive biomarkers of exposure to asbestos (Agency
for Toxic Substances and Disease Registry 2001) and synthetic vitreous fibers (Dumortier et al. 2001), 
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development of noninvasive biomarkers of exposure may be useful to monitor workers exposed to dusty
working conditions when installing or removing materials containing synthetic vitreous fibers.  
Effect. No specific and sensitive biomarkers of disease induced by synthetic vitreous fibers are known.  
The chest x-ray represents the most widely used method to detect nonneoplastic and neoplastic lesions in 
the lung or pleura that may occur (as indicated by animal experiments) after long-term exposure to 
synthetic vitreous fibers (American Thoracic Society 1986).  However, the chest x-ray would detect 
changes only after significant injury has occurred and would not indicate directly whether or not the 
changes were caused by synthetic vitreous fibers or some other lung toxicant such as cigarette smoke or 
asbestos. Computerized tomography has shown some promise for detecting early asbestos-related effects 
such as pleural plaques or thickening (Agency for Toxic Substances and Disease Registry 2001), and may
be useful to monitor the health of workers repeatedly exposed to high levels of airborne synthetic vitreous 
fibers. Tests of lung function also detect relatively early signs of effects from lung toxicants, but provide 
only limited information regarding the possible cause.  Given the evidence that pulmonary or pleural 
effects are not expected at airborne concentrations below current recommendations for occupational 
exposure limits (1 fiber/cc for insulation wools and 0.2 fiber/cc for refractory ceramic fibers; ACGIH 
2001), current methods to monitor possible effects from synthetic vitreous fibers appear adequate, albeit 
lacking in specificity (i.e., chest x-ray, lung function tests, and computerized tomography).  No data needs 
have been identified at this time.  
Absorption, Distribution, Metabolism, and Excretion.  As discussed in Section 3.4, rates of 
absorption of synthetic vitreous fibers across the epithelial layers of the respiratory tract, the 
gastrointestinal tract, and the skin are expected to be negligible given the relatively large physical 
dimensions of these elongated particles. The toxicokinetic variables of greatest relevance to the exposure 
route of greatest public health concern (inhalation) are:  the extent and location of fiber deposition in the 
respiratory tract; the rates of deposited fiber removal by mucociliary transport, macrophage-mediated 
engulfment and clearance, and dissolution in lung fluid; and the translocation of fibers within and across 
the lung. These variables are of toxicological interest because fibers can accumulate in the lung leading 
to chronic and persistent pulmonary inflammation and, for the more durable synthetic vitreous fibers, 
tissue damage when rates of fiber deposition exceed rates of removal.  For a variety of synthetic vitreous 
fibers and some amphibole fibers (which do not undergo dissolution in lung fluid), correlations have been 
demonstrated between the ability to induce pulmonary or pleural inflammation or tissue damage and 
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fiber lung clearance half-times (Bernstein et al. 2001a, 2001b; Eastes and Hadley 1996; Eastes et al. 2000; 
Hesterberg et al. 1998a).   
For several types of synthetic vitreous fibers, these processes have been well studied in animals, but not 
directly in human subjects.  The animal study results provide enough information to support the 
development of models that predict lung deposition and retention of inhaled refractory ceramic fibers and 
other synthetic vitreous fibers (glass wools and rock wools) in rats (Yu et al. 1994, 1995b, 1996, 1998a, 
1998b).  Good agreement has been observed between model predictions and observed concentrations of 
fibers in the lungs of rats exposed to aerosols of refractory ceramic fibers or insulation wools for 
intermediate or chronic durations.  Models to predict the deposition and retention of inhaled refractory
ceramic fibers in humans have been developed based on known anatomical and physiological differences 
between rats and humans (Yu et al. 1995a, 1997).  In the only testing of the human model, it was used to 
predict exposure concentrations from autopsied lung concentration data for three refractory ceramic fiber 
manufacturing workers (Yu et al. 1997).  The predicted exposure concentrations were within the range of 
air concentrations measured for some manufacturing plants.   
Models for lung retention and clearance of other synthetic vitreous fibers have not been developed.  
Development of human models for insulation wools will decrease uncertainty in extrapolating from
chronic inhalation data for pulmonary inflammation in rats and facilitate the derivation of intermediate- 
and chronic-duration inhalation MRLs for these materials.  Additional research to compare predictions 
from the human models with lung concentration data for human subjects with known exposures may help 
to decrease uncertainty in the validity of the model predictions.   
The lung deposition and retention models incorporate information from the animal studies that the 
fraction of inhaled synthetic vitreous fibers deposited on the epithelial surfaces of the respiratory tract and 
the region where deposition occurs are determined by fiber dimensions, fiber mass density, ventilation 
parameters, and the structure and airway size of the respiratory tract (Dai and Yu 1998; Lippmann 1990; 
Morgan 1995; Yu et al. 1995a).  Fibers with aerodynamic diameters >3–5 µm are predominately
deposited in the upper airways and do not travel to the lower lung where gas exchange occurs.  Fibers 
deposited in the upper airways are quickly removed by mucociliary transport to the pharynx and 
swallowing. The models also incorporate information from animal studies illustrating the following 
features of clearance of synthetic vitreous fibers from the lower lung:  (1) fibers are cleared from the 
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of macrophages are poorly engulfed and cleared (i.e., shorter fibers are more rapidly cleared than longer 
fibers); (3) macrophage-mediated clearance is dependent on lung burden of particles (the rate of clearance 
slows at high lung burdens); (4) dissolution of synthetic vitreous fibers occurs in lung fluid (the
dissolution rate varies with fibers of varying chemical composition); and (5) partially dissolved fibers 
more readily break into shorter fibers.  The models do not describe translocation of deposited fibers from
the lower lung into pleural tissue or the lymphatic system, although there is evidence from animal studies 
that small numbers of short and thin fibers are rapidly translocated to pleural tissues (Everitt et al. 1997; 
Gelzleichter et al. 1996a, 1999) and that translocation to lymph nodes can be considerable only under 
conditions that overload macrophage-mediated clearance mechanisms (Lee et al. 1981a; Morgan et al. 
1982). Additional research on the extent and rate of translocation of fibers into pleural tissue, and 
conditions governing this process, may be useful in providing more a specific description of the target 
organ dose-response relationship for pleural effects (pleural fibrosis and mesothelioma) observed in rats 
exposed to the most durable of synthetic vitreous fibers, refractory ceramic fibers. 
There are no toxicokinetic studies in humans or animals following oral or dermal exposure.  Absorption 
and retention in the gastrointestinal tract and the skin are expected to be negligible.  No data needs are 
identified at this time for toxicokinetic data for these routes of exposure.  
Comparative Toxicokinetics.    As discussed in Sections 3.4 and 3.5.3, differences in respiratory tract 
size and geometry, ventilation rates and patterns, and macrophage size between animal species and 
humans are expected to influence the retention of synthetic vitreous fibers in the lung.  Lung deposition 
and clearance models that incorporate many of these interspecies differences have been developed for 
refractory ceramic fibers in rats, hamsters, and humans (Dai and Yu 1998; Yu et al. 1994, 1995a, 1995b, 
1996, 1997).  The models assume that dissolution rates, as well as transverse breakage rates and patterns 
(i.e., breakage of long fibers into shorter ones), are the same in animals and humans.  The models predict 
that for refractory ceramic fiber size ranges and concentrations encountered in workplaces, (1) mouth-
breathing leads to higher fractional deposition of inhaled fibers than nose-breathing in humans; 
(2) fractional deposition of inhaled fibers is less in rats and hamsters than in nose-breathing humans; 
(3) humans have 1–2.5 times less deposited fiber per unit alveolar surface area than rats and hamster; and 
(4) size dimensions (length and width) of fibers deposited in human lungs are larger than those of fibers 
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The rat model has been extended to other synthetic vitreous fibers (i.e., several types of insulation wools), 
but, to date, the human model has not.  As discussed in the previous section, development of human 
models for insulation wools will decrease uncertainty in extrapolating from chronic inhalation data for 
pulmonary inflammation in rats and facilitate in the derivation of intermediate- and chronic-duration 
inhalation MRLs for these materials. 
There are no comparative toxicokinetic studies in humans or animals following oral or dermal exposure.  
Absorption and retention in the gastrointestinal tract and the skin are expected to be negligible in animals 
and humans.  No data needs are identified at this time for comparative toxicokinetic data for these routes 
of exposure. 
Methods for Reducing Toxic Effects.    Information specific to synthetic vitreous fibers regarding 
treatment of acute irritation effects or possible chronic effects from exposure or reduction of body
burdens have not been identified, although minimizing exposure, wearing protective clothing, and rinsing 
of exposed areas (e.g., skin and eyes) with water are recommended (Ellenhorn et al. 1997; Goldfrank et 
al. 1998; Jeffress 1999; Mentzer 1999; OSHA 1999).  
As discussed in Section 3.5.1, the dose of fibers retained in the lower lung is a key determinant of the 
potential for fibers to induce toxic effects such as pulmonary inflammation, pulmonary fibrosis, lung 
cancer, or mesothelioma.  Lung retention of fibers is the net result of lung deposition and clearance 
mechanisms including direct mucociliary clearance, macrophage-mediated clearance, dissolution rates, 
and transverse breakage of long fibers into shorter fibers.  Once fibers are inhaled and deposited in the 
lung, there are no known treatment options to enhance the natural clearance mechanisms and reduce body 
burden after exposure. Additional research on physiological and molecular details of clearance 
mechanisms and mechanisms governing translocation into pleural tissue may provide clues for 
developing treatments to enhance clearance of the more biopersistent synthetic vitreous fibers from the 
lower lung and pleural tissue. 
Observed correlations between toxic potencies and dissolution rates for various types of vitreous and 
mineral fibers indicate that the dissolution of fibers in lung fluid is a key determinant of potential toxicity
that is influenced by chemical composition and structure and manufacturing processes (Bernstein et al. 
2001a, 2001b; Eastes and Hadley 1996; Eastes et al. 2000; Hesterberg et al. 1998a; Hesterberg and Hart 
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biopersistent holds promise as a method to avert or decrease the potential for producing toxic effects.  For 
example, vitreous fibers with relatively high alumina and silica contents have been shown to favor a 
relatively uniform, slower rate of dissolution, but increasing content of oxides of calcium, magnesium, 
and potassium can lead to nonuniform rates of dissolution, faster breakage, and faster clearance (Eastes et 
al. 2000; Hesterberg and Hart 2001; Morgan 1994b; Potter and Mattson 1991).  
As briefly discussed in Section 3.5.2, cellular and molecular events involved in fiber-induced 
nonneoplastic and neoplastic effect are poorly understood, but mechanistic studies (predominately with 
asbestos fibers) indicate that fibers retained in lung or pleural tissue may lead to cytotoxic and 
cytoproliferative changes as a result of increased production of reactive oxygen species that can damage
cellular macromolecules, lead to cytotoxicity, and stimulate the release of inflammatory mediators, 
cytokines, and growth hormones (Churg et al. 2000; Driscoll 1996; IARC Expert Panel 1996).  Several 
other mechanisms also have been proposed.  Additional research on mechanisms of fiber-induced toxicity
may eventually lead to the development of therapeutic approaches for reducing toxic effects from the 
biopersistent synthetic vitreous fibers or more efficient screening methods to evaluate the potential 
toxicities of newly developed synthetic vitreous fibers. 
Children’s Susceptibility.    No information was located specifically concerning health effects in 
children exposed to synthetic vitreous fibers, and no studies were located that have compared immature
and mature animals with respect to pharmacokinetics of, or susceptibility to, inorganic fibers of any type 
(including asbestos) by any route of exposure. There is no indication from the available literature that the 
pulmonary clearance mechanism might be less active or underdeveloped in children relative to adults.  
Direct effects on the developing fetus are not expected given the low absorption of synthetic vitreous 
fibers by the lung, gastrointestinal tract, and skin. Thus, there does not appear to be a need to conduct 
developmental toxicity tests for synthetic vitreous fibers.  Additional research comparing pulmonary and 
pleural responses of immature and mature animals to the more biopersistent synthetic vitreous fibers may
provide relevant information regarding the relative susceptibility of adults and children to the potential 
toxicity of synthetic vitreous fibers.  Such experiments may be difficult to perform with immature 
animals, however, given the stress experienced by animals when they are fitted with nose-only inhalation 
apparatus (McConnell 1999).   
Child health data needs relating to exposure are discussed in Section 6.8.1 Identification of Data Needs:  
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3.12.3 Ongoing Studies 
Ongoing studies funded solely by the U.S. government have not been identified.  Other organizations 
have funded several large ongoing epidemiological studies of synthetic vitreous fiber manufacturing 
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4.1 CHEMICAL IDENTITY 
Synthetic vitreous fibers are inorganic substances, largely composed of aluminum and calcium silicates 
that are derived from rock, clay, slag, or glass (IARC 1988, 2002).  While naturally occurring mineral 
fibers such as asbestos are crystalline in structure, synthetic vitreous fibers are amorphous materials.  
There are several methods of categorizing synthetic vitreous fibers based either on origin, chemical 
structure, morphology, application, or method of manufacturing.  The most recent classification scheme 
proposed by the International Agency for Research on Cancer (IARC) has divided these compounds into 
two broad classes: filaments and wools.  The filaments contain continuous glass filaments, while the 
wools contain glass wool, rock (stone) wool, slag wool, refractory ceramic fibers, and other newly
engineered biosoluble fibers (IARC 2002).  Glass wools are further subdivided into insulation wools and 
special purpose wools (see Figure 2-1). Continuous filament products are produced by drawing or 
spinning the molten mix from nozzles, while the wools are manufactured with a rotary or centrifugal 
process without using a nozzle (see Chapter 5 for details).  Generally, the wool fibers tend to be shorter 
and finer than the continuous filament fibers, and their diameters may be more variable (IARC 1988).
The typical chemical composition of these types of synthetic vitreous fibers is represented in Table 4-1.  
Special purpose glass fibers are sometimes used in high technology industries and have very specific 
properties that are tailored to their specific use. Although the procedures used to make these fibers are 
similar to those of glass wool, the operating parameters are usually adjusted to create products with 
extremely small diameters.  One example of a special purpose glass fiber is included in Table 4-1. 
Fibrous glass products are derived from powdered sand and largely consist of silicon and aluminum
oxides. The final properties of the glass are dictated by the percent composition of other oxides including 
alkali metal oxides, alkaline earth oxides, and metal oxides like ZrO2 and Fe2O3. Glass, like other 
insulating materials, provides a high resistance to the passage of electricity.  Electrical glass (E-glass) is a 
continuous filament type of fibrous glass developed for electrical applications that has excellent heat and 
water resistance (IARC 1988, 2002).  The high resistivity of E-glass is related to its low alkali oxide 
content. The majority of continuous filament fibrous glass produced is E-glass (IARC 1988, 2002).  
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Table 4-1. Chemical Identity of Some Types of Synthetic Vitreous Fibersa,b 
Rock wool Rock wool from Special 
Percent from basalt basalt and other Slag wool purpose glass 
com- E- S- AR- Glass melted in a material melted melted in RCF fiber 475 
position Glass Glass Glass wool furnace in a cupola a cupola RCF kaolin zirconia formulationc 
SiO2 52–56 65 60.7 55–70 45–48 41–53 38–52 49.5–53.5 47.5–50 57–58 
Al2O3 12–16 25 0–7 12–13.5 6–14 5–15 43.5–47 35–36 5–6 
B2O3 5–10   3–12 10–11 
K2O 0–2 2 0–2.5 0.8–2 0.5–2 0.3–2 <0.01 <0.01 2–3 
Na2O 0–2   13–18 2.5–3.3 1.1–3.5 0–1 0.5 <0.3 10–11 
MgO 0–5 10 0–5 8–10 6–16 4–14 <0.1 0.01 0–0.5 
CaO 16–25   5–13 10–12 10–25 20–43 <0.1 <0.05 2–3 
TiO2 0–1.5 0–0.5 2.5–3 0.9–3.5 0.3–1 2 0.04 0–0.1 
Fe2O3 0–0.8 0.1–0.5 1 <0.05 0–0.1 
FeO 11–12 3–8 0–2 
Li2O 1.3 0–0.5 
SO3  0–0.5 
S 0–0.2 0–0.2 0–2 
F2 0–1 0–1.5 
BaO 0–3 5 
ZrO2 21.5 0.1 15–17 
P2O5 0–0.5 
Cr2O3 <0.03 <0.01 
ZnO 4
aNavy Environmental Health Center 1997; TIMA 1993 

bAs is standard practice, the chemical composition of the elements are reported as oxides, even though no such individual crystals 

exist in the fibers. 

cThere are several formulations applicable to this category and formulation 475 is generally representative. 

AR-glass = alkali resistant glass; E-glass = electrical glass (so called because the low alkali oxide content makes it useful for 
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chemical composition of the glass can result in significant changes to its optical, electrical, chemical, and 
mechanical properties.  Chemical glass (C-glass) is highly resistant to attack by chemicals such as 
hydrofluoric acid, concentrated phosphoric acid (when hot), and superheated water.  The chemical 
resistance is determined by the relative amounts of the acidic oxides (SiO2, B2O3), basic oxides (CaO, 
MgO, Na2O, K2O), and amphoteric oxides (Al2O3). High-strength glass (S-glass) is almost completely
composed of aluminum, silicon, and magnesium oxides and finds use in sophisticated high technology
applications where high tensile strength is required; its tensile strength is typically 30–40% greater than 
E-glass. Alkali resistant glass (AR-glass) contains a high percentage of zirconium oxide, which makes 
this type of glass highly resistant to acidic and alkaline compounds. 
The term mineral wool is often used to collectively refer to rock wool and slag wool, although 
occasionally, glass wool was included in this category.  Similar to other glass fibers, the chemical 
composition of rock wool and slag wool are primarily aluminum and silicon oxides.  However, these 
wools possess a higher alkaline earth oxide content (MgO and CaO) and lower alkali metal oxide content 
(Na2O and K2O) than glass wool. Rock wool is derived from igneous rocks such as diabase, basalt, or 
olivine, while slag wool is derived from blast furnace slag from the steel industry (Navy Environmental 
Health Center 1997).  
Refractory ceramic fibers are a specialized type of synthetic vitreous fiber that are highly heat resistant 
and thus find use in high-temperature applications.  Refractory ceramic fibers contain a much higher 
concentration of alumina than the other fibers listed in Table 4-1 and are sometimes referred to as 
aluminosilicate glasses.  Although refractory ceramic fibers are amorphous at low temperatures, they
undergo partial crystallization (devitrification) to quartz, cristobalite, or tridymite at elevated temperatures 
(Maxim et al. 1999b). 
4.2 PHYSICAL AND CHEMICAL PROPERTIES 
The important physical properties that are pertinent for organic compounds are generally not applicable to 
inorganic materials like fibrous glass.  Properties such as vapor pressure, Henry’s law constant, and 
octanol/water partition coefficient are exceedingly low and not measurable.  Even properties like melting 
point are difficult to define since fibrous glass products are amorphous and do not experience a distinct 
melting point as crystalline materials do, but soften over a fairly broad temperature range.  The term
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when discussing synthetic vitreous fibers.  It represents the temperature at which plastic flow becomes 
viscous flow, and is specifically defined as the temperature at which the viscosity of the partial molten 
glass is 107.6 poise (TIMA 1993).  Since synthetic vitreous fibers are often used in textile products as a 
reinforcing material, the softening point is an important physical property.  Some physical properties of 
the synthetic vitreous fibers listed in Table 4-1 are shown in Table 4-2.  Since the final products within 
each class of fibers can be varied according to manufacturing specifications, the values listed in Table 4-2 
should only be considered representative of the properties for each class in a very general sense.  
Synthetic vitreous fibers are not actually soluble in water, but the term dissolution is often used to 
describe the durability of synthetic vitreous fibers, especially as it pertains to biological fluid.  This 
should not be confused with solubility, which is the amount of material that dissolves in solution before it 
reaches chemical equilibrium.  The dissolution rate is the rate at which a fiber reacts with a solution and is 
degraded in it.  Under alkaline and acidic conditions, the silicate network of synthetic vitreous fibers can 
be attacked, resulting in the leaching of individual ions and the eventual disruption of the entire fiber 
network. Due to the larger surface area, fine fibers have greater dissolution rates than course fibers (see 
Section 3.4 for details).   
Because the toxicity of fibers is related to their physical dimensions, it is important to characterize the 
size of synthetic vitreous fibers.  In a typical glass fiber product, the average length is usually on the order 
of several centimeters, but the average diameter is usually on the order of a few microns.  The nominal 
diameter is defined as the average fiber diameter in the finished product and varies according to fiber 
type, use, and manufacturing process involved (ACGIH 2001).  The diameters of airborne fibers are an 
important physical property from a biological standpoint because thin fibers are considered respirable and 
may be deposited in the peripheral lung airways.  Airborne fibers with diameters <3 µm are generally
considered respirable in humans.  There is also a strong correlation between the fiber diameter and the 
airborne fiber levels found in workplaces (Esmen and Erdal 1990; Esmen et al. 1979a, 1979b).  Generally, 
the greater the fiber diameter, the lower the airborne fiber concentration.  The nominal fiber diameter of 
continuous filament fibrous glass is usually in the range of 3–25 µm, depending upon the application, 
with typical diameters in the range of 6–15 µm (Navy Environmental Health Center 1997).  The method 
of producing continuous filament fibers allows for excellent control of the preset fiber diameter and as a 
result, there is little variation in range of diameters for the resulting product.  The production of rock 
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Table 4-2. Physical Properties of Some Types of Synthetic Vitreous Fibersa 












glass fiber 475 
formulationb 
Molecular N/A N/A N/A N/A N/A N/A N/A N/A 
weight 
Density (g/cm3) 2.60– 2.5 2.52 2.40– 2.7–2.9 2.7–2.9 2.6–2.7 2.4 
2.65 2.55 
Softening point 835– 970 680 650– No data No data 1,740–1,800 650 
°C 860 700 
Dielectric 5.8–6.4c 4.9–5.3c No No data No data No data No data No data 
constant at data 
1 MHz 
Modulus of 70–75 85 70–75 55–62 55–62 48–76 76–100d No data 
elasticity (GPa) 
Refractive 1.55– 1.52 1.525 1.51– 1.6–1.8 1.6–1.8 1.55–1.57 1.53 
index 1.57 1.54 
Tensile 
strength (MPa) 





aAll data derived from TIMA 1993 unless otherwise noted.   

bThere are several formulations applicable to this category and formulation 475 is generally representative. 

cFitzer et al. 1988 

dNavy Environmental Health Center 1997
 
eThere are various commercial products of boron or silicon carbide filaments or yarns with high tensile strength, but 

these are crystalline fibers and technically not synthetic vitreous fibers. 
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diameters in the range of about 3–7 µm for rock wool and slag wool and 3–15 µm for ordinary glass wool 
(Navy Environmental Health Center 1997).  The smaller diameters of these fibers in comparison to 
continuous filament fibers, allows for the possibility that a small fraction of these fibers may be respirable 
when they become airborne.  Special purpose glass fibers are produced by a flame attenuation process 
whereby the hot, molten glass is poured in front of a high temperature gas flame, resulting in fibers with a 
mean diameter of <3 µm and very often <1 µm.  Refractory ceramic fibers (RCFs) are produced by
melting and spinning or blowing of calcinated kaolin, aluminum silicates and metallic oxide blends, and 
high purity aluminum silicate.  The typical fiber diameter of RCFs is 1–5 µm.   
Christensen et al. (1993) employed light microscopy (LM) and scanning electron microscopy (SEM) to 
measure the length-weighted diameters of 22 synthetic vitreous fiber products obtained from 11 different 
manufacturers.  In this study, nine different glass wool products, nine rock wool or slag wool products, 
three refractory ceramics, and a single special purpose glass fiber were analyzed.  The results of this study
are summarized in Table 4-3.  
The results of a recent comprehensive workplace monitoring study using transmission electron 
microscopy (TEM) was reported by Mast et al. (2000), which characterized the airborne fiber dimensions 
of refractory ceramic fibers.  Measurements of 3,357 fibers obtained at 98 workplaces yielded an airborne 
diameter range of 0.067–4.0 µm.  The arithmetic mean and standard deviation were reported as 1.05 µm
and 0.64 µm, respectively, while the geometric mean and standard deviation were reported as 0.84 µm
and 2.05 (the geometric standard deviation is unitless), respectively (Mast et al. 2000).  Fiber lengths 
ranged from 0.6 to 138 µm, with an arithmetic mean length and standard deviation of 20.6 µm and 
19.3 µm, respectively.  The geometric mean length and geometric standard deviation were reported as 
14.1 µm and 2.48, respectively.  The size distributions of airborne synthetic vitreous fibers at different 
locations under a variety of occupational settings were summarized in the most recent IARC monograph 
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Table 4-3. Measured Diameters of Glass Wool, Rock Wool, Slag Wool, Refractory
 















diameter range (µm) 
SEM 
Glass wool 
9 2.4–8.1 1.7–6.6 1.2–7.7 0.8–6.3 
Special purpose glass fiberb 
1 Not applicableb
Mineral wool 
 Not applicableb 0.6 0.4 
9 2.5–4.7 1.7–3.3 2.4–5.3 1.7–4.0 
Refractory ceramic fibers
3 2.3–3.9 1.5–2.8 2.4–3.8 1.7–2.8 
aData obtained from Christensen et al. (1993); for all samples, between 400 and 490 individual fibers were
 
measured in order to derive the statistical quantities presented in the table.

bA single special purpose glass wool fiber was studied with a diameter too small to be accurately measured by LM. 
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GM diameter GSD GM length GSD Length-diameter 
SVF product or setting (µm) diameter (µm) length correlation 
Rock wool production 0.3–0.5 1.9–2.7 7.0–9.0 2.2–3.0 0.4–0.6 
Rock wool use 1.2 2.7 22 4.0 0.7 
Glass wool use 0.75 2.8 16 3.5 0.7 
Glass wool use 0.8–1.9 1.4–1.9 9.5–30 1.4–2.5 0.2–0.7 
Rock wool use 1.6–1.9 1.6–1.9 19 1.7–2.7 0.4–0.6 
Glass wool house 0.91–1.2 1.7–1.8 9.2–9.3 2.3–2.5 No data 
prefabrication
Rock wool house prefabrication 1.3–1.7 1.9 12–17 2.5–2.8 No data 
Installation of SVF batts 0.9–1.3 2.2 22–37 2.8–2.9 0.5–0.6 
Installation of loose SVF with 1.0–2.0 1.8–2.2 30–50 2.3–2.6 0.4–0.6 
binder 
Installation of loose SVF 0.60 1.9 14–15 2.4–2.6 0.5–0.6 
without binder
RCF production and use 0.84 2.05 14.1 2.5 0.4 
RCF factory 0.96–1.2 1.7–1.9 12–19 2.4–2.6 No data 
RCF factory 0.86 1.9–2.0 11–13 2.4–2.6 No data 
aIARC 2002 
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5.1 PRODUCTION  
Synthetic vitreous fibers are unlike common minerals because they are amorphous and do not occur 
naturally in the environment.  Fibrous glass and glass wool are made by melting sand in combination with 
other oxides such as lime or soda without crystallizing them.  Rock wool is derived from igneous rock 
containing high levels of calcium, while slag wool is produced from the by-products of metal smelting.  
Although rock wool and slag wool were being produced in Europe in the mid to late 19th century, it was 
not until after World War I that its production within the United States became significant (IARC 1988).  
In 1928, there were 8 manufacturing plants in the United States that produced rock wool or slag wool, by
1939, the number had grown to 25, and in 1985, there were 58 facilities in the United States producing 
fibrous glass, mineral wool, and refractory ceramics (IARC 1988).  
Historical U.S. production volumes for synthetic vitreous fibers are shown in Tables 5-1 and 5-2.  Glass 
wool products comprise the vast majority of synthetic vitreous fibers produced in the United States.  The 
Glass Manufacturing Industry Council (GMIC) reports that there are currently 10 major manufacturers 
operating about 40 plants around the United States, and estimates that the current production volume of 
glass fibers, including glass wool, is about 3 million tons (2.72x109 kg) annually (GMIC 2002).  The 
annual U.S. production of mineral wool is roughly 550,250 tons (5.0x108 kg), and accounts for 
approximately 10–15% of the total amount of synthetic vitreous fibers produced.  The total domestic 
production of refractory ceramic fibers was approximately 107.7 million pounds (4.9x107 kg) in
1997 (Mast et al. 2000).  For comparison, the total production volume of all synthetic vitreous fibers in 
Canada was estimated as 250–300 kilotons (2.26x108–2.71x108 kg) in 1991, of which 70% was glass 
wool, 20% was mineral wool, 10% was continuous filament glass, and <1% was refractory ceramic fibers
(Environment Canada 1993).   
The production of fibrous glass differs depending upon whether the final product being formed is 
continuous filament glass fibers or glass wool.  In general, a glass-making furnace is used to melt the raw 
materials and a separate device is frequently used to convert the melt into marbles.  The preformed 
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Table 5-1. Production Volumes of Glass Wool, Rock Wool, and Slag Wool 

Products in the United Statesa
 
Product Quantity (million kg), 1977 Quantity (million kg), 1982 
Wool for insulation (homes and commercial/industrial buildings) 
Loose and granulated fiber 373.2 327.2 
Building batts, blankets, and rolls 359.9 (R-19 or more)b 530.0 (R-19 or more)b 
403.9 (R-11 to R-18.9) 418.4 (R-11 to R-18.9) 
Not available (R-10.9 or less) 52.3 (R-10.9 or less) 
Acoustical, such as wall and ceiling Not available 46.3 
Wool for industrial, equipment, and appliance insulationc 
Flexible blankets, rolls, and batts (plain) 167.8 173.2 
Flexible blankets, rolls, and batts 16.5 21.4 
(coated)
Flexible blankets, rolls, and batts (faced) 24.0 Not available
Special purpose insulation 19.6 11.5 
Blocks and boards 46.0 10.0 
 Pipe insulation 30.5 26.8 
Acoustical, including pads, boards, and 24 Not available
patches 
aIARC 1988 
bThe R-value is the reciprocal of the amount of heat energy per area of material per degree difference between the 
outside and inside. 
cIncludes amounts from products produced in the same establishment as well as products purchased or transferred 
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Table 5-2. Continuous Filament Glass Fiber Production in the United Statesa 
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employed, which produces the fibers while avoiding the conversion of the melt into marbles.  In the 
production of continuous filament fibers, nozzles are attached to the bushings on the furnace forehearth, 
and mechanical drawing is used to form the fibers from the melt.  A fine mist of water is sprayed onto the 
strands as they are extruded through the bushing and a lubricating agent is applied before the strands are 
wound into a cake (IARC 1988).   
Glass wool and mineral wool are manufactured with a rotary or centrifugal process without the use of 
nozzle extruders. In this process, the molten material from the furnace is transferred into a rotating 
spinner, and the fibers are produced as centrifugal force extrudes the material through small holes in the 
side of the spinning device.  The final wool fibers are generally shorter and thinner than continuous 
filament fibers.  Sometimes, a blowing process in which the melt is forced through the bushings at the 
bottom of the crucible by a downward directed stream of gas is used to extrude the fibers (Fitzer et al. 
1988).  The resultant fiber strands are usually about 3–6 µm in diameter and about 3–10 cm in length 
(Fitzer et al. 1988).  Prior to converting the fibers to final products, binders, sizings, or lubricants are 
usually added.  Binders are phenol-formaldehyde resins that impart structural rigidity to the fiber.  
Lubricating oils or paraffin oils are added to reduce dust and lint formation of the final product and reduce 
the amount of airborne fibers during their use.  Sizings are added to promote adhesion between fibers and 
the matrix material in reinforced applications.  Several sizings are used, including polyvinyl acetate 
chrome mixture, polyvinyl acetate silane, and epoxy silane (Navy Environmental Health Center 1997).   
Special purpose glass fibers are usually produced with a flame attenuation process, which results in the 
production of very small diameter fibers.  The flame attenuation method of producing fibers is a two-step 
procedure TIMA 1993).  In the first step, the melt is drawn through the bushings of the furnace to produce
strands of course fibers. The course fibers are then remelted and attenuated into several finer fibers with a 
high temperature gas flame, normally impinging at right angles to the primary fiber.  Fibers are usually
propelled by high velocity gasses through a forming tube, upon which a binder is sprayed, before 
producing the final wool fiber (TIMA 1993).   
Refractory ceramic fibers are produced by blowing and spinning processes similar to those used in the 
production of wool, but the starting material is kaolin clay rather than rock or slag (IARC 1988).  Since 
refractory fibers are relatively new materials, the exact processes used for producing these individual 
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5.2 IMPORT/EXPORT 
Data regarding the quantities of manmade glass filaments (including glass wool), mineral wool, and 
refractory ceramic goods imported and exported to and from the United States from 1998 to 2001 are 
summarized in Table 5-3 (USDOC 2002). 
5.3 USE 
Synthetic vitreous fibers are an important substitute for asbestos in a variety of products where thermal, 
acoustical, and electrical resistance is required.  Fibrous glass (including glass wool) accounts for about 
80% of the production of synthetic vitreous fibers in the United States (WHO 1988).  The majority of this 
production is in the form of glass wool, which is used for insulation purposes, similar to the mineral 
wools. Continuous filament fibers are used as reinforcement in plastics and building products, and in 
industrial fabrics (ACGIH 2001).  Mineral wool accounts for about 10–15% of the production of 
synthetic vitreous fibers in the United States (WHO 1988).  Similar to glass wool, the vast majority of 
rock wool and slag wool is produced for thermal and acoustical insulation applications for construction of 
homes, buildings, and other structures (IARC 1988).  Appliances and plumbing applications also use 
glass wool and mineral wool for insulation purposes.  The end products are usually in the form of bats, 
boards, blankets, and sheets.  Refractory ceramics fibers and special purpose fibers only account for about 
2% of all synthetic vitreous fibers produced in the United States (WHO 1988).  Refractory ceramic 
materials are very heat resistant and find use in applications that require high temperatures.  Final 
products are often in the form of blankets, boards, felts, bulk fibers, and paper and textile products (IARC 
1988).  Refractory ceramic blankets or boards are often used as insulation in ships and in firewalls to 
contain fires or in catalytic converters in the automobile industry and in aircraft and aerospace engines 
(IARC 1988). Ceramic blankets and boards are commonly used as linings for furnaces and kilns.  
Ceramic fiber textile products such as yarns or fabrics find use in flame resistant clothing, curtains, and 
other materials.  Specialty purpose glass fibers are very expensive to manufacture and only find use in 
high technology applications such as high performance insulation in the aircraft industry and specialty
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Table 5-3. U.S. Import/Export Volume of Glass Fibers (Including Glass Wool), 

Mineral Wool and Refractory Ceramic Goodsa
 
Year Import quantity (kg) Export quantity (kg) 
Glass fibers including glass wool 
1998 73,074,090 119,386,619 
1999 96,924,030 112,438,061 
2000 103,001,680 119,829,077 
2001 93,045,850 122,598,785 
Mineral wool 
1998 4,096,373 13,507,235 
1999 4,732,083 12,856,177 
2000 5,086,956 15,736,857 
2001 4,330,133 15,760,666 
Refractory ceramic goods
1998 26,677,254 21,567,397 
1999 23,552,712 11,044,364 
2000 28,520,534 16,464,014 
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5.4 DISPOSAL 
No components in synthetic vitreous fibers are identified by the EPA as hazardous waste in Resource 
Conservation and Recovery Act (RCRA) (40CFR Part 261), and as such they may be disposed of in 
landfills; however, state and local regulations may apply.  Provided that refractory ceramic fibers and 
other synthetic vitreous fibers have an average diameter >1 µm, the EPA agrees that these substances 
would not fall within the fine mineral fibers category under Comprehensive Environmental Response, 
Compensation and Liability Act (CERCLA) and, thus, would not be subject to release reporting and 
liability requirements.  Should synthetic vitreous fibers, however, have an average diameter of ≤1 µm, 
these substances would be considered hazardous substances and, therefore, would be subject to CERCLA 
requirements (EPA 1995). The U.S. Navy suggest that all synthetic vitreous fiber material be wetted 
before placing the material in heavy duty plastic bags or other impermeable objects before being 
discarded at landfills (Navy Environmental Health Center 1997). 
Glass and insulating material are often recycled for further use after being removed or discarded.  
According to the North American Insulation Manufacturers Association (NAIMA), over 18 billion 
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6.1 OVERVIEW
Synthetic vitreous fibers were not identified in any of the 1,647 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2004).  However, the number 
of sites evaluated for synthetic vitreous fibers is not known.  The frequency of these sites can be seen in 
Figure 6-1. 
Like other inorganic substances, synthetic vitreous fibers do not undergo typical transformations in the 
environment, such as photolysis and biodegradation, which are important for organic compounds.  Under 
acidic or alkaline conditions, synthetic vitreous fibers may undergo dissolution, whereby the silicate 
network may be attacked and slowly degraded.  Experimental dissolution rates of tested fibers have been 
reported to span over 5 orders of magnitude.  This degradation mechanism is more relevant in biological 
systems than it is in the environment (see Section 3.4 for more details).  The transport and partitioning of 
synthetic vitreous fibers are largely governed by their size.  Large fibers are removed from air and water 
by gravitational settling at a rate dependent upon their size, but small fibers may remain suspended for 
long periods of time. 
The general population can be exposed to low levels of synthetic vitreous fibers when insulating material 
or other synthetic vitreous fiber-containing material such as ceiling boards are physically disturbed and 
fibers become suspended in the air.  Home, building, and appliance insulation are often composed of glass 
wool, rock wool, or slag wool, and low levels of synthetic vitreous fibers have been detected in indoor air.  
These levels are usually on the order of about 1x10-4 fiber/cc, although higher levels are often observed 
during the installation of insulation in attics or ceilings; however, these levels quickly return to pre-
installation levels, usually in 1 or 2 days.  Low levels of synthetic vitreous fibers have also been detected 
in outdoor air, and available data suggest that there are little differences in the concentration of these 
fibers near source dominated areas (e.g., near production plants) when compared to other locations.  
Typical levels of synthetic vitreous fibers in outdoor ambient air can vary, but are also on the order of 
about 1x10-4 fiber/cc. 
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The overwhelming majority of human exposure to synthetic vitreous fibers occurs as occupational 
exposure through inhalation and dermal contact.  Occupational exposure is estimated to be several orders 
of magnitude greater than environmental exposure.  Employees at manufacturing facilities where 
synthetic vitreous fiber products are produced, as well as workers who regularly install or come into 
contact with insulating material are most at risk for elevated levels of exposure.  Workers involved in 
demolition work, as well as in building maintenance and repair, are potentially exposed to higher levels of 
synthetic vitreous fibers once these materials are disturbed or demolished.  Workers involved in the 
removal of refractory ceramic fiber insulation in high temperature furnaces may also be exposed to 
quartz, cristobalite, and tridymite, which form as refractory ceramic fibers devitrify at elevated 
temperatures (Maxim et al. 1999b).  
In the literature discussing data on airborne synthetic vitreous fibers, total dust or total fiber levels are 
occasionally reported.  These levels include all types of fibers, not just the synthetic vitreous fibers, and 
quite often synthetic vitreous fibers only constitute a small percentage of the total concentration of fibers 
in the sample.  The precise definition of what constitutes an actual fiber, and how these fibers should be 
counted under microscopic examination is not standardized, and different studies have used different 
counting methods (see Chapter 7).  A fiber is usually defined as having length of at least 5 µm, and a 
length to diameter ratio (aspect ratio) of either 5:1 or 3:1 (TIMA 1993).  Frequently, only the levels of 
respirable fibers are reported. Respirable fibers are those fibers that can be inhaled into the lower lung 
and usually only fibers with diameters of <3 µm are considered respirable in humans (although some
authors have used larger values in older publications).  It is also generally accepted that fibers longer than 
200–250 µm are too large to be deposited in the lung, and are therefore not respirable (TIMA 1993).  
Recently, the American Conference of Governmental Industrial Hygienists (ACGIH) has defined 
respirable fibers as possessing a diameter <3 µm, length ≥5 µm, and an aspect ratio of ≥3:1 (ACGIH 
2001). The term respirable fiber in this chapter refers to fibers possessing diameters of <3 µm, unless 
otherwise noted. Section 3.4 (Toxicokinetics) discusses the deposition and clearance of fibers in the lung 
in more detail. 
Phase contrast microscopy (PCM) is most frequently used to measure fiber levels, but this method cannot 
detect fibers with diameters smaller than 0.25 µm.  PCM uses visible light photons for analysis, and 
because the resolution of a microscope is a function of the wavelength of photons used for analysis and 





















182 SYNTHETIC VITREOUS FIBERS
6. POTENTIAL FOR HUMAN EXPOSURE 
improved upon.  Transmission electron microscopy (TEM) or scanning electron microscopy (SEM) are 
often employed to improve sensitivity since these techniques can measure fibers with smaller diameters 
than PCM because electrons with much shorter wavelengths than visible photons are used in these 
experiments (see Chapter 7 for details).  It is often difficult to directly compare results of early studies to 
more recent ones due to the methods in which fibers were sampled and analyzed.  Many early monitoring 
studies employed a set of fiber counting rules specifying a fiber as a particle with length >5 µm and 
aspect ratio of ≥3:1 (counting rules A).  More recent studies frequently use a counting rule in which fibers 
are counted if their lengths are >5 µm, their diameters are <3 µm, and their aspect ratio is ≥5:1 (counting
rules B). While the differences in actual fiber counts are usually small, calculating fibers using counting 
rules A generally yield higher counts as compared to the counting rules B (Breysse et al. 1999; Miller et 
al. 1995).  See Chapter 7 for more details regarding the analysis, sampling, and counting of fibers. 
The Toxics Release Inventory (TRI) has not listed synthetic vitreous fibers for inclusion in its database 
(TRI01 2003). 
6.2 RELEASES TO THE ENVIRONMENT 
Low levels of synthetic vitreous fibers may be released to the environment during their production or use.  
Demolishing buildings or houses that contain synthetic vitreous fibers in insulating products, ceiling 
boards etc., may also release low levels of synthetic vitreous fibers locally.  The majority of releases most
likely arise from the disposal of material containing synthetic vitreous fiber in landfills. 
6.2.1 Air 
Very limited data are available regarding the emission of synthetic vitreous fibers to ambient air.  The 
concentration of synthetic vitreous fibers in air emissions from fibrous glass, rock wool, and slag wool 
plants in Germany were on the order of 0.01 fiber/cc, and the total fibrous dust emissions from these 
plants were estimated as 1.8 tons/year (WHO 1988). Concentrations of respirable fibers as high as 
2.7 fibers/cc were measured by PCM in stack gasses at several older glass, rock, and slag wool plants in 
the United States (Environment Canada 1993).  Concentrations of total fibers in stack gasses measured in 
1991 using TEM at four refractory ceramic fiber production plants and three refractory ceramic fiber 
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Synthetic vitreous fibers were not identified in any of the current or former NPL hazardous waste sites 
(HazDat 2004). Synthetic vitreous fibers were not included in the TRI (TRI01 2003). 
6.2.2 Water 
Few data exist regarding the frequency or levels of synthetic vitreous fibers released to water.  Glass 
fibers were identified in samples of sewage sludge from five cities in the United States; however, the 
specific form and exact quantity of the glass fibers were not reported (Bishop et al. 1985). 
Synthetic vitreous fibers were not identified in any of the current or former NPL hazardous waste sites 
(HazDat 2004). Synthetic vitreous fibers were not included in the TRI (TRI01 2003). 
6.2.3 Soil 
No data exist regarding the frequency or levels of synthetic vitreous fibers released to soil.  Most of these 
releases are expected to be in the form of discarded construction material (e.g., insulation, ceiling boards, 
etc.) that have been disposed of at landfills. 
Synthetic vitreous fibers were not identified in any of the current or former NPL hazardous waste sites 
(HazDat 2004). Synthetic vitreous fibers were not included in the TRI (TRI01 2003). 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
The transport, distribution, and degradation of synthetic vitreous fibers in the environment have not been 
studied (WHO 1988).  However, synthetic vitreous fibers are nonvolatile and generally insoluble, so their 
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6.3.2 Transformation and Degradation  
6.3.2.1 Air 
Synthetic vitreous fibers are not known to undergo any significant transformation or degradation in air 
(WHO 1988).
6.3.2.2 Water 
Synthetic vitreous fibers are not known to undergo any significant transformation or degradation in water 
(WHO 1988).  The silicate network of all synthetic vitreous fibers can be attacked by acids or alkaline 
solutions, but this does not occur to any significant extent under environmentally relevant conditions.  
Using in vitro tests at 37 °C with simulated extracellular fluid (pH 7.4), the dissolution rates of glass, 
rock, and slag wools with diameters of 1 µm were reported as 0.4, 1.2, and 2.0 years, respectively 
(Environment Canada 1993).  Lifetimes for refractory ceramic fibers were about 5 years.  Because of their 
larger surface area, fine fibers will undergo dissolution more readily than course fibers (see Section 3.4 
for more details regarding dissolution in biological media). 
6.3.2.3 Sediment and Soil 
Synthetic vitreous fibers are not known to undergo any significant transformation or degradation in soil or 
sediment (WHO 1988). 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
6.4.1 Air 
Available monitoring data suggest that the concentration of synthetic vitreous fibers in the atmosphere is 
very low.  The levels of fibrous glass in ventilation systems and in the ambient air from various locations 
of California were studied from 1968 to 1971, in order to investigate the erosion of fibers from air 
transmission systems (Balzer et al. 1971; NIOSH 1976).  The concentration of fibrous glass in 36 ambient 
air samples collected from Berkeley, San Jose, Sacramento, the Sierra Mountains, and Los Angeles 
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determined by PCM and TEM (NIOSH 1976).  The fiber diameters ranged from 0.10–17.7 µm, with an 
arithmetic mean of 4.3 µm.  The concentration of fibrous glass in 37 ventilation system samples ranged 
from not detected to 2.0x10-3 fiber/cc (8.7x10-4 fiber/cc, arithmetic mean), and the fiber diameters were 
0.10–17.7 µm (3.7 µm, arithmetic mean).  The mean airborne concentrations of fibers were monitored at 
one rural location and three cities in Germany in 1981–1982 (Hohr 1985).  Samples were analyzed with 
TEM in conjunction with energy-dispersive x-ray analysis (EDXA), and electron diffraction analysis.  
The fibers identified as synthetic vitreous fibers constituted about 1–5% of the inorganic fibers, with a 
concentration range of 4.0x10-5–1.7x10-3 fiber/cc (Hohr 1985).  The results of these, and several other 
past monitoring studies have been compiled and summarized in IARC (1988, 2002) and WHO (1988). 
The concentration of respirable glass fibers near a large fiberglass wool manufacturing facility in Newark, 
Ohio ranged from below the detection limit of 1.0x10-5 fiber/cc to 1.4x10-4 fiber/cc, during four sampling 
periods in 1988–1989 as determined by PCM (Switala et al. 1994).  These levels were similar to the 
measured levels in ambient air from a rural site located 10 miles away from the plant in Granville, Ohio.  
The range of concentrations at the rural location was from below the detection limit of 1.0x10-5 fiber/cc to 
1.5x10-4 fiber/cc, during the same sampling period.  Furthermore it was shown that only 16% of the 
460 samples obtained at the Newark (plant) location had concentrations of glass fibers above the 
detection limit and only 4% of the 485 samples obtained from the Granville (rural) location had 
concentrations above the detection limit.  Glass fibers accounted for <1% of the total respirable fibers 
measured at these sites.  The total respirable fiber concentrations (this includes all fibers, not just 
synthetic vitreous fibers) at the Newark location ranged from below the detection limits to 
0.02318 fiber/cc, while the levels of total respirable fibers at the Granville site ranged from below the 
detection limits to 0.04290 fiber/cc.  The majority of non-glass fibers were reported to be pollen and 
trichome, seed hairs, and insect parts (Switala et al. 1994).  Low levels of synthetic vitreous fibers in 
ambient air have also been measured in various locations in France (Gaudichet et al. 1989).  The 
maximum concentration of respirable synthetic vitreous fibers in outdoor air at 18 locations in Paris was 
1.5x10-5 fiber/cc, with a mean value of 2.0x10-6 fiber/cc as determined by PCM (Gaudichet et al. 1989). 
In general, indoor air concentrations of synthetic vitreous fibers are very low under non-occupational 
settings, unless there is a disturbance in the fiberglass insulation system or ceiling boards of the home or 
building.  A comprehensive study using PCM was carried out in Denmark in order to study the 
concentration of synthetic vitreous fibers in the indoor air of public buildings (Schneider et al. 1990).  The 
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1.66x10-3 fiber/cc in air samples collected from 105 rooms using 10 different types of ceiling boards.  The 
mean respirable levels were in the range of 2.60x10-5–2.13x10-4 fiber/cc.  The levels of nonsynthetic 
vitreous fibers were at least an order of magnitude greater than the levels of synthetic vitreous fibers.  It 
was also reported that no respirable airborne levels of synthetic vitreous fibers were observed in 65 of the 
rooms, but that low levels of respirable synthetic vitreous fibers were found on other objects such as 
tables or cupboards (Schneider et al. 1990).  The results of this study pertaining to the levels of airborne 
synthetic vitreous fibers are summarized in Table 6-1.
A recent study employing both PCM and SEM analyzed 51 residential and commercial buildings 
throughout the United States, and found respirable synthetic vitreous fibers were present in only 2 of the 
50 samples analyzed by SEM (Carter et al. 1999).  It was demonstrated that the majority of airborne fibers 
were organic, and that inorganic fibers, including synthetic vitreous fibers, composed <10% of the 
detectable respirable amount.  Gaudichet et al. (1989) measured the levels of synthetic vitreous fibers at 
79 indoor locations in France where synthetic vitreous fiber materials were used in a variety of 
applications, and found the levels of respirable synthetic vitreous fibers to be low.  A range of respirable 
synthetic vitreous fibers were reported as not detected to 6.23x10-3 fiber/cc with a median value of 
3.0x10-6 fiber/cc (Gaudichet et al. 1989).  The levels of respirable fibers (diameter <3 µm and lengths 
>5 but <100 µm) were measured in 12 houses during the installation of rock wool or glass wool insulation 
material by PCM and TEM (Jaffrey 1990).  Almost no differences were noticed in the pre-installation 
airborne levels, which were on the order of 1.0x10-4 fiber/cc, and the post insulation samples, which were 
taken 2 days after installation was complete.  Comparable results were obtained by Miller et al. (1995)
when analyzing the fiber concentrations in living spaces of 14 homes prior to installation of insulation and 
the evening following installation.  Total fiber levels ranged from 0.0020 to 0.011 fiber/cc before 
installation, and from 0.0030 to 0.015 fiber/cc 1 day post-installation using PCM and counting rules A 
(see Chapter 7).  Fiber concentrations calculated using counting rules B were slightly lower, but there 
were no statistically significant differences when comparing levels calculated by either the A or 
B counting rules.  Similar results were obtained when using SEM methods and the two counting rules to 
measure only synthetic vitreous fibers levels, although the level of fibers classified as synthetic vitreous 
fibers were about an order of magnitude lower than the total fiber levels.  The maximum pre-installation 
level of synthetic vitreous fibers was 0.001 fiber/cc, and the post-installation levels ranged from below the 
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Respirable fiber level 
fibers/cc; range (mean) 
Non-respirable fiber level 
fibers/cc; range (mean) 
Karlit mineral 11 Yes 0–1.66x10-3 (2.13x10-4) 0–3.3x10-4 (5.7x10-5) 
Hotaco mineral 14 Yes 0–4.3x10-4 (5.6x10-5) 0–1.9x10-4 (2.1x10-5) 
Ny Hotaco mineral 










Soft mineral wool 
sealed on three sides 
13 No 0–3.4x10-4 (2.6x10-5) 0–1.0x10-4 (8.0x10-6) 
Hard mineral wool 
sealed on three sides 
9 No 0–1.3x10-4 (3.1x10-5) 0–7.0x10-5 (1.0x10-5) 
Unsealed mineral 
wool 
12 No 0–1.03x10-3 (1.8x10-4) 0–4.0x10-4 (6.7x10-5) 
Sealed mineral wool 
on all six surfaces
9 No 0–6.1x10-4 (9.4x10-5) 0–2.4x10-4 (4.6x10-5) 
Batts on top of 
perforated panels 
No synthetic vitreous 









aSchneider et al. 1990 
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6.4.2 Water 
No data exist regarding the ambient levels of synthetic vitreous fibers in water. 
6.4.3 Sediment and Soil 
No data exist regarding the ambient levels of synthetic vitreous fibers in soil or sediment. 
6.4.4 Other Environmental Media 
No data exist regarding the levels of synthetic vitreous fibers in foods, plants, or animals. 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
The exposure of the general population (non-occupational exposure) to synthetic vitreous fibers in both
indoor and outdoor air is low.  Persons that install their own home insulation may briefly be exposed to 
higher than normal levels during the installation; however, these exposures can be significantly reduced 
with the use of protective equipment such as ventilators and gloves.  Furthermore, it has been shown that 
the airborne levels of synthetic vitreous fibers attenuate rapidly following installation (Jaffrey 1990; 
Miller et al. 1995). No exposures from food, drinking water, or other environmental media are expected.  
A recent study measured the density (fibers/mm2) of synthetic vitreous fibers on material surfaces (desks, 
floors, shelves, etc.) inside 20 buildings located in Cambridge and Boston, Massachusetts (Vallarino et al. 
2003).  It was determined that nearly 60% of the samples collected had zero or one countable synthetic 
vitreous fiber when using NIOSH Method 7400 and counting rules B.  Only about 4% of the samples had 
densities >1 fiber/mm2. A second survey was undertaken that analyzed the synthetic vitreous fibers on 
the surface of objects inside 20 buildings located in 10 cities within the United States (Vallarino et al. 
2003). In this survey, counting rules A were employed, which allows fibers possessing diameters >3 µm
to be counted.  Using counting rules A, the number of samples having zero countable synthetic vitreous 
fibers decreased from about 43 to 14%.  It was also shown that surfaces seldom contacted or cleaned (tops 
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Although there was a large degree of variability in the fiber loadings, it is clear that only low levels of 
synthetic vitreous fibers are expected to be present on common surfaces within buildings used by the 
general population.  
The airborne levels of synthetic vitreous fibers have been shown to be higher under occupational settings 
as compared to ambient air levels, and thus, occupational exposure is far greater than the exposure for the 
general population.  Esmen and Erdal (1990) concluded that occupational exposure is several orders of 
magnitude greater than environmental exposure.  The Occupational Safety and Health Administration 
(OSHA) estimates that there are over 250,000 workers in the United States who are exposed to synthetic 
vitreous fibers in manufacturing and downstream use (OSHA 2002).  This number is expected to increase 
as use of products containing synthetic vitreous fibers increases.   
Workers involved in the installation of fiberglass insulating material are exposed to synthetic vitreous 
fibers through both dermal and inhalation routes.  Airborne fiber levels were studied by PCM during the 
installation of fibrous glass insulating materials in northern California (NIOSH 1976).  The concentration 
of fibrous glass in 40 air samples obtained during the installation of this material ranged from 5.0x10-4 to
2.41 fibers/cc (0.406 fiber/cc, arithmetic mean) with diameters in the range of 0.30–25.0 µm (6.5 µm, 
arithmetic mean).  These airborne levels were 2–3 orders of magnitude greater than levels typically found 
in ambient air (Balzer 1971; NIOSH 1976; Switala et al. 1994).  Differences were noted in the 
concentration of glass fibers in personal air samples when comparing the installation of batt-type material 
with blown-in insulation. The arithmetic mean concentration of total glass fibers during the installation of 
batt-type insulation was 0.13 fiber/cc and the arithmetic mean respirable glass fiber concentration was 
0.042 fiber/cc as determined by PCM (Jacob et al. 1992).  The personal air concentrations were higher for 
applications involving blown-in insulation wool as compared to batt-type material.  The arithmetic mean 
concentrations of total glass wool fibers were 0.68 fiber/cc (cubed blown wool) and 1.7 fibers/cc (milled 
blown wool) during the installation process.  The corresponding arithmetic mean concentrations of 
respirable glass wool fibers were 0.30 fiber/cc for the milled blown wool and 0.82 fiber/cc for the cubed 
blown wool (Jacob et al. 1992).  The levels of airborne respirable glass fibers were shown to decrease 
significantly after installation, with levels on the order of 1x10-4 fiber/cc 1 day after installation (Jacob et 
al. 1992).  The respirable airborne concentrations of refractory ceramic fibers, rock wool, and glass wool 
fibers were measured by PCM and TEM at five construction sites using products containing these 
materials (Perrault et al. 1992).  The greatest airborne levels were observed during the removal of 

















190 SYNTHETIC VITREOUS FIBERS
6. POTENTIAL FOR HUMAN EXPOSURE 
mean concentrations ranging from 0.39 to 3.51 fibers/cc.  The geometric mean concentration of respirable 
fibers during the installation of blown in rock wool in the attic of a residential apartment building was 
0.32 fiber/cc, while the geometric mean concentration was 0.15 fiber/cc for sprayed-on rock wool 
insulation at an industrial construction site.  The lowest airborne levels were observed during the 
installation of fiberglass panels around ventilation ducts at an industrial construction site, with a 
geometric mean concentration of 0.010 fiber/cc (Perrault et al. 1992).  Using TEM and PCM, the mean 
concentration of respirable airborne fibers were measured in the range of 0.080–1.76 fibers/cc during the 
installation of either glass wool or rock wool insulating material in 12 houses in England (Jaffrey 1990).  
The lowest airborne concentrations were observed during the installation of rock wool blanket material, 
and the highest level occurred during the installation of a fine glass wool blanket material, in which 
approximately 80% of the fibers had diameters <1 µm. 
In a study of four facilities producing fibrous glass insulation and one producing fibrous glass textile 
products, the range of concentrations for total respirable fibers having lengths >5 µm were reported as not 
detected to 1.97 fibers/cc, with mean levels in the range of 0.020–0.97 fiber/cc (Johnson et al. 1969).  No 
data were provided regarding what percentage of total fiber counts were glass fibers as opposed to other 
fibers, and respirable fibers in this study were defined as fibers having a diameter <5 µm, rather than the 
currently accepted value of <3 µm.  The airborne level of fibers in various parts of 16 manufacturing 
facilities producing glass wool, continuous glass filament, rock and slag wool, and refractory ceramic 
fibers were measured by Esmen et al. (1979a, 1979b), and the details of this study have been summarized 
in other publications (IARC 1988, 2002; WHO 1988).  Table 6-2 shows the levels of total suspended 
particulate matter in various regions of these 16 plants, and Table 6-3 shows the corresponding 
concentrations of total airborne fibers measured by PCM.  The greatest airborne fiber levels of were 
observed at a plant producing refractory ceramic and special purpose fibers (plant 15), where the nominal 
fiber diameter of the product ranged from 0.050 to 1.6 µm.  Additional studies employing transmission 
electron microscopy to detect small diameter fibers showed airborne fiber levels as high as 6.49 fibers/cc 
for this location. More recent monitoring data on workplace airborne levels confirm that higher 
concentrations are observed under occupational settings as compared to the levels observed under non-
occupational conditions.  In a study of airborne fiber levels during 11 different manufacturing operations 
involving Owens-Corning Fiberglass insulation products, the mean concentration of airborne total glass 
fibers ranged from 0.0020 to 0.14 fiber/cc and the mean concentration of respirable glass fibers ranged 
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Table 6-2. Concentrations (mg/m3) of Total Suspended Airborne Particulate 

Matter in 16 Facilities in the United Statesa
 
Quality Shipping Overall 
Forming Production Manufacturing Maintenance control mean mean 
Plant mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) (SD) (SD) 
1 0.47 (0.47) 1.04 (1.34) 0.96 (0.96) 0.71 (0.45) 0.21 (0.12) 0.39 (0.09) 0.89 (1.12) 
2 1.65 (1.17) 2.53 (2.30) 2.28 (1.51) 2.05 (1.32) 1.53 (0.63) 1.34 (0.58) 1.94 (1.68) 
3 No data 0.51 (0.30) No data 0.83 (0.61) No data 0.70 (0.42) 0.65 (0.46) 
4 1.22 (0.51) 0.77 (0.49) 1.23 (0.95) 2.08 (4.40) 0.52 (0.14) 1.32 (0.96) 1.24 (2.26) 
5 0.76 (0.25) 0.67 (1.52) 0.29 (0.95) 0.55 (0.32) 0.09 (No 0.62 (0.33) 0.60 (1.04) 
data) 
6 1.30 (0.71) 1.77 (2.23) 0.51 (0.39) 2.00 (2.50) 0.49 (0.82) 0.45 (0.19) 1.17 (1.72) 
7 2.18 (1.62) 2.05 (0.31) 4.31 (4.03) 6.72 (7.84) No data 1.77 (1.02) 4.00 (4.27) 
8 No data 8.48 (9.02) 1.17 (0.55) 4.64 (8.28) No data 0.84 (0.67) 4.73 (8.69) 
9 1.18 (0.48) 1.90 (1.52) 1.14 (0.53) 1.33 (0.57) No data 1.08 (0.46) 1.33 (1.02) 
10 2.45 (0.93) 0.75 (0.47) 0.73 (0.33) 1.25 (1.07) 0.32 (0.09) 0.69 (0.15) 1.07 (0.91) 
11 2.18 (1.64) 1.08 (1.82) 0.87 (0.46) 1.26 (0.49) 1.25 (No 1.04 (0.41) 1.37 (1.09) 
data) 
12 0.34 (0.35) 0.20 (0.30) 0.28 (0.26) 0.53 (0.26) 0.53 (0.66) 0.88 (0.08) 0.21 (0.16) 
13 4.10 (No 1.34 (0.46) 1.19 (1.08) 1.80 (1.69) No data 1.31 (0.59) 1.40 (1.08) 
data) 
14 3.00 (1.37) 0.85 (0.59) 1.06 (0.47) 1.57 (1.41) No data 0.91 (0.72) 1.42(1.21) 
15 0.30 (0.21) 0.61 (0.51) 1.08 (0.80) 1.09 (0.75) 1.66 (0.73) 0.54 (0.18) 0.75 (0.67) 
16 0.77 (0.46) 0.82 (0.69) 0.86 (0.52) 1.79 (1.50) 0.44 (No 0.76 (0.53) 1.07 (1.02) 
data) 
aEsmen et al. 1979b; measurements obtained with phase contrast microscopy
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Table 6-3. Concentrations (fiber(s)/cc) of Total Airborne Fibers in 16 Facilities in 
the United Statesa 
Forming Production Manufactur- Mainten- Quality Shipping Overall 
ND area mean area mean ing area ance area control area area mean mean 
Plant µm (SD) (SD) mean (SD) mean (SD) mean (SD) (SD) (SD) 
1 1–12 0.002 0.38 (0.32) 0.03 (0.02) 0.02 (0.02) 0.07 (0.10) 0.01 (0.001) 0.01 
(0.001) (0.25)
2 6 0.07 (0.03) 0.17 (0.14) 0.12 (0.11) 0.08 (0.05) 0.19 (0.16) 0.07 (0.06) 0.11 
(0.12)
3 3–6 No data 0.02 (0.02) No data 0.07 (0.18) No data 0.005 (0.01) 0.04 
(0.1) 
4 1–6 0.01 (0.004) 0.07 (0.12) 0.04 (0.05) 0.03 (0.02) 0.01 (0.01) 0.02 (0.01) 0.04 
(0.08)
5 8 0.02 (0.01) 0.03 (0.02) 0.03 (0.02) 0.02 (0.01) 0.03 (No 0.03 (0.01) 0.02 
data) (0.02)
6 5–15 0.05 (0.10) 0.01 (0.01) 0.008 (0.01) 0.01 (0.03) 0.01 (0.02) 0.005 0.01 
(0.004) (0.03)
7 5 0.15 (0.03) 0.24 (0.12) 0.43 (0.32) 0.44 (0.37) No data 0.15 (0.17) 0.34 
(0.35)
8 7–10 No data 0.03 (0.02) 0.04 (0.03) 0.01 (0.01) No data 0.01 (0.01) 0.02 
(0.02)
9 7–10 0.02 (0.02) 0.01 (0.01) 0.02 (0.07) 0.01 (0.006) No data 0.004 0.02 
(0.002) (0.01)
10 6–16 0.001 0.003 0.004 0.002 0.003 0.002 0.002 
(0.001) (0.004) (0.004) (0.003) (0.003) (0.002) (0.003) 
11 7 0.09 (0.11) 0.05 (0.03) 0.04 (0.03) 0.04 (0.04) 0.08 (0.08) 0.03 (0.02) 0.05 
(0.05)
12 6–115 0.01 (0.01) 0.020 0.01 (0.004) 0.01 (0.02) 0.01 (0.003) 0.007 0.01 
(0.030) (0.005) (0.02)
13 7 0.58 (No 0.08 (0.06) 0.11 (0.17) 0.09 (0.08) No data 0.03 (0.02) 0.10 
data) (0.10)
14 6–13 0.01 (0.01) 0.04 (0.09) 0.05 (0.05) 0.05 (0.13) No data 0.03 (0.03) 0.04 
(0.03)
15 0.05– 0.19 (0.22) 0.92 (1.02) 1.56 (3.79) 0.11 (0.10) 0.89 (0.33) 0.10 (0.09) 0.78 
1.6 (2.1) 
16 6–10 0.02 (0.01) 0.02 (0.02) 0.05 (0.03) 0.07 (0.23) 0.04 (No 0.02 (0.01) 0.04 
data) (0.12)
aEsmen et al. 1979b 
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also studied during the removal of pipe installation and ceiling boards.  For these removal processes, the 
mean airborne concentration of total glass fibers was 0.10 fiber/cc and the mean airborne concentration of 
respirable glass fibers was 0.042 fiber/cc (Jacob et al. 1993).  While these levels are greater than levels 
found in ambient air, they are far lower than a 1992 proposed OSHA exposure limit of 1 fiber/cc per 
8-hour time-weighted-average (TWA) (OSHA 2002).
The North American Insulation Manufacturers Association (NAIMA) has recently developed a Health 
and Safety Partnership (HSPP) with the participation and oversight of OSHA (Marchant et al. 2002;
Maxim et al. 2003a).  As part of this program, a database that estimates the level of potential exposure to 
respirable fibers from fiber glass, rock wool, and slag wool was developed.  Textile glass fibers were not 
included in the program because they are generally considered non-respirable due to their relatively large 
nominal diameters.  The database contains current information regarding time-weighted average exposure 
levels, which are categorized by product type and specific work function.  Information from this database 
regarding exposure by industrial sector is provided in Table 6-4.  Additional exposure data categorized by
product description and job description are presented in Tables 6-5 and 6-6, respectively.  Maxim et al. 
(2003a) estimated the probable cumulative lifetime exposure (fiber-month/cc) to persons that install 
fiberglass or rock/slag wool insulation materials in residential, commercial and industrial buildings.  This 
analysis concluded that due to smaller exposure times, both do it yourself and professional insulation 
installers had much lower lifetime exposures than workers employed in the manufacturing of fiberglass, 
rock/slag wool products (Maxim et al. 2003a).  The authors noted that recent epidemiological studies 
have concluded that there is no significant increase in respiratory system cancer among the manufacturing 
cohorts, and therefore, there is even less risk for installers (Maxim et al. 2003a). 
The concentration of respirable (defined in this study as having diameters ≤3 µm) refractory ceramic
fibers in personal air samples in seven manufacturing plants located in France, the United Kingdom, and 
Germany ranged from about 0.2 to 1.0 fiber/cc as determined by PCM (Trethowan et al. 1995).  The 
levels of respirable airborne refractory ceramic fibers were studied by PCM at five manufacturing plants 
located in the United States over a 6-year period to assess differences in exposure levels during different 
work shifts in the plants (Hall et al. 1997). The geometric mean TWA exposure for all shifts at these five 
plants ranged from 0.080 to 0.35 fiber/cc, and little differences were observed in the level of exposure and 
which shift the measurements were obtained.  Based on a 2-year survey of occupational exposure to 
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Industrial sector Samples Mean (f/cc) Standard deviation Median Range 
Glass wool manufacturing 1,648 0.23 0.53 0.03 0.01–4.63
Glass wool fabrication 475 0.28 0.49 0.10 0.01–3.80
Glass wool installation 344 0.38 0.73 0.16 0.01–7.49
Glass wool retrofit/removal 6 0.26 0.26 0.21 0.03–0.74
All glass wool 2,473 0.26 0.55 0.05 0.01–7.49 
Mineral wool manufacturing 429 0.20 0.19 0.15 0.01–1.41
Mineral wool installation 74 0.15 0.17 0.09 0.02–0.82
Mineral wool retrofit/removal 2 0.10 0.01 0.10 0.10–0.11
All mineral wool 505 0.19 0.19 0.14 0.01–1.41
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Table 6-5. Exposures to Synthetic Vitreous Fibers Categorized by Product Typea 
Product type Samples Mean (f/cc) SDb (f/cc) Median (f/cc) Range (f/cc)
Glass Wool Manufacturing 
Air handling products 12 0.03 0.03 0.02 0.01–0.13 
Aircraft insulation 67 0.19 0.36 0.06 0.01–2.29
Appliance insulation 28 0.12 0.29 0.03 0.01–1.30
Automotive insulation 102 0.02 0.03 0.01 0.01–0.18
Separator and filtration media 376 0.80 0.84 0.51 0.01–4.63
Blowing wool with binder 71 0.04 0.03 0.03 0.01–0.02 
Blowing wool without binder 53 0.11 0.12 0.08 0.01–0.49
High-density board 14 0.02 0.02 0.01 0.01–0.09
Pipe insulation 114 0.05 0.10 0.02 0.01–0.70
Batts and blankets 472 0.05 0.09 0.02 0.01–0.97
Otherc 339 0.07 0.18 0.02 0.01–2.30
Glass Wool Installation 
Air handling products 11 0.28 0.34 0.23 0.02–1.23 
Appliance insulation 31 0.08 0.16 0.02 0.01–0.06
Automotive insulation 17 0.02 0.02 0.01 0.01–0.05
Blowing wool with binder 19 0.30 0.30 0.24 0.04–1.13 
Blowing wool without binder 133 0.79 1.02 0.50 0.01–7.49
Cavity loose fill insulation 12 0.15 0.12 0.11 0.04–0.47
Pipe insulation 28 0.05 0.05 0.03 0.01–0.19
Batts and blankets 62 0.17 0.10 0.16 0.01–0.46
Otherd 25 0.05 0.04 0.02 0.01–0.16
Glass Wool Fabrication 
Acoustical panels 11 0.07 0.07 0.03 0.01–0.23 
Air handling products 66 0.05 0.05 0.03 0.01–0.22 
Appliance insulation 37 0.14 0.15 0.10 0.01–0.65
Automotive insulation 19 0.05 0.04 0.03 0.01–0.10
Battery separator media 122 0.55 0.77 0.20 0.01–3.80
Air and water filters 146 0.32 0.41 0.15 0.01–1.90
Othere 74 0.10 0.10 0.09 0.01–0.64
Mineral Wool Manufacturing  
Ceiling panel/tile 412 0.20 0.19 0.15 0.01–1.41 
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Table 6-5. Exposures to Synthetic Vitreous Fibers Categorized by Product Typea 
Product type Samples Mean (f/cc) SDb (f/cc) Median (f/cc) Range (f/cc)
Mineral Wool Installation 
Ceiling panel/tile 33 0.23 0.21 0.17 0.02–0.82 
Spray–on fireproofing 15 0.08 0.10 0.05 0.02–0.42
Insulation batts/blankets 12 0.09 0.04 0.08 0.04–0.16
Otherf 14 0.11 0.11 0.06 0.02–0.40
aMarchant et al. 2002.  Exposures are presented as 8-hour time-weighted average (TWA) exposures. 
bStandard deviation 
cIncludes acoustical panels and nonspecified products 
dIncludes flex duct and nonspecified products
eIncludes aircraft and pipe insulation; batts, blankets with binder, and nonspecified products 
fIncludes air handling board, appliance insulation, blowing wool with binder, cavity loose fill insulation, pipe insulation, 
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Table 6-6. Exposures to Synthetic Vitreous Fibers Categorized by Job Typea 
Job description Samples Mean (f/cc) SDb (f/cc) Median (f/cc) Range (f/cc)
Glass Wool Manufacturing 
Scrap baler/compactor 29 0.05 0.05 0.04 0.01–0.25
Batch/binder mixer 40 0.18 0.33 0.04 0.01–1.30
Cutting/hot press mold 109 0.04 0.12 0.01 0.01–0.88
Forming 289 0.11 0.23 0.02 0.01–2.30 
General laborer/maintenance 62 0.11 0.33 0.02 0.01–2.29
Packaging 890 0.34 0.67 0.04 0.01–4.63
Quality control/research 75 0.18 0.23 0.09 0.01–1.20
Sewing/laminating/assembly 91 0.08 0.11 0.03 0.01–0.62
Shipping/receiving 53 0.01 0.01 0.01 0.01–0.06 
Otherc 10 0.11 0.20 0.05 0.01–0.66
Glass Wool Installation 
Assembly 34 0.04 0.06 0.02 0.01–0.35 
Feeder 63 0.36 0.37 0.20 0.01–2.18 
Installer 232 0.45 0.85 0.18 0.01–7.49 
Otherd 9 0.16 0.14 0.07 0.03–0.37
Mineral Wool Manufacturing 
Supervisory 17 0.13 0.11 0.10 0.01–0.40
Forming 162 0.24 0.22 0.18 0.01–1.41 
Maintenance 79 0.18 0.16 0.14 0.01–0.79
Packaging 62 0.25 0.20 0.23 0.01–1.00
Quality control 20 0.21 0.21 0.16 0.01–0.80
Shipping/receiving 55 0.14 0.14 0.08 0.01–0.57 
Othere 34 0.09 0.10 0.05 0.01–0.42
Mineral Wool Installation 
Installers 65 0.16 0.17 0.10 0.02–0.82
Othere 9 0.09 0.12 0.05 0.02–0.40




cIncludes administration and blowing wool chopper operator and nodulator.

dIncludes cutting/sawing and maintenance. 
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description or job type were compiled (Friar and Phillips 1989).  The results of this survey are 
summarized in Table 6-7  While high levels of exposure were estimated for certain job descriptions, it
was noted that over 60% of the exposure levels fall within the 0–0.5 fiber/cc range (Friar and Phillips 
1989).
The results of a comprehensive 54-month workplace monitoring study for exposure to refractory ceramic 
fibers in the United States have been published (Mast et al. 2000; Maxim et al. 1994).  Although large 
differences were noted in the TWA exposures to workers performing various job functions, it was 
reported that of the nearly 3,000 samples obtained at facilities that process or use refractory ceramic
fibers, 77% of the TWA measurements were below the industry recommended exposure guideline of 
0.5 fiber/cc (Mast et al. 2000). It was also reported that approximately 84% of the samples obtained at 
refractory ceramic fiber producing facilities were below the recommended exposure guideline.  Workers 
involved in the removal and installation of insulation from furnaces, as well as the finishing (use of drill 
presses, sanding, and sawing) of refractory ceramic fibers had the highest TWA exposures, while workers 
involved in mixing/forming, fiber manufacturing, product assembly, and auxiliary job categories had the 
lowest TWA.  The TWA exposures ranged from about 0.2 fiber/cc for auxiliary and assembly workers to 
about 1.2 fibers/cc for workers involved in the removal of refractory ceramic fiber containing insulating 
material (Maxim et al. 1994).  A significant decrease in the TWA exposure to workers over the period of 
1990–1998 was observed as engineering controls and respirator use has improved (Mast et al. 2000).
Exposure to refractory ceramic fibers may pose an additional health hazard for workers involved in the 
removal of ceramic fiber insulation from high temperature industrial furnaces, since refractory ceramic 
fibers may be partially converted to quartz, cristobalite, and tridymite at elevated temperatures (Maxim et 
al. 1999).  Tests performed on three refractory ceramic fiber containing insulation blankets showed that 
between 3 and 21% of the bulk fibers had been converted to cristobalite at temperatures in the range of 
500–2,550 °F, with the majority of devitrification occurring on the surface layers of the hot face (Gantner 
1986).  The percentage of cristobalite in corresponding air samples ranged from 4.0 to 14.7% (Gantner 
1986).  No quartz or tridymite was detected.  An analysis of the monitoring data led to the conclusion that 
personal exposure to cristobalite while removing insulation from the furnaces reached or exceeded the 
threshold limit value of 0.05 mg/m3 in about 75% of the samples (Gantner 1986).  The phase changes and 
devitrification process of refractory ceramic fibers that occur as a function of temperature have been 
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Process description or job Exposure level (fiber(s)/cc) 
Manufacture
Needle operator 0.5 
Baling raw fiber 0.4 
Fiber chopping 0.8 
Product reeling 0.8 
Bagging/chopping raw fiber 1.2 
Mixing during product formation 0.4 
Packing products 0.02 
Use 
Wrapping refractory ceramic fiber blanket around pipe weld 0.8 
Stripping and relining furnace panel 1.2 
Kiln building 1.75 
Handling blanket refractory ceramic fiber 1.0 
Machining and ventilation control of refractory ceramic fiber fireboard 0.6 
Insulation work using blanket 1.0 
Handling operations; manual handling, but with little cutting or machining 0.1 
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refractory ceramic fibers during the installation and removal of insulation in 13 furnaces situated in 
6 refineries and 2 chemical plants located in the United States (Cheng et al. 1992).  The majority of 
exposures to refractory ceramic fibers were found to be low, with 8-hour TWA exposure levels of 
≤0.2 fiber/cc for most of the tasks involved.  However, airborne levels as high as 17 fibers/cc were 
observed when removing refractory ceramic fiber containing blankets inside of furnaces or when welders 
cut through crude oil furnace tubes when cutting away damaged metal parts while repairing a furnace 
(Cheng et al. 1992). Furthermore, the study found that workers who replaced worn out refractory ceramic 
fiber modules from the furnaces had exposure to cristobalite in dust samples ranging from 0.03 to 
0.2 mg/m3, with a geometric mean of 0.06 mg/m3, which is above the OSHA established permissible 
exposure limit (PEL) of 0.05 mg/m3 (Cheng et al. 1992). A more recent study conducted from 1993 to 
1998 found that respirable quartz was detectable in only 14 of the 158 samples taken during the removal 
of insulation from industrial furnaces, respirable cristobalite was only detectable in 3 samples, and 
respirable tridymite was only detected in 1 sample (Maxim et al. 1999).  However, the short sampling 
time of many of these collections led to relatively poor limits of detection due to the low volume of air 
collected during the analysis, and longer sampling times would likely indicate a higher percentage of 
detectable crystalline silica exposure. 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Children may be exposed to low levels of synthetic vitreous fibers in the same ways that adults are 
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vitreous fibers from ambient and household air, or air from schools and other public buildings. 
Differences in breathing patterns, airflow velocity, and airway geometry between adults and children can 
result in age-related differences in deposition of inhaled particles in the respiratory tract (Phalen et al. 
1985).  Deposition of particles in various regions of the respiratory tract in children may be higher or 
lower than in adults depending on particle size, but for particles with diameters <1 µm, fractional 
deposition in the alveolar, tracheobronchial, and nasopharyngeal regions in 2-year-old children has been 
estimated to be about 1.5 times higher than in adults (Xu and Yu 1986).  A study conducted by Schneider 
et al. (1996) attempted to evaluate the personal exposure of individuals residing in different parts of 
Europe to organic and inorganic fibers.  It was determined that out of the four groups studied (suburban 
school children, rural retired persons, office workers, and taxi drivers), schoolchildren had the greatest 
exposure to total fiber counts.  The mean concentration of total respirable fibers in the personal air 
samples of schoolchildren was 0.02 fiber/cc (Schneider et al. 1996).  However, it was shown that the 
majority of respirable fibers were organic fibers and inorganic fibers other than synthetic vitreous fibers 
(particularly gypsum), and the level of exposure to fibers consistent with synthetic vitreous fibers was 
very low.   
The airborne fiber concentration in kindergartens in Denmark was studied to determine if there was a 
correlation between respiratory problems and fiber concentrations in the schools (Rindel et al. 1987;
Schneider 1986). The mean concentrations of respirable fibers in schools with ceiling boards containing 
synthetic vitreous fibers with water-soluble binders and resin binders were 1.1x10-4 and 9.7x10-5 fiber/cc, 
respectively. The mean concentration in kindergartens using ceiling boards that did not contain synthetic 
vitreous fibers was 4.1x10-5 fiber/cc. It was concluded that no correlation existed between respiratory
symptoms or disease and synthetic vitreous fibers exposure (Rindel et al. 1987; Schneider 1986). 
Since children tend to play on carpets and floors, they may also be exposed to synthetic vitreous fibers 
that have been deposited on theses surfaces, but the levels are expected to be very low (Schneider et al. 
1990).
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
The people most likely to have high exposure to synthetic vitreous fibers are workers who come into 
contact with products containing these fibers while on the job.  This includes people involved in the 
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or use these products. Workers engaged in the demolition of buildings with synthetic vitreous fiber-
containing materials are also potentially exposed.  Workers involved in the installation or servicing of 
furnaces that contain refractory ceramic fiber insulation may also be exposed to quartz, cristobalite, and 
tridymite.  Workers may also carry home deposited synthetic vitreous fibers from their clothing or in their 
hair, resulting in exposure of family members; however, this is not likely to be of concern at the present. 
Lung tissue samples were obtained from the autopsies of 145 former employees of 17 synthetic vitreous 
fiber plants located in the United States (McDonald et al. 1990).  Levels of total fibers were 
approximately 60% greater in workers than in people who were not occupationally exposed, but the 
majority of detectable fibers were not synthetic vitreous fibers.  While certain fibers were classified as 
synthetic vitreous fibers, no further identification as to exact type of synthetic vitreous fibers was 
possible. Furthermore, only four individuals that were occupationally exposed had synthetic vitreous 
fibers lung concentrations >0.2 fiber/µg lung tissue (one worker had a concentration of 1 fiber/µg), the 
rest had concentrations below 0.2 fiber/µg (McDonald et al. 1990).  The geometric mean fiber length, 
fiber diameter, and aspect ratio were 7.5 µm, 1.0 µm, and 8.0, respectively, for those occupationally 
exposed, while the values for the referents were 6.6 µm, 1.2 µm, and 6.1, respectively.  Autopsy reports 
indicated that synthetic vitreous fibers were not detected in the lung tissue of one female and eight male 
subjects who were employed in glass wool production plants for at least 1 year between 1946 and 1978 
(Gibbs et al. 1996). These findings suggest that glass wool and other types of synthetic vitreous fibers do 
not have a prolonged durability in human lung tissue. 
Although data are scarce, current monitoring data do not support the assumption that persons residing 
near plants where synthetic vitreous fibers are produced will be exposed to higher levels of these fibers in 
the ambient air than persons who reside distal from such plants (Switala et al. 1994).  It is noted that in 
1990, the EPA intended to regulate all synthetic vitreous fibers under the Clean Air Act, but instead chose 
to list only those mineral fibers having an average diameter less than 1 µm, following an industry-funded 
study, which showed that emissions of such fibers from synthetic vitreous fiber producing facilities were 
insignificant (EPA 1992). 
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
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adequate information on the health effects of synthetic vitreous fibers is available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a 
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of synthetic vitreous fibers.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of synthetic vitreous 
fibers are generally well characterized (see Chapter 4), and there does not appear to be a need for further 
research in this area.  However, continuing characterization of new fibers, particularly the physical 
dimensions of the fibers and products, will be necessary as they are produced. 
Production, Import/Export, Use, Release, and Disposal. Data regarding the import and export 
volumes of glass fibers, refractory ceramic goods, and mineral wool exist (USDOC 2002).  Although 
some production volume data are available for synthetic vitreous fibers (GMIC 2002; Mast et al. 2000), 
more recent data would be useful.  There is also a data need to have an estimate of the annual amount of 
synthetic vitreous fiber containing material that is either disposed of at landfills or incinerated at 
hazardous waste incinerators. Synthetic vitreous fibers are primarily used for insulation purposes and 
reinforcing other materials (IARC 1988, 2002; WHO 1988).
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C.
Section 11023, industries are required to submit substance release and offsite transfer information to the 
EPA. TRI, which contains this information for 2001, became available in 2003. This database is updated 
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Environmental Fate. Synthetic vitreous fibers are fundamentally inert and are not considered to 
undergo transport or degradative processes in the environment analogous to organic pollutants (WHO 
1988). Additional studies on the behavior of fibers in water (processes such as change in metal ion and 
hydroxyl ion composition, adsorption to organic materials, flocculation and precipitation, etc.) would be 
helpful in evaluating water-based transport of fibers, as well as in improving methods for removal of 
fibers from water.  Transport of fibers in air is governed by processes and forces that apply to all 
particulate matter, and these processes are reasonably well understood (WHO 1988). 
Bioavailability from Environmental Media.    Synthetic vitreous fibers are generally insoluble and 
are not absorbed following dermal exposure.  Most exposures occur to fibers in air, so the effect of 
matrices such as soil or food is largely unknown.  It is possible that adsorption of fibers onto other dust 
particles could influence the location of deposition in the lung, and might even influence the cellular 
response to the fibers. Research to determine if this occurs and whether this is biologically significant  
would be helpful. 
Food Chain Bioaccumulation.    No data were located on synthetic vitreous fiber levels in the tissues 
of edible organisms.  However, it is not expected that either aquatic or terrestrial organisms will 
accumulate a significant number of fibers in their flesh.  Consequently, food chain bioaccumulation or 
biomagnification does not appear to be of concern.  No data needs have been identified at this time. 
Exposure Levels in Environmental Media.    Data exist regarding the levels of synthetic vitreous 
fibers in ambient air (Balzer et al. 1971; NIOSH 1976; Switala et al. 1994) and indoor air (Gantner 1986; 
Jacob et al. 1992, 1993; Schneider et al. 1990; Trethowan et al. 1995).  Generally, these levels are very
low, with the exception of indoor air concentrations when insulating material is being installed (Jacob et 
al. 1993).  No data exist regarding the levels of synthetic vitreous fibers in other environmental media 
such as water or soil.  It would be useful to have airborne measurements of synthetic vitreous fibers near 
municipal landfills where construction material containing synthetic vitreous fibers are often discarded.  
Airborne levels in the vicinity of waste incinerators where synthetic vitreous fiber containing material 
may be burned would also be useful. 
Exposure Levels in Humans. The general population is exposed to low levels of synthetic vitreous 
fibers from ambient and indoor air (Balzer et al. 1971; Gantner 1986; Jacob et al. 1992, 1993; NIOSH 
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the general population (Esmen and Erdal 1990).  There are few data regarding the levels of synthetic 
vitreous fibers in human tissue due to the difficulty in analyzing for these substances (Dumortier et al. 
2001; McDonald et al. 1990; Roggli 1989; Schneider and Stockholm 1981).  Body burden data, 
particularly for workers frequently exposed to synthetic vitreous fibers occupationally, would be useful to 
better evaluate human exposure. 
Exposures of Children.    No data exist regarding the levels of synthetic vitreous fibers in children.  It 
was shown that exposure of children residing in Europe to synthetic vitreous fibers is significantly lower 
than exposure to organic and other inorganic fibers (Schneider et al. 1996).  Other studies have indicated 
that there is no correlation between respiratory problems in children and synthetic vitreous fibers 
concentrations in schools (Rindel et al. 1987; Schneider 1986).  Children may be exposed to these 
substances in the same ways that adults are exposed outside the workplace, from synthetic vitreous fibers 
in the air. Just as children are exposed to synthetic vitreous fibers in the same way as non-occupationally
exposed adults, there are no childhood-specific means to decrease exposure.  Because childhood exposure 
to synthetic vitreous fibers is considered low and it is difficult to analyze for synthetic vitreous fibers in 
humans, there is no data need to conduct body burden studies at this time.   
Child health data needs relating to susceptibility are discussed in Section 3.12.2 Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for synthetic vitreous fibers were located.  These 
substances are not currently one of the compounds for which a subregistry has been established in the 
National Exposure Registry. These substances will be considered in the future when chemical selection is 
made for subregistries to be established. The information that is amassed in the National Exposure 
Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be 
related to exposure to synthetic vitreous fibers. 
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2002) database provides additional information obtainable 
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A light-scattering-based optical sensor is being developed for the online analysis of fiber diameters during 
the manufacturing and production process of fiberglass, by Mission Research Corporation, Santa Barbara, 
California. Such a sensor will allow for the rapid measurement of fiber diameters and allow for improved 
production efficiency and control (FEDRIP 2002).  The Vortec Corporation (J.G. Hnat, principal 
investigator) is developing an advanced coal-fired incinerator/glass melter as a means of eliminating the 
solid/hazardous waste disposal problems associated with the production of insulation products and 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring synthetic vitreous fibers, its metabolites, and other biomarkers of exposure 
and effect to synthetic vitreous fibers.  The intent is not to provide an exhaustive list of analytical 
methods. Rather, the intention is to identify well-established methods that are used as the standard 
methods of analysis.  Many of the analytical methods used for environmental samples are the methods 
approved by federal agencies and organizations such as EPA and the National Institute for Occupational 
Safety and Health (NIOSH).  Other methods presented in this chapter are those that are approved by
groups such as the Association of Official Analytical Chemists (AOAC) and the American Public Health 
Association (APHA). Additionally, analytical methods are included that modify previously used methods 
to obtain lower detection limits and/or to improve accuracy and precision. 
As discussed in Chapter 4, synthetic vitreous fibers are not a single chemical entity, but rather a group of 
amorphous polysilicates.  Because the toxicity of fibrous particles appears to be related primarily to fiber 
size and chemical durability, modern analytical methods focus on providing information on these 
parameters, as well as on total number of fibers.  At present, the number and size distribution of fibers in 
a sample can only be determined by direct microscopic examination.  This may be performed using either 
light or electron microscopy, as discussed below.  A complicating factor in the analysis of synthetic 
vitreous fibers is distinguishing small fibrous particles from asbestos or other inorganic fibers, and 
identifying and quantifying the various forms of synthetic vitreous fibers.  NIOSH methods for 
determining fiber concentrations are geared to counting fibers of certain dimensions utilizing detailed 
rules as to how to count different objects (e.g., objects with split ends or attached particles) (NIOSH 
1994a). 
Light Microscopic Methods.  Phase contrast microscopy (PCM) is most frequently employed to measure 
the levels of synthetic vitreous fibers.  Currently, the standard method for the determination of airborne 
fibrous particles in the workplace is NIOSH Method 7400, Asbestos and Other Fibers by Phase Contrast 
Microscopy (NIOSH 1994a).  In NIOSH Method 7400, samples are collected on 25 mm cellulose ester 
filters (cassette-equipped with a 50 mm electrically-conductive cowl).  The filter is treated to make it 
transparent and then is analyzed by microscopy at 400–450x magnification, with phase-contrast 
illumination, using a Walton-Beckett graticule.  Different counting rules may be employed when 
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respectively), and these different counting rules often make comparing data from various studies difficult.  
The details of these counting rules are available in the NIOSH Manual of Analytical Methods (1994).  
Briefly, when using counting rules B, only fibers <3 µm in diameter and >5 µm in length with aspect 
ratios of ≥5:1 are counted.  The rules further specify the counting of fiber ends only, with sufficient fields 
to yield at least 200 fiber ends.  The counting of fibers in a minimum of 20 fields is also required for 
statistical validity.  When using counting rules A, fibers with diameters >3 µm may be counted as well as 
fibers possessing an aspect ratio of ≥3:1.  A recent study has concluded that using the A counting rules 
generally gives higher fiber counts than the B counting rules when analyzing the same samples (Breysse 
et al. 1999). Another recent study recommends using counting rules A in order to decrease the number of 
non-detects when analyzing for synthetic vitreous fibers on contact surfaces such as desks, floors, 
bookshelves, etc. inside of office buildings (Vallerino et al. 2003). Fiber concentrations in air are usually
reported as fibers/mL or fibers/cc, although fibers/m3 or fibers/L are occasionally employed.  Fiber 
densities are used to quantify the amount of synthetic vitreous fibers on the surface of objects; these units 
are usually given in fibers/mm2 (Vallerino et al. 2003).  
Although the PCM method is relatively fast and inexpensive, it does not specifically distinguish between 
the various forms of synthetic vitreous fibers, and it not sensitive to enough to detect fibers possessing 
very small diameters.  The resolution of a microscope (the ability to distinguish between two very closely
spaced objects) is limited by the wavelength of light used for analysis and the numerical aperture of the 
microscope (Hecht 1989).  Because PCM uses visible light of approximately 400–700 nm, the maximum
resolution than can be achieved is about 0.25 µm.  Frequently, synthetic vitreous fibers can be 
distinguished from other fibers, like asbestos, based upon their morphology (Switala et al. 1994).  Glass 
fibers have clean, well defined, mostly parallel sides, while other fibers such as asbestos usually have 
irregular sides or hair-like appendages emanating from the sides (Switala et al. 1994).  The ends of glass 
fibers have three distinctive features that can be useful in their identification:  (1) The edges possess a 
clean break that occurs transverse to the fiber length; (2) the ends exhibit a notch-type break; and (3) the 
ends will taper similar to that of a sharpened pencil. Other materials will fan or fry, and therefore, the 
morphology of glass fibers is often distinctive from that of other fiber types.  When morphology alone 
cannot distinguish between synthetic vitreous fibers and other fibers, or greater sensitivity is required, 
other microscopic techniques may be employed to augment the analysis.  
Since synthetic vitreous fibers are amorphous substances, polarized light microscopy is often employed to 
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linear polarized radiation is used to illuminate the sample and a second polarizer placed after the sample 
is used to analyze the light that is transmitted as the sample is rotated in various spatial directions 
(NIOSH Method 9002).  Amorphous samples like synthetic vitreous fibers have the same refractive index 
in each direction, while anisotropic materials such as asbestos have optical properties that vary with the 
orientation of incident light with the crystallographic axes, and demonstrate a range of refractive indices 
depending both on the propagation direction of light through the substance and on the vibrational plane 
coordinates. 
If improved resolution is required to analyze fibrous samples, transmission electron microscopy (TEM) 
(NIOSH Method 7402) or scanning electron microscopy (SEM) are often employed.  Fibers with 
diameters as small as 0.05 and 0.005 µm can be counted by SEM and TEM methods, respectively.  In the 
TEM experiment, the wavelength of a 100 KeV electron is 0.0037 nm, which is about 143,000 times 
smaller than the wavelength of light used in PCM.  Hence, using electrons for analysis rather than visible 
light photons leads to much better resolution than can be achieved with light microscopy.  Identification 
techniques such as energy-dispersive x-ray analysis (EDXA) can be used with SEM and TEM to identify 
fibers on the basis of elemental composition (Spurny 1994).  Because EDXA only identifies the elemental 
composition of the fibers, it can only distinguish between organic and inorganic fibers, as well as things 
such as silicate or nonsilicate type fibers. In the TEM experiment, it is also possible to measure the 
diffraction of electrons by crystalline structures that are traversed by the electron beam.  This technique 
can be useful to distinguish between crystalline structures and amorphous fibers like synthetic vitreous 
fibers. 
Methods for preparing biological and environmental samples for microscopy are described below. 
7.1 BIOLOGICAL MATERIALS  
The analysis of fibers in biological samples involves digesting the biological material in a strong base 
(e.g., potassium hydroxide) or a powerful oxidant (e.g., hypochlorite).  The insoluble residue (including 
the fibrous portion) is collected by ultracentrifugation or filtration, and may be further cleared of 
biological material by ashing.  In some cases, biological material may be removed by ashing without prior
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Methods for sampling fibrous particles in biological tissue are not standardized and it is often difficult to 
compare results of one laboratory with another (WHO 1988).  There is also evidence that indicates that 
digestion of biological materials with potassium hydroxide or sodium hypochlorite can cause substantial 
loss of synthetic vitreous fibers in the samples (McDonald et al. 1990).  A review on the methods of 
sampling, analysis, and identification of fibers in lung tissue has been published (Davis et al. 1986).  It
was concluded that low temperature ashing in the presence of nascent oxygen is a superior extraction 
method than chemical digestion alone (Davis et al. 1986).  A method for the sampling and identification 
of nonrespirable fibers in the eyes of workers frequently exposed to synthetic vitreous fibers has been 
published (Schneider and Stockholm 1981).  In this procedure, mucous threads and dried mucous samples 
were ashed in a low temperature asher and examined by PCM.  A correlation was reported between 
synthetic vitreous fibers levels in the eyes and total dust samples in the workplace.  The techniques used 
to analyze synthetic vitreous fibers in biological samples are summarized in Table 7-1. 
7.2 ENVIRONMENTAL SAMPLES 
For the analysis of fibers in air, a sample of air is drawn through a filter by a vacuum pump (usually at a 
flow-rate of around 1–2 L/minute), and the fibers retained on the filters are examined microscopically. 
Two types of filters are commonly employed for air sample collection, cellulose ester membrane filters 
(MF) and polycarbonate (Nuclepore) filters (NPF) (Spurny 1994).  The NPF is a surface filter that retains 
fibers on the exterior of the filter, while the MF is a spongy depth type filter.  The sensitivity of the 
methods depends on the volume of air drawn through the filter, the filtration procedure, and the 
microscopic method employed.  Filtration studies have shown that an MF with pore size of 0.8 µm and an 
NPF with a pore size of 0.4 µm are capable of collecting most fibers in the workplace (Spurny 1994).  Air 
samples obtained using NPFs can be applied directly for SEM or EDXA analysis without further 
preparation; however, specimen preparation for TEM analysis is more complex.  In the workplace, where 
PCM is the standard method, the working range of countable fibers for a short-term sample (15 minutes) 
is around 0.5–0.04 fiber/cc, but may be reduced to 0.001 fiber/cc using an 8-hour sample because a larger 
volume of air is collected (NIOSH 1976).  Improvements in filter preparation procedures now allow for 
viewing at higher magnification (1,250x), resulting in a several-fold improvement in sensitivity for these 
fibers (Pang et al. 1989). Recently, detection limits of 1x10-5 f/cc have been obtained using a 12-hour 
sampling procedure (Switala et al. 1994).  It is important to keep in mind that only fibers with diameters 
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Digestion with sodium 
hypochlorite; membrane 
filter; dry 
PCM No data No data Spurny 1994
Urine Membrane filtration followed 
by ashing and dispersion in 
1% acetic acid followed by 
nuclepore filtration (0.1 µm) 
TEM No data No data Spurny 1994
Eye mucous Low temperature ashing PCM No data No data Schneider and 
Stockholm 1981 
Lung tissue Low temperature ashing in a 
plasma asher; filtration with 
0.2 µm nuclepore 
TEM 0.04 µm (diameter) 
0.09 µm (length) 
No data McDonald et al. 
1990 
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counted by SEM and TEM methods, respectively (WHO 1988).  The techniques used to analyze synthetic 
vitreous fibers in air samples are summarized in Table 7-2. 
While no methods were located for the analysis of synthetic vitreous fibers in water, TEM-based methods 
exist that can quantify asbestos concentrations in water samples, and these methods should also be 
applicable toward the measurement of synthetic vitreous fibers (Brackett et al. 1992; Melton et al. 1978).
No methods were located for the analysis of asbestos or synthetic vitreous fibers in soil. 
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of synthetic vitreous fibers is available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a 
program of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of synthetic vitreous fibers.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.    Standardized techniques to 
evaluate the levels of synthetic vitreous fibers in biological tissues do not exist.  In general, biological 
tissues are subject to digestion with a strong base or oxidizing agent, followed by ashing.  The tissue is 
then analyzed by microscopic examination.  A method for the sampling and identification of 
nonrespirable fibers in the eyes of workers frequently exposed to synthetic vitreous fibers has been 
published (Schneider and Stockholm 1981).  A data need exists to develop reliable methods to analyze for 
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Sample Preparation Analytical Sample Percent Reference 
matrix method method detection limita recovery 
Air Pump air through PCM 0.01 f/cc ±35 ASTM 1988 
filter membrane; 
convert to optically 
transparent gel 
Air Filter with 0.45– NIOSH 7400; 0.003 f/cc No data Jacob et al. 1993; 
1.2 µm cellulose PCM NIOSH 1994a 
ester membrane 
filter 
Air Filter with 0.45– PCM; polarized 1x10-5 f/cc No data Switala et al. 
1.2 µm cellulose light microscopy 1994 
ester membrane 
filter 
Air Filter with 0.45– NIOSH 7402; 0.001 f/cc No data NIOSH 1994a; 
1.2 µm cellulose TEM Spurny 1994
ester membrane 
filter 




print lifters; transfer 
to microscope slide 
aSample detection limits in air are a function of the volume of air collected and thus the sampling time.  Detection 
limits on the surface of an object are a function of the number of fibers collected per unit area. 
f/cc = fibers per cubic centimeter; NIOSH = National Institute for Occupational Safety and Health; PCM = phase 
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Exposure. Uncoated or coated fibers in bronchoalveolar lavage fluid samples or in autopsied or
surgically resected lung tissue samples are the principal biomarkers of exposure to biopersistent asbestos 
fibers (Agency for Toxic Substances and Disease Registry 2001).1  However, similar biomarkers to 
identify or quantify human exposure to synthetic vitreous fibers, which are less biopersistent than 
asbestos fibers, have not been developed for routine clinical use.  Nevertheless, aluminum-silicate fibers 
with chemical compositions consistent with synthetic vitreous fibers have been detected in human lung 
tissues (McDonald et al. 1990; Roggli 1989; Sébastien et al. 1994) and in bronchoalveolar lavage samples 
(Dumortier et al. 2001). 
Among 1,800 bronchoalveolar samples submitted to a Belgium hospital between 1992 and 1997 for fiber 
analysis, pseudoasbestos bodies were detected in samples from nine patients (0.5%) (Dumortier et al. 
2001). In samples from these nine patients (all of whom had occupational experience with furnaces or 
welding), fibers of composition consistent with refractory ceramic fiber composition were detected in 
42% of core fibers analyzed (Dumortier et al. 2001). Other nonasbestos fibers and asbestos fibers 
accounted for 28% and 30% of the core fibers analyzed in these samples. 
Effect. Epidemiological studies of synthetic vitreous fiber manufacturing workers have not found 
consistent evidence for increased risks of malignant or nonmalignant respiratory or pleural effects, but 
results from animal experiments indicate that repeated inhalation exposure to synthetic vitreous fibers 
may result in pulmonary or pleural fibrosis, lung cancer, or mesothelioma, depending on fiber 
dimensions, fiber durability in the lung, duration of exposure, and exposure levels.   
The chest x-ray is the most common means of detecting the onset of pleural or pulmonary changes that 
may precede or accompany fibrosis (i.e., irreversible scarring of lung or pleural tissue that can lead to 
restricted breathing). The International Labour Office (ILO) established a classification system for 
profusion of opacities in chest x-rays that includes four categories of increasing severity, each with three 
subcategories: 0 (0/-, 0/0, 0/1); 1 (1/0, 1/1, 1/2); 2 (2/1, 2/2, 2/3); and 3 (3/2, 3/3, 3/4) (ILO 1989).  The 
American Thoracic Society (1986) recommends that chest x-rays be scored for pleural and pulmonary
changes separately because of the experience with asbestos-exposed workers indicating that pleural and 
pulmonary fibrosis have differences in “epidemiology, clinical features, and prognosis.”  Lung function 
1 Particles or fibers that are deposited in the lung and are too large to be phagocytized by alveolar macrophages may
become coated with an iron-rich protein coat.  The generic term for these structures is ferruginous bodies.  When the 
core fiber is asbestos, the resultant structure is termed an asbestos body (Agency for Toxic Substances and Disease
Registry 2001).  Ferruginous bodies having the appearance of asbestos bodies under light microscopy and a 
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tests are also useful to characterize the development of pulmonary or pleural fibrosis; forced vital capacity
is diminished with increasing severity of pulmonary or pleural fibrosis. 
Development of sensitive and specific chemical or biochemical tests for synthetic vitreous fibers effects 
would be useful. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media.    Methods are available to measure synthetic vitreous fibers in air (Jacob et al. 1993; NIOSH 
1994a; Spurny 1994; Switala et al. 1994).  These methods are precise, and are sensitive enough to detect 
levels that are frequently encountered in both occupational and non-occupational settings.  No specific 
methods of measuring the levels of synthetic vitreous fibers in other environmental media such as soil, 
water, and sediment exist. Since exposure to synthetic vitreous fibers primarily occurs through inhaling 
air, no data need has been identified at this time. 
7.3.2 Ongoing Studies 
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The international, national, and state regulations and guidelines regarding synthetic vitreous fibers in air, 
water, and other media are summarized in Table 8-1.
The U.S. Department of Health and Human Services, National Toxicology Program (NTP 1998, 2000, 
2002) classified glass wool (respirable size) as reasonably anticipated to be a human carcinogen, based 
on sufficient evidence of carcinogenicity in experimental animals. This assessment was originally 
prepared in 1993–1994 for the 7th Report on Carcinogens (NTP 1994), but has not been updated since 
then in the 8th, 9th, or 10th Reports on Carcinogens (NTP 1998, 2000, 2002).  Continuous filament glass, 
rock wool, slag wool, or refractory ceramic fibers were not listed or assessed for carcinogenicity in the 
7th, 8th, 9th, or 10th Report on Carcinogens (NTP 1994, 1998, 2000, 2002). 
The International Agency for Research on Cancer (IARC 2002) concluded that epidemiologic studies 
published since the previous IARC (1988) assessment provided no evidence of increased risks of lung 
cancer or of mesothelioma from occupational exposure during the manufacture of man-made vitreous 
fibers and inadequate evidence overall of any excess cancer risk.  IARC (2002) concluded that there was 
(1) sufficient evidence in experimental animals for the carcinogenicity of certain special purpose glass 
fibers and of refractory ceramic fibers; (2) limited evidence in experimental animals for the carcino­
genicity of insulation glass wool, rock (stone) wool, and slag wool; and (3) inadequate evidence in 
experimental animals for the carcinogenicity of continuous glass filament and certain newly developed, 
less biopersistent fibers such as X-607 and MMVF34.  Insulation glass wool, rock (stone) wool, slag 
wool, and continuous filament glass were classified in Group 3, not classifiable as to carcinogenicity to 
humans because of the inadequate evidence of carcinogenicity in humans and the relatively low bio­
persistence of these materials.  In contrast, refractory ceramic fibers and certain special-purpose glass 
fibers (104 E-glass and 475 glass fibers) not used as insulating materials were classified in Group 2B, 
possibly carcinogenic to humans, because of their relatively high biopersistence. 
The U.S. EPA Integrated Risk Information System (IRIS) (2004) has not classified the potential carcino­
genicity of glass wool, continuous filament glass, rock wool, or slag wool, but assigned refractory
ceramic fibers to Group B2, probable human carcinogen, based on no data on carcinogenicity in humans 
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Table 8-1. Regulations and Guidelines Applicable to Synthetic Vitreous Fibers 
Agency Description Information References 
INTERNATIONAL
Guidelines:  
 IARC Carcinogenicity classification 
Insulation glass wool, rock (stone) wool, slag 
wool, and continuous filament glass 
Refractory ceramic fibers and certain special-




 IARC 2002 
 IARC 2002 
NATIONAL
Regulations and Guidelines: 
a. Air 
ACGIH TLV (8-hour TWA) 
Synthetic vitreous fibers ACGIH 2001
  Continuous filament glass fibers, glass wool 
fibers, rock wool fibers, slag wool fibers,
special purpose glass fibers
Continuous filament glass (inhalable fraction) 
1.0 fibers/ccc 
5 mg/m3 
Refractory ceramic fibers 0.2 fibers/ccc 
NIOSH REL (10-hour TWA) 
Fibrous glass dust (fiber glas®, fiberglass, 
glass fibers, and glass wool); fibers ≤3.5 µm in 
diameter and ≥10 µm in length) 




Refractory ceramic fibers No data NIOSH 1992
 OSHA PEL (8-hour TWA) 
Fiberglass and mineral wool (glass wool, rock 




Synthetic vitreous fibers as an inert or nuisance 
dust 
 OSHA 2001b
  Respirable fraction 
  Total dust 
5 mg/m3
15 mg/m3 
b. Water No data 
c. Food No data 
d. Other 
 ACGIH Carcinogenicity classification 
Synthetic vitreous fibers 
  Continuous filament glass fibers (respirable 
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Table 8-1. Regulations and Guidelines Applicable to Synthetic Vitreous Fibers 
Agency Description Information References 
NATIONAL (cont.)
ACGIH   Glass wool fibers, rock wool fibers, slag wool 




 EPA Carcinogenicity classification 
Glass wool, continuous filament glass, rock 
wool, and slag wool 
No data IRIS 2002 
Refractory ceramic fibers Group B2g IRIS 2002 
Inhalation unit risk No data 
Oral slope factor No data 
NTP Carcinogenicity classification 
Glass wool (respirable size) 
Continuous filament glass, rock wool, slag
wool, and refractory ceramic fibers 
Reasonably 




 NTP 2002 
STATE
Regulations and Guidelines: 
a. Air No data 
b. Water No data 
c. Food No data 
d. Other No data 
aGroup 3: not classifiable as to carcinogenicity to humans, based on inadequate evidence of carcinogenicity in 
humans and inadequate or limited evidence in experimental animals 
bGroup 2B: possibly carcinogenic to humans, based on limited evidence of carcinogenicity in humans and less than 
sufficient evidence of carcinogenicity in experimental animals
cRespirable fibers:  length >5 µm; aspect ratio ≥3:1, as determined by the membrane filter method at 400– 
450X magnification (4-mm objective), using phase-contrast illumination. 
dGroup A4: not classifiable as a human carcinogen 
eGroup A3: confirmed animal carcinogen with unknown relevance to humans 
fGroup A2: suspected human carcinogen, based on limited evidence of carcinogenicity in humans and sufficient 
evidence of carcinogenicity in experimental animals with relevance to humans 
gGroup B2:  probable human carcinogen, based on sufficient evidence of carcinogenicity in animals 
hNot listed or assessed in the 9th Report on Carcinogens (NTP 2001) 
ACGIH = American Conference of Governmental Industrial Hygienists; EPA = Environmental Protection Agency;
IARC = International Agency for Research on Cancer; IRIS = Integrated Risk Information System; NIOSH = National 
Institute of Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and 
Health Administration; PEL = permissible exposure limit; REL = recommended exposure limit; TLV = threshold limit 
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assessment for refractory ceramic fibers based on recent multiple-exposure chronic inhalation animal 
bioassays.  The assessment is considering the development of quantitative inhalation unit risk estimates 
for refractory ceramic fibers based on the animal tumorigenic responses, but, as of February 2004, the 
assessment was not completed. 
In 1999, a Health and Safety Partnership Program was established as a voluntary workplace safety
program for workers involved in the manufacture, fabrication, installation, and removal of glass wool, 
rock wool, and slag wool products (Marchant et al. 2002; OSHA 1999).  The program was established as 
a result of negotiations between OSHA, the North American Insulation Manufacturers Association, the 
National Insulation Association, and the Insulation Contractors Association of America.  The program
established a voluntary eight-hour time-weighted average (TWA) permissible exposure limit (PEL) of 
1 respirable fiber/cc. Respirable fibers are counted as particles with length >5 µm, diameter <3 µm, and 
aspect ratio ≥3:1. The agreement specifies that when the PEL is exceeded in a workplace (such as when 
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10.  GLOSSARY 
Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
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10. GLOSSARY 
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
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10. GLOSSARY 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been 
reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation 
that has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a 
chemical is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
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Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism.  Utilizing computational techniques, it provides the means of studying the 
absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
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points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical information 
such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also called 
biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL-from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
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Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value - Time Weighted Average (TLV-TWA) may
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The study of the absorption, distribution, and elimination of toxic compounds in the 
living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
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observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
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APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Refractory Ceramic Fibers
CAS Number: None 
Date: July 13, 2004
Profile Status: Final Post Public Comment 
Route: [X] Inhalation [ ] Oral 
Duration: [ ] Acute   [ ] Intermediate   [ X ] Chronic 
Graph Key: 78 
Species: Fischer 344 Rats 
Minimal Risk Level: 0.03 [ ] mg/kg/day  [ ] ppm [X] WHO fiber/cc 
References: 
Mast RW, McConnell EE, Anderson R, et al.  1995a.  Studies on the chronic toxicity (inhalation) of four 
types of refractory ceramic fiber in male Fischer 344 rats.  Inhal Toxicol 7:425-467. 
Mast RW, McConnell EE, Hesterberg TW, et al.  1995b. Multiple dose chronic inhalation toxicity study
of size-separated kaolin refractory ceramic fiber in male Fischer 344 rats.  Inhal Toxicol 7(4):469-502.  
Bernstein DW, Sintes JMR, Ersboell BK, et al.  2001b.  Biopersistence of synthetic mineral fibers as a 
predictor of chronic inhalation toxicity in rats.  Inhal Toxicol 13:823-849. 
Maxim LD, Yu CP, Oberdörster G, et al.  2003.  Quantitative risk analyses for RCF:  survey and 
synthesis.  Regul Toxicol Pharmacol 38:400-416.  
Experimental design and effects noted: 
In the multiple-exposure level study (Mast et al. 1995b), four groups of about 140 male F344 rats were 
exposed via nose-only inhalation to 0 (filtered air controls), 3, 9, or 16 mg/m3 of a refractory ceramic
fiber called RCF1, 6 hours/day, 5 days/week for up to 24 months.  The companion study (Mast et al. 
1995a) exposed two groups of about 140 male F344 rats to 0 or 30 mg/m3 RCF1 (from the same lot as the 
multiple-exposure level study) via the same protocol.   
The RCF1 test material was prepared from a bulk sample of kaolin-based refractory ceramic fiber 
obtained from Carborundum Company, Niagara Falls, New York.  The bulk material was separated 
(before aerosol generation) to concentrate the numbers of fibers with a targeted nominal arithmetic mean 
diameter of 1 µm and length of 20–30 µm.  These dimensions were chosen based on results of an 
unpublished simulated workplace exposure study showing airborne fibers to be principally of this size 
range. The generated aerosols had the characteristics listed in Table A-1.  In addition to fibers (i.e., 
particles with length:diameter ≥3:1), the aerosols contained nonfibrous particles, often referred to as 
“shot”. In the experimental aerosols, the ratios of nonfibrous particles (with diameters <3 µm) to total 
fibers or to WHO fibers were reported by Mast et al. (1995b) to range from 0.9 to 1.5 or from 1.3 to 1.96, 
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Table A-1. RCF1 Aerosol Characteristics in the 2-Year Inhalation Bioassays with 

F344 Rats (Mast et al. 1995a, 1995b) 

Character (mean [± standard deviation]) 3 mg/m3 9 mg/m3 16 mg/m3 30 mg/m3 
Gravimetric concentration (mg/m3) 3.0±0.4 8.8 ±0.7 16.5±1.1 29.1±5.2 
Total fibers/cc (L:D≥3) 36±17 91±34 162±37 234±35 
WHO fibers/cc (L>5 µm; D<3 µm; L:D≥3) 26±12 75±35 120±35 187±53 
Diameter (D) range (µm) 0.08–5.32 0.08–5.37 0.07–4.83 0.12–4.53
Length (L) range (µm) 0.77–93.93 1.09–98.25 1.24–97.88 1.30–76.6 
Arithmetic mean D (µm) 1.02±0.73 1.02±0.71 1.02±1.70 0.98±0.61
Geometric mean D (µm) 0.80±2.06 0.80±2.03 0.82±1.99 0.82±1.89
Arithmetic mean L (µm) 20.2±18.10 20.3±17.1 19.6±16.5 22.3±17.0 
Geometric mean L (µm) 13.5±2.60 13.9±2.50 13.8±2.4 15.9±2.4 
Nonfibrous particle counts 
≤1 µm/cc 28.3±19.3 85.7± 63.2 88.0±52.4 17±154 
1–3 µm/cc 23.0±11.8 54.8±38.4 68.4±24.2 135±45 
3 µm/cc 17.1±8.4 43.6±25.2 58.6±27.1 81±29 
Ratio nonfibrous particles (<3 µm):total fibers 1.41 1.54 0.97 1.31 
Ratio nonfibrous particles (<3 µm):WHO fibers 1.96 1.87 1.30 1.63 
Groups of 3–6 rats from each exposure group were killed at 3, 6, 12, 18, and 24 months of exposure.  
Additional groups of 3–6 rats were removed from exposure at 3, 6, 12, and 18 months and exposed to 
filtered air until they were sacrificed at 24 months.  Remaining rats exposed for 24 months (15–32 rats per 
group) were held without further exposure until 30 months when survivors were killed.  All rats were 
necropsied. Lung tissues were removed, and weighed, and the left lung was prepared for routine 
histopathology that included staining for collagen deposition.  Other tissues processed for histopathology 
included the nasal cavity, larynx, trachea, bronchi, mediastinal and mesenteric lymph nodes, liver, spleen, 
kidneys, heart, and all tissues with grossly visible lesions.  The concentration and size distributions of 
fibers in lung tissue were determined after ashing of accessory lung lobes.  All fibers detected in lungs 
had diameters <3 µm.  Concentrations were expressed as total fibers per mg dry lung (length:diameter >3) 
or WHO fibers per mg dry lung (length >5 µm, diameter <3 µm, and length:diameter ≥3). 
Observed nonneoplastic lung lesions were classified with two different grading scales.  One scale (the 
Wagner scale) contained eight grades ranging from a normal grade of 1 (with no lesions observed), 
through “cellular change” grades 2 and 3 (few to conspicuous macrophages in terminal bronchioles and 
alveoli and no collagen deposition at the bronchiolo-alveolar junction), to five “fibrosis” grades.  The 
fibrosis grades increased in severity as follows: grade 4 (minimal), minimal collagen deposition at the 
bronchoalveolar junction, increased bronchiolization, and associated mucoid debris; grade 5 (mild), 
interlobular linking of collagen deposition; grade 6 (moderate), early consolidation and decrease in 
parenchyma tissue; grade 7 (severe), marked fibrosis and consolidation; and grade 8, complete 
obstruction of most airways.  The other scale contained five grades (0=normal; 1=minimal; 2=mild; 
3=moderate; 4=marked; 5=severe) and was applied to specific histopathological findings (macrophage 
aggregation, bronchiolization, granuloma presence, interstitial [i.e., pulmonary] fibrosis, and pleural 
fibrosis). 
Survival was not statistically significantly affected in any of the exposed groups compared with controls.  
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9 mg/m3). At sporadic intervals of exposure, rats exposed to 16 or 30 mg/m3 displayed statistically
significant decreases in body weight, compared with controls.  The decreases were not >10% of control 
values, and are not considered an adverse effect.  In 16- and 30-mg/m3 rats, absolute and relative lung 
weights were significantly greater than in control rats, as early as after 3 months of exposure.  After 
24 months of exposure, mean absolute lung weights in these groups were respectively increased by
32 and 65%, compared with controls.  The lung weight changes are considered to be an indicator of 
pulmonary inflammation from repeated exposure to RCF1.   
Lung fiber concentrations increased with increasing exposure duration and concentration.  At 24 months, 
mean values of WHO fibers/mg lung were 4.29x104, 15.60x104, 22.10x104, and 27.50x104 for the 3-, 9-, 
16-, and 30-mg/m3 groups, respectively. Mean values for total fibers/mg lung were 5.55±1.71, 
18.80±3.59, 27.80±6.06, and 37.00±8.01, respectively.
Exposure-related nonneoplastic histopathological lesions were restricted to the lung or pleura.  Signs of 
pulmonary inflammation (macrophage aggregation, bronchiolization, and granuloma presence) were 
observed in all exposed groups after 3 months of exposure, whereas these lesions did not occur in the 
control rats at any interval (see Table A-2).  At 24 months, mean scores (on the five-grade scale) in the 
3- and 30-mg/m3 groups ranged from 2 to 3.2 for macrophage aggregation, from 1.2 to 2.7 for
bronchiolization, and from 1.5 to 2 for granuloma presence (Table A-2).  The mean scores reflect 
progression of the severity of the inflammatory lesions with increasing exposure concentration 
(Table A-2). There is also some evidence of progression of the severity of the inflammatory lesions with 
increasing duration of exposure, most notably between 3 and 12 months (Table A-2).   
Signs of interstitial (i.e., pulmonary) fibrosis and pleural fibrosis appeared in rats exposed to 
concentrations ≥9 mg/m3 (Table A-2). The five-grade scores for interstitial fibrosis and pleural fibrosis 
(see note about these scores below) showed some progression in severity with exposure duration and 
concentrations, but the average severity scores for the exposed groups did not progress beyond a score of 
3 (moderate) for pulmonary fibrosis or a score of 2 (mild) for pleural fibrosis (Table A-2).  Signs of 
fibrosis did not appear until 12 months of exposure. Using the eight-grade Wagner scale to classify the 
pulmonary cellular changes and fibrosis, the mean scores at 24 months were 1.0 (normal), 3.2, 4.0, 4.2, 
and 4.0 for the control, 3-, 9-, 16-, and 30-mg/m3 groups, respectively. In rats exposed for 24 months and 
allowed to live without exposure to 30 months, respective mean scores were 1.0, 2.9, 3.8, 4.0, and 4.3 
(Table A-2). These scores indicate that the pulmonary lesions produced by 24 months of exposure 
showed only minor, if any, regression and that, on average, the most severe nonneoplastic lesions formed 
were classified as minimal to mild fibrosis.  It was reported that the principal difference between 
24-month exposed rats killed at 24 and 30 months was a reduction in the number of pulmonary 
macrophages and granulomas in the 30-month rats; pulmonary or pleural fibrosis showed no signs of 
regression. 
In a later published report, Bernstein et al. (2001b) reported that the pathologist, who originally scored the 
histological slides from the RCF1 2-year bioassay, had provided scores for collagen deposition at the 
bronchoalveolar junction. This lesion was scored in each rat on a five-scale system as follows:
 0=normal; 

1=minimal–very few (1 or 2 foci) and very small foci of collagen deposition of insufficient 

severity to score as Grade 4 in the eight-grade Wagner scale;  

2=mild–slight, but easily detected, few, small foci of collagen deposition, minimally sufficient 

to classify in Grade 4 of the Wagner scale; 

3=moderate–easily detected foci of collagen deposition in considerably enlarged areas, 
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4=marked–marked, obvious, or extensive foci of collagen deposition extending into the 
interstitium, and corresponding to Grade 4 of the Wagner scale; 
5=severe–widespread collagen deposition with consolidation at the bronchoalveolar junction, 
sometimes with interlobular linking, corresponding to Grade 4 to 5 of the Wagner scale.   
In accordance with this scale, collagen deposition at the bronchoalveolar junction is taken as an early
response at the site where fibrosis can develop.  The lesion is not classified as pulmonary fibrosis at a 
minimal score of 1, but is classified as minimal to mild fibrosis at scores of 2–5.  The mean scores 
(±standard deviations) for the collagen deposition scores reported by Bernstein et al. (2001b) for the six 
rats in each of the groups sacrificed at 24 months were:  control (n=12), 0 (normal); 3 mg/m3, 0.67±0.8;
9 mg/m3, 2.0±0; 16 mg/m3, 2.83±0.4; and 30 mg/m3, 2.17±0.4. These mean scores for collagen 
deposition are identical to the mean scores for the lesion named “pulmonary fibrosis” in the Mast et al. 
(1995a, 1995b) report and shown in Table A-2.  Thus, the scores for “pulmonary fibrosis” shown in 
Table A-2 are actually for collagen deposition as per the original pathology reports. 
Neoplastic lesions (lung adenomas, lung carcinomas, and mesotheliomas) were found most prominently
in rats exposed to 30 mg/m3. The tumors appeared predominately late in life.  The first adenoma occurred 
in rats sacrificed at 18 months; carcinomas and mesotheliomas were detected only in the 30-month­
sacrifice animals.  Incidences for rats (that survived to 12 months) with bronchoalveolar hyperplasia were
8/129, 10/123, 16/127, 13/124, and 17/123 for the control through high-exposure groups.  Combined 
incidences for lung adenomas or carcinoma were 1/129, 2/123, 5/127, 2/124, and 16/123.  Incidences for 
mesothelioma were 0/129, 0/123, 1/127, 0/124, and 2/123.  Incidences for mesothelial proliferation were 
1/129, 0/123, 1/127, 1/124, and 9/123. 
Table A-2. Mean Severity Scores for Pulmonary Lesions in F344 Rats Exposed to 
RCF1 (Mast et al. 1995a, 1995b)a 
Exposure Pleural 
level/ Macrophage Bronchio- Pulmonary fibrosis 8-Grade 
sacrifice Number Aggregation lization (0– Granuloma fibrosis (0– (0– Wagner 
month of rats (0–5 scale) 5 scale) (0–5 scale) 5 scale) 5 scale) scale score 
Control 
3 3 0 0 0 0 0 1.0 
6 3 0 0 0 0 0 1.0 
12 6 0 0 0 0 0.3 1.0 
18 6 0 0 0 0 0 1.0 
24 6 0 0 0 0 0 1.0 
30b 32 0.1 0.1 0 0 0 1.0 
3 mg/m3 
3 3 1.7 0 0.7 0 0 2.0 
6 3 1.7 0 1 0 0 2.0 
12 6 2 1 1.3 0.2 0 3.0 
18 6 2 1.2 1.7 0.7 0.7 3.2 
24 6 2 1.2 1.5 0.7 0.5 3.2 
30b 23 2.4 1.7 1.5 0.8 0.5 2.9 
9 mg/m3 
3 3 2 0.3 1.3 0 0 2.3 
6 3 2 0.7 2 0 0.3 2.7 
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Table A-2. Mean Severity Scores for Pulmonary Lesions in F344 Rats Exposed to 

RCF1 (Mast et al. 1995a, 1995b)a 

Exposure Pleural 
level/ Macrophage Bronchio- Pulmonary fibrosis 8-Grade 
sacrifice Number Aggregation lization (0– Granuloma fibrosis (0– (0– Wagner 
month of rats (0–5 scale) 5 scale) (0–5 scale) 5 scale) 5 scale) scale score 
18 6 2.3 1.8 2.2 1.8 0.7 4.0 
24 6 2.5 1.8 2.2 2 0 4.0 
30b 25 2.7 1.7 1.7 1.7 0.5 3.8 
16 mg/m3 
3 3 2 1 2 0 0 3.0 
6 3 2.3 1.3 2 0 0 3.0 
12 6 3 1.8 2.8 2.8 0.7 4.0 
18 6 3 2.7 2.7 2.2 1.2 4.0 
24 6 3 2.7 2.7 2.8 1.5 4.2 
30b 20 3 2.5 2.1 2 1 4.0 
30 mg/m3 
3 3 2 1 2 2 0 3.3 
6 3 2.7 2 2 2 0 4.0 
12 6 3 2.3 2.5 2.5 1.5 4.0 
18 3 3 2 2.3 2.3 1 4.3 
24 6 3.2 2.7 2 2 0.5 4.0 
30b 15 2.8 2.9 1.9 1.9 1.3 4.3 
a0–5 Scale for different types of lesions:  0=normal; 1=minimal; 2=mild; 3=moderate; 4=marked: 5=severe.  8-Grade 
Wagner Scale for pulmonary cellular change and fibrosis:  1=normal; 2 or 3=cellular change consistent with 
inflammation; 4=minimal fibrosis with collagen deposition, bronchiolization, and mucoid debris; 5=mild fibrosis with 
some interlobular linking of collagen; 6=moderate fibrosis with consolidation and parenchymal decrease; 7=severe 
fibrosis and consolidation; 8=complete obstruction of airways. 
bExposed for 24 months and sacrificed at 30 months. 
cBernstein et al. (2001b) reported that the original pathologist’s score for this lesion was for collagen deposition at 
the bronchoalveolar junction, not for pulmonary fibrosis; in the five-grade scale used for collagen deposition, a 
minimal score of 1 is of insufficient severity to be classified as minimal fibrosis (Grade 4 on the Wagner scale).   
Dose and end point used for MRL derivation: 
Benchmark concentration analysis was conducted for lung weights (absolute weight expressed as percent 
of control), macrophage aggregation scores, bronchiolization scores, and scores for collagen deposition at 
the bronchoalveolar junction.  Changes in the first three variables are taken as signs of pulmonary
inflammation induced by refractory ceramic fibers deposited in the lung.  ATSDR policy considers 
pulmonary fibrosis to be a serious adverse effect that is inappropriate for MRL derivation.  Scores for 
collagen deposition at the bronchoalveolar junction were included in the analysis, because a score of 1 for 
this lesion is not of sufficient severity to be considered fibrosis; only scores ≥2 were classified as 
pulmonary fibrosis. 
Continuous-variable models available in the EPA Benchmark Dose Software were fit to the lung weight, 
macrophage, bronchiolization, and bronchoalveolar collagen deposition data shown in Table A-3.  Each 
of these end points was increasingly affected with increasing exposure level and increasing concentrations 
of fibers in the lungs at 24 months (Table A-3).  Group means and standard deviations of the lung weight,
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the Mast et al. (1995a, 1995b) 24-month-sacrifice data by Yu and Oberdörster (2000). The mean scores 
and standard deviations for collagen deposition at the bronchoalveolar junction were obtained from data 
in the report by Bernstein et al. (2001b).  The published report by Mast et al. (1995a, 1995b) only cited 
mean values and did not cite standard deviations.  Dr. Yu’s analysis did not include scores (and standard 
deviations) for granuloma presence.   
The benchmark response level for lung weight was set at 10% increase in weight.  Percentage change 
below this value is assumed to be nonadverse.  Benchmark response levels for scores for macrophage 
aggregation, bronchiolization, and bronchoalveolar collagen deposition were set at 1.0 (minimal rating on
the 0–5 scale, where 0=normal). 
Table A-3. Non-neoplastic Lung Responses in F344 Rats Exposed for 24 Months 
to RCF1 (Mast et al. 1995a, 1995b) 
Exposure Fiber concentrations Lung 
level in lungs at 24 months  weight Mean score±standard deviation (0–5 Scale) 
(total 
fibers/cc) 
(mean total fibers per 







Collagen deposition at the 
bronchoalveolar junction 
0 (n=12) NR 100.0±14.0 0±0 0±0 0±0 
36 (n=6) 5.55±1.71 116.8±12.3 2.0±0 1.2±0.4 0.7±0.82 
91 (n=6) 18.80±3.59 110.9±8.1 2.5±0.6 1.8±0.4 2±0 
162 (n=6) 27.80±6.06 131.8±15.3 3.0±0 2.7±0.5 2.8±0.4 
234 (n=6) 37.00±8.01 164.7±44.2 3.2±0.4 2.7±0.5 2.2±0.4 
0–5 Scale:  0=normal; 1=minimal; 2=mild; 3=moderate; 4=marked; 5=severe; NR= not reported 
[ ] NOAEL   [ ] LOAEL  [X] Benchmark Concentration:  Lower 95% confidence limits on benchmark 
concentrations (BMCLs = lower 95% confidence limit on the estimated concentrations associated with a 
mean score of 1.0 for macrophage aggregation, bronchiolization, or collagen deposition, or 10% increase 
in lung weight) were considered for selection of the point of departure for the MRL.  The rat exposure-
response data for these four end points were first fit to continuous-variable models.  The best-fitting 
models were then used to calculate rat BMCLs for each of the end points.  The point of departure for the 
MRL was selected from the rat BMCLs.  The selected rat BMCL was then converted to a BMCLHEC using 
a cross-species scaling factor derived from the lung deposition and clearance models developed for RCF1 
in rats and humans (Maxim et al. 2003b; Yu and Oberdörster 2000; Yu et al. 1995a, 1995b, 1996, 1997, 
1998a, 1998b).    
Benchmark Concentration Modeling Results.  Available continuous-variable models in the EPA 
Benchmark Dose Software (linear, polynomial, power, and Hill models; BMDS version) were fit to the 
data shown in Table A-3.   
Lung Weight. Adequate fits to the data (as assessed by chi-square residuals and log-likelihood ratio fit 
tests in the BMDS) were obtained with the linear, polynomial, power, and Hill models with constant 
variance assumed. Statistical tests indicated that variances were not constant across exposure groups (this 
is reflected in the standard deviations listed in Table A-3).  Models with non-homogeneous variance (i.e., 
variance as a power function of dose) generally provided improved fits to the data as assessed with 
Aikake’s Information Criteria, AIC (Table A-4).  Comparing across models, a better fit is indicated by a 
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geneous variance, which predicted a rat BMC and BMCL of 133 and 79 total fibers/cc, respectively
(Figure A-1). 
Table A-4. BMC Modeling Results for Lung Weights in Rats Exposed to RCF1 for 
24 Months (Mast et al. 1995a, 1995b) 
Model BMC (total fibers/cc) BMCL (total fibers/cc) AIC-fitted 
Linear 40 30 220.12 
Linear-nonhomogeneous .9 32 213.51 
Polynomial 95 34 220.08 
Polynomial-nonhomogeneous 94 43 211.52 
Power 110 35 222.00 
Power-nonhomogeneous* 133* 79* 209.30* 
Hill 10 35 224.00 
Hill-nonhomogeneous 60 6 228.90 
*Best Fitting Model 
Figure A-1. Predicted (Power Model with Nonhomogeneous Variance) and Observed 
Lung Weights in Rats Exposed to RCF1 for 24 Months (Mast et al. 1995a, 1995b)  
(Dose Refers To Rat Exposure Concentrations, Total Fibers/cc) 
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09:37 02/13 2004 
Macrophage Aggregation Scores. Adequate fits to the data (as assessed by chi-square residuals and log-
likelihood fit tests in the BMDS) were obtained with the polynomial, power, and Hill models with 
constant variance assumed.  Models with variance as a power function of dose did not improve the fits to 
the data. As assessed by AIC (Table A-5), the Hill model provided the best fit to the data, yielding a rat 
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Table A-5. BMC Modeling Results for Scores for Pulmonary Macrophage Aggregation in 

Rats Exposed to RCF1 for 24 Months (Mast et al. 1995a, 1995b)  

Model BMC (total fibers/cc) BMCL (total fibers/cc) AIC-fitted 
Hill* 12* 9* -33.05* 
Polynomial 21 13 -12.08 
Polynomial-nonhomogeneous 13 0 -8.44 
Power 6 0 13.67 
Power-nonhomogeneous 51 0 15.02 
*Best Fitting Model
Figure A-2. Predicted (Polynomial Model with Constant Variance) and Observed Scores 
for Pulmonary Macrophage Aggregation in Rats Exposed to RCF1 for 24 Months (Mast  
et al. 1995a, 1995b) (Dose Refers to Rat Exposure Concentrations, Total Fibers/cc) 
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09:56 02/13 2004 
Bronchiolization Scores. Adequate fits to the data (as assessed by chi-square residuals and log-likelihood 
fit tests in the BMDS) were obtained with the polynomial and Hill models with constant variance 
assumed.  Benchmark concentration calculations failed when models with variance as a power function of 
dose were fit to the data.  The best-fitting model, as assessed by AIC, was the polynomial (2-degree) 
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Table A-6. BMC Modeling Results for Scores for Bronchiolization in Rats Exposed to 

RCF1 for 24 Months (Mast et al. 1995a 1995b)  

Model BMC (total fibers/cc) BMCL (total fibers/cc) AIC-fitted 
Polynomial* 37* 30* -19.91* 
Hill 30 22 -18.28 
*Best Fitting Model
Figure A-3. Predicted (Polynomial Model with Constant Variance) and Observed Scores 
for Bronchiolization in Rats Exposed to RCF1 for 24 Months (Mast et al. 1995a, 1995b) 
(Dose Refers to Rat Exposure Concentrations, Total Fibers/cc) 
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10:44 02/13 2004 
Collagen Deposition Scores.  Adequate fits to the data (as assessed by chi-square residuals and log-
likelihood ratio fit tests in the BMDS) were obtained with the polynomial and Hill models with constant 
variance assumed.  Benchmark concentration calculations failed when models with variance as a power 
function of dose were fit to the data.  The best-fitting model, as assessed by AIC, was the polynomial 
(2-degree) model (Table A-7), which yielded a rat BMC and BMCL of 37 and 32 total fibers/cc, 
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Table A-7. BMC Modeling Results for Scores for Collagen Deposition at the 

Bronchoalveolar Junction in Rats Exposed to RCF1 for 24 Months  

(Mast et al. 1995a, 1995b)  

Model BMC (total fibers/cc) BMCL (total fibers/cc) AIC-fitted 
Polynomial* 37* 32* -12.52* 
Hill 45 37 -5.25 
*Best Fitting Model
Figure A-4. Predicted (Polynomial Model with Constant Variance) and Observed Scores 
for Collagen Deposition at the Bronchoalveolar Junction in Rats Exposed to RCF1 for 
24 Months (Mast et al. 1995a, 1995b) (Dose Refers to Rat Exposure Concentrations, 
Total Fibers/cc) 
Polynomial Model with 0.95 Confidence Level 
0 50 100 150 200 250 
dose 
11:26 02/13 2004 
Selection of Point of Departure for the MRL.  BMCs and BMCLs for the four modeled end points are 
shown in Table A-8. The BMCL for lung weight represents the 95% lower confidence limit on the 
concentration estimated to increase lung weight by a mean of 10% over control values.  The BMCLs for 
the pulmonary lesion scores represent the 95% lower confidence limits on the concentration estimated to 
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Table A-8. BMCs and BMCLs for Lung Weight and Pulmonary Lesion Scores in 

Rats Exposed to RCF1 for 24 Months (Mast et al. 1995a, 1995b). 

End point BMC (total fiber/cc) BMCL (total fiber/cc) 
Lung weight 133 79 
Pulmonary macrophage aggregation 12 9 
Bronchiolization 37 30 
Collagen deposition at the bronchoalveolar junction 37 32 
The rat BMCL of 9 total fiber/cc for pulmonary macrophage aggregation was selected as the point of 
departure for the MRL, because this lesion is the most sensitive among those measured in the bioassay (as 
indicated by having the lowest BMCL in Table A-8).  ATSDR considers minimal pulmonary
inflammation a reversible response to fibers and nonfibrous particles that, although near the boundary
between adverse and nonadverse, is an appropriate critical effect on which to base the MRL.  As shown in 
the data in Table A-3, the severity of pulmonary macrophage aggregation in rats in the principal study
showed a clear increase in severity with increasing exposure levels of RCF1, as well as with increasing 
concentrations of fibers in the lungs of the rats sacrificed after 24 months of exposure. 
Dosimetric Adjustment of Rat Benchmark Concentrations to Human Equivalent Concentrations (HECs)  
The BMC and BMCL for pulmonary aggregation in rats were converted to human equivalent exposure 
levels using an average scaling factor derived from rat and human lung deposition and clearance models 
for RCF1 developed by Dr. C.P. Yu and colleagues (Yu et al. 1995a, 1995b, 1996, 1997, 1998a, 1998b).  
Equations for deposition in the models are functions of fiber length, fiber diameter, and time.  The 
equations for mechanical macrophage-mediated clearance rate are functions of fiber length, alveolar 
macrophage volume, and lung burden (total accumulated volume of fibers and particles).  The clearance 
models include dissolution-rate and transverse breakage-rate equations.  
Values for key parameters in the dosimetric models included the following (Maxim et al. 2003b;Yu and 
Oberdörster 2000): 
Rat lung weight: 1.48 g; Human lung weight: 1,000 g
Rat lung surface area:  4.3x103 cm2; Human lung surface area:  6.5x105 cm2 
Rat macrophage volume per lung:  26 mm3; Human macrophage volume per lung:  1.75x104 mm3 
Rat macrophage diameter:  10.68 µm; Human macrophage diameter:  16.82 µm
Dissolution rate (same in rats and humans):  6.46x10-5 (µm/day) or 0.73 ng/cm2/hour 
Breakage rate and scheme:  same in rats and humans 
Size distribution of refractory ceramic fibers in the human model:   
Bivariate lognormal distribution (geometric mean±standard deviation) similar to workplace RCF 
size data: fiber diameter:  0.84 µm (±2.05); fiber length:  14.1 µm (±2.48) 
Rat model:  retained volume of nonfibrous plus fibrous particles (lung burden) impacts clearance 
rate 
Human model:  only retained fibrous particle volume impacts clearance rate. 
Initially, Yu and Oberdörster (2000) calculated HECs from the rat exposure levels, using number of 
WHO fibers per cm2 of lung surface area as the cross species lung burden normalization unit.  The rat 
models were set to the exposure scenarios experienced by rats in the Mast et al. (1995a, 1995b) bioassays 
(6 hours/day, 5 days/week for 2 years), and two human exposure scenarios were examined, one involving 
continuous, lifetime (70-year) exposure assuming a tidal volume of 750 cc and nasal breathing with a 
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5 days/week, 50 weeks/year for 40 years) assuming a tidal volume of 1290 cc and nasal breathing with a 
respiratory frequency of 15.5 per minute.  Calculated HECs for the two human exposure scenarios from
the rat exposure levels are shown in Table A-9.  The mean ratios of the rat:human equivalent exposure 
concentrations were 14.7 for the continuous exposure scenario and 7.3 for the occupational exposure 
scenario. From these ratios, mean rat-to-human dosimetric scaling factors are 0.07 (1/14.7) for the 
continuous exposure scenario and 0.13 (1/7.3) for the occupational exposure scenario. 
Table A-9. HECs Calculated for Two Human Exposure Scenarios from Rat Exposure 
Levels Using WHO Fibers per cm2 of Lung Surface area for Cross-Species Normalization. 
(Source: Tables 7.1 and 7.2; Yu and Oberdörster, 2000) 
Human exposure scenario Rat exposure levels (total fibers/cc) Mean ratio 
0 36 91 162 234 rat:human (±SD) 
HECs (WHO fibers/cc)
Continuous 0 2.4 8.1 11.0 13.2 14.7 ±2.7 
Occupational 0 4.7 16.2 22.3 27.1 7.3 ±1.3 
More recently, Maxim et al. (2003) showed that selection of the cross species lung burden normalization 
unit (i.e., number of fibers per cm2 of lung surface area versus number of fibers per mg dry weight of 
lung) is a key determinant in species conversion of exposure levels when using the lung and deposition 
models developed by Yu and colleagues.  Using a human occupational exposure scenario assuming a tidal 
volume of 1,060 cc and nasal breathing with a respiratory frequency of 12.74 per minute and a minute 
ventilation of 13.5 L per minute, human equivalent concentrations corresponding to a rat exposure level 
of 36 total fiber/cc were calculated to be 5.7 total fiber/cc, based on a WHO fibers per cm2 of lung surface 
area normalization, compared with 33.8 total fibers/cc, based on a WHO fibers per lung mg dry weight 
normalization.  The ratios of rat:human equivalent exposure concentrations for these occupational 
exposure scenarios were 6.3 on a lung surface area basis (similar to the mean of 7.3 shown in Table A-9) 
and 1.1 on a lung dry weight basis.  For this occupational exposure scenario, rat-to-human dosimetric 
scaling factors based on lung surface area normalization or lung dry weight normalization are 0.16 (i.e., 
1/6.3) and 0.9 (1/1.1), respectively, indicating an approximate 6-fold difference between lung surface area 
and lung dry weight normalizations.  
A rat-to-human scaling factor of 0.07, based on a human continuous exposure scenario and lung surface 
area cross-species normalization, was used to convert the rat BMC and BMCL of 12 and 9 total fibers/cc 
to human equivalent concentrations of 0.8 and 0.6 WHO fibers/cc, respectively.  This scaling factor was 
used, because data are not available to confirm which cross-species lung burden normalization method is 
more accurate, and calculations of mean rat-to-human dosimetric scaling factors, based on lung dry
weight normalization with continuous exposure scenarios, are not available.  It is recognized that the 
analysis by Maxim et al. (2003) indicates that an alternative scaling factor, based on lung dry weight cross 
species normalization, could be about 6-fold higher. The point of departure for the MRL is the 
BMCLHEC of 0.6 WHO fibers/cc, rounded to 1 WHO fibers/cc. 
Uncertainty Factors used in MRL derivation: 
[X] 3 for interspecies extrapolation with dosimetric adjustment.  The dosimetric adjustment takes into 
account physiological differences between rats and humans expected to influence deposition and 
clearance of refractory ceramic fibers from the lung.  It is recognized that the cross species dosimetric 
scaling factor used (based on fiber per lung surface area normalization) may underestimate the human 
equivalent concentration associated with the development of pulmonary lesions, compared with a scaling 
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normalization is likely to be protective of the public health, and an additional factor to account for this 
dosimetric uncertainty is unnecessary.  The derivation assumes that rats and humans are equally
responsive to retained fibers in the lung, in the absence of conclusive evidence to indicate otherwise.  The 
uncertainty factor of 3 accounts for the uncertainty associated with this assumption of interspecies 
pharmacodynamic equivalence.  
[ ] 10 for use of a LOAEL:  No uncertainty factor was necessary for the use of a BMCLHEC for minimal 
pulmonary macrophage aggregation, an effect just above the boundary between nonadverse and adverse.   
[ X ] 10 for human variability
Was a conversion used from ppm in food or water to a mg/body weight dose? No. 
Was a conversion used from intermittent to continuous exposure? Yes. The human lung and deposition 
model used a continuous, 70-year, exposure scenario, whereas the rat lung and deposition model used the 
experimental exposure conditions, 6 hours/day, 5 days/week for 2 years. 
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: See 
previous discussion of the derivation of the rat-to-human dosimetric scaling factor of 0.07. 
Other additional studies or pertinent information which lend support to this MRL:  The Mast et al. (1995a, 
1995b) study provides the best available data describing exposure-response relationships for 
nonneoplastic lesions in the lung and pleura from chronic inhalation exposure to refractory ceramic fibers.  
The study identifies pulmonary inflammation as the critical nonneoplastic end point of concern and 
identifies other more serious effects at higher exposure levels (pulmonary and pleural fibrosis and cancer 
of the lung and pleura).  Other studies of rats exposed to RCF1 by inhalation provide strong support for 
pulmonary inflammation as the critical end point (Bellman et al. 2001; Everitt et al. 1997; Gelzleichter et 
al. 1999; McConnell et al. 1995), as well as other animal inhalation studies of other refractory ceramic 
fibers (Mast et al. 1995a) and other synthetic vitreous fibers such as insulation glass wools, MMVF10 and 
MMVF11 (Hesterberg et al.1993c; McConnell et al. 1999), slag wool MMVF22 (McConnell et al. 1994), 
and rock wool MMVF21 (McConnell et al. 1994). 
There are distinct differences between laboratory animal species and humans in respiratory tract size and 
geometry, ventilation rate and pattern, and macrophage sizes that influence the retention (the net result of 
deposition and clearance) of fibers in the lung.  Yu and colleagues (Yu et al. 1995a, 1995b, 1996, 1997, 
1998a, 1998b) have developed lung retention models for RCF1 in rats and humans that incorporate many
of these interspecies differences.  Although these models significantly decrease uncertainty in 
extrapolating doses from rats to humans, in vivo human data on internal doses of inhaled synthetic 
vitreous fibers are limited, and validation exercises with the human model are correspondingly limited.  
Several reviewers of draft versions of this Toxicological Profile disagreed with ATSDR’s selection of 
macrophage aggregation as the critical effect for the MRL.  Reasons for not selecting macrophage 
aggregation included:  (1) this end point is not a response that is specific to fibers (nonfibrous particles 
can also cause this effect), and (2) it is a reversible and adaptive effect and therefore nonadverse.  The 
ATSDR MRL Workgroup acknowledged that although there were confounding effects from nonfibrous 
particles in the principal study, the data in Table 2 show that there was a clear relationship between 
concentrations of fibers in the lung and increasing severity of macrophage aggregation.  The MRL 
Workgroup acknowledged the reversibility of macrophage aggregation, but does not consider reversibility
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The ATSDR MRL Workgroup discussed an alternative MRL derivation with collagen deposition as the 
critical effect, but preferred selection of macrophage aggregation as the critical effect.  If collagen 
deposition was selected as the critical effect for the MRL, an alternative MRL of 0.02 WHO fibers/cc was 
derived as follows (using a benchmark response=a concentration that would produce an average score of 
1 for bronchoalveolar collagen deposition in a population and a total uncertainty factor of 90:  3 for cross-
species extrapolation, 10 for human variability, and 3 for the selection of a potentially serious adverse 
effect as the critical effect):   
1. [Rat BMCLcollagen deposition] x [cross-species scaling factor] = BMCLcollagen depositionHEC 
32 total fiber/cc x 0.07 = 2.24 WHO fibers/cc = 2 WHO fibers/cc (rounded) 
2. MRL = BMCLcollagen depositionHEC ÷ 90 = 2 ÷ 90 = 0.02 WHO fibers/cc. 
The Workgroup noted the similarity of the values of the MRLs based on macrophage aggregation 
(0.03 WHO fibers/cc) or collagen deposition (0.02 WHO fibers/cc).  The approximate 3-fold difference in 
the benchmark concentrations (9 total fibers/cc for macrophage aggregation and 32 total fibers/cc for 
collagen deposition) was offset by the 3-fold difference in the total uncertainty factors (30 for 
macrophage aggregation and 90 for collagen deposition).   
The MRL derivation assumes that rats and humans are equally sensitive to the inflammatory effects of 
refractory ceramic fibers.  Understanding of the relative pharmacodynamic sensitivity of rodents and 
humans to synthetic vitreous fibers, asbestos fibers, or nonfibrous particulate matter is poor.  Varying 
opinions on the relative sensitivity of rodents and humans to deposited fibers have been expressed by
Rodelsperger and Woitowitz (1995), Rowe and Springer (1986), Yu and Oberdörster (2000), Maxim and 
McConnell (2001), and Maxim et al. (2003).  The uncertainty factor of 3 is used in the MRL derivation to 
account for the uncertainty of the assumption of pharmacodynamic equivalence between rats and humans. 
Available comparative data with other refractory ceramic fibers (e.g., data for RCF2, RCF3, and RCF4 
reported by Mast et al. 1995a) suggest that RCF1 is as potent or more potent in inducing various 
pulmonary effects than other refractory ceramic fibers.  Thus, the chronic MRL based on RCF1 data is 
expected to be protective of the public health for exposure to other refractory ceramic fibers.   
A significant contributing factor to the high potency of RCF1 relative to other refractory ceramic fibers is 
the high content of nonfibrous particles in RCF1.  Bellmann et al. (2001) have reported that the mass 
concentration of total fibers (particles with aspect ratio >3:1) and nonfibrous particles (with aspect ratios 
<3:1) in RCF1 are 0.76 and 0.26 ng/ng RCF1, respectively.  Evidence that the presence of the nonfibrous 
particles can enhance the effects on the lung was provided by comparing responses in rats exposed by
inhalation for 3 weeks to concentrations of about 125 fibers (with lengths >20 µm)/cc of either RCF1 or a 
sample of refractory ceramic fibers, called RCF1a, in which only 2% of the mass was accounted for by
nonfibrous particles (Bellmann et al. 2001).  Expressed as WHO fibers/cc, the respective mean 
concentrations were 481 fibers/cc for RCF1a and 679 fibers/cc for RCF1.  Pulmonary clearance ability
was markedly depressed by RCF1, but not by RCF1a, and indices of pulmonary inflammation were more
persistently increased by RCF1 than by RCF1a (Bellmann et al. 2001).   
The ratio of nonfibrous particles:fibers for the RCF1 material used in the 2-year rat bioassay (Mast et al., 
1995a, 1995b) has been reported to be about 3:1 by Bellmann et al. (2001), about 1-2:1 from data 
reported by Mast et al. (1995a, 1995b), and 9:1 by Maxim et al. (1997) and Mast et al. (2000).  In 
contrast, workplace air samples (n=10) showed a ratio of about 0.5:1 (Mast et al. 2000; Maxim et al. 
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to the observed lung responses to some undetermined degree.  As such, the MRL may underestimate the 
daily human exposure that is likely to be without appreciable risk of adverse noncancer health effects, and 
is expected to be protective of public health. 
Bernstein et al. (2001b) conducted an analysis to determine if there was a statistically significant 
relationship between scores for collagen deposition at the bronchoalveolar junction and lung fiber 
concentrations (of various size classes) in the data collected in chronic rat bioassays with five types of 
synthetic vitreous fibers (RCF1, MMVF21—a stone wool, MMVF 11—an insulation glass wool, 
MMVF10—an insulation glass wool, and MMVF22—a slag wool).  In the analysis, logistic and 
proportional odds regression models were fit to data for scores for collagen deposition at the broncho­
alveolar junction and associated lung fiber concentrations in the rats sacrificed after 24 months of 
exposure. In these analyses, lesion score was the dependent variable and lung fiber concentration (of 
various size classes) was the explanatory variable. Bernstein et al. (2001b; Figure 2) noted that the score 
for collagen deposition showed a statistically significant relationship with increasing lung concentrations 
of the five types of fibers with lengths >20 µm (and not with lung concentrations of fibers in smaller 
length categories). 
In comments provided to ATSDR (ATSDR Docket No. ATSDR-187; January 23, 2003), Dr. Bernstein 
noted that his analysis extended to 10 other pulmonary end points evaluated in these bioassays (including 
scores for macrophage aggregation and bronchiolization), and that he did not find statistically significant 
relationships for these scores with the concentrations of the various types of fibers in the lungs of the rats.  
Dr. Bernstein’s analysis indicates that only the scores for collagen deposition (and not the other 
pulmonary end points) showed a statistically significant relationship with lung burden across the five 
types of synthetic vitreous fibers included in the analysis.  Dr. Bernstein interpreted this to mean that, 
among the 11 pulmonary end points evaluated in these bioassays and this analysis, only collagen 
deposition had a statistically significant relationship with fiber lung burden at 24 months.  Dr. Bernstein 
proposed that one reason for selecting bronchoalveolar collagen deposition as the critical end point for 
MRL derivation is that there was a lack of association for the other end points with lung fiber 
concentration at 24 months.  An alternative interpretation of Dr. Bernstein’s analysis is that it shows that 
only the most biopersistent of the fibers evaluated (i.e., those, such as RCF1, that accumulated to a 
sufficiently high level in the lung after 2 years) produced moderate collagen deposition and that all of the 
fiber types included in the analysis induced the other less adverse responses (such as macrophage 
aggregation and bronchiolization) to degrees that were indistinguishable between fiber types.  The data 
from the principal RCF1 study shown in Table A-3 clearly show that the severity of all of the pulmonary
end points (including scores for macrophage aggregation and bronchiolization) increased with increasing 
exposure level and with increasing lung fiber concentration at 24 months.  Thus, even though the 
nonfibrous particles in the RCF1 atmospheres may have contributed to the pulmonary responses in the 
rats, the data show a clear relationship between the severity of macrophage aggregation (and other more 
severe end points) and the internal dose of fibers deposited in the lung.  As such, it appears reasonable to 
select macrophage aggregation as the critical effect for MRL derivation.   
The chronic MRL is expected to be appropriately applied to intermediate-duration exposure scenarios, 
based on evidence from interim sacrifice data from the Mast et al. (1995b) bioassay that exposure-
response relationships for pulmonary inflammation and chronic exposure are similar to those for 
intermediate-duration exposure.  Scores for pulmonary inflammation progressed to only a limited degree 
with progression from intermediate to chronic duration.  For example, mean scores for macrophage 
aggregation in rats exposed to 3, 9, 16, and 30 mg/m3 at 3 months were 1.7, 2, 2, and 2, respectively. The 
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Exposure-response relationships for pulmonary inflammation from acute inhalation exposure to synthetic 
vitreous fibers are inadequately characterized for deriving an acute inhalation MRL for any type of 
synthetic vitreous fiber.   
Any use of the MRL for refractory ceramic fibers in assessing health hazards from the insulation wools 
should acknowledge the evidence that many of the insulation wools are markedly less durable and less 
potent than refractory ceramic fibers (Bernstein et al. 2001a, 2001b; Eastes and Hadley 1996; Eastes et al. 
2000; Hesterberg et al. 1998a).  There are data from multiple-exposure-level 2-year rat inhalation 
bioassays on the glass wools, MMVF10 and MMVF11 (Hesterberg et al.1993c; McConnell et al. 1999), 
the slag wool MMVF22 (McConnell et al. 1994), and the rock wool MMVF21 (McConnell et al. 1994) 
that adequately describe exposure-response relationships for nonneoplastic pulmonary effects from
intermediate- and chronic-duration exposure to these materials.  However, lung deposition and clearance 
models for these synthetic vitreous fibers (such as those developed by C.P. Yu and colleagues for RCF1) 
are not yet fully developed to carry out physiologically based dosimetric calculations of human equivalent 
concentrations. When these models are available, they could be used to convert rat exposure 
concentrations to human equivalent concentrations, and use the data for MMVF10, MMVF11, MMVF22, 
and MMVF21 to derive inhalation MRLs for insulation wools.  
There are no adequate data (from multiple-exposure level studies) for deriving inhalation MRLs for the 
other types of synthetic vitreous fibers (special applications glass fibers or continuous filament glass 
fibers that are woven). 
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Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans?
3. 	What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
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meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
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The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically when 
sufficient data exists, three LSE tables and two LSE figures are presented in the document.  The three 
LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE 
Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation (LSE Figure 3-1) and oral 
(LSE Figure 3-2) routes.  Not all substances will have data on each route of exposure and will not, 
therefore, have all five of the tables and figures. 
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  In this 
example, an inhalation study of intermediate exposure duration is reported.  For quick reference to health 
effects occurring from a known length of exposure, locate the applicable exposure period within the LSE 
table and figure. 
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer.  Systemic effects are further 
defined in the "System" column of the LSE table (see key number 18). 
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 
two "18r" data points in sample Figure 3-1). 
(5) Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, 
"Toxicokinetics," contains any available information on comparative toxicokinetics.  Although NOAELs 
and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an 
MRL. 
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from different 
studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation for 6 hours/day, 
5 days/week, for 13 weeks.  For a more complete review of the dosing regimen refer to the appropriate 
sections of the text or the original reference paper (i.e., Nitschke et al. 1981). 
(7) System. This column further defines the systemic effects.  These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular.  
"Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems.  In 
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(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, which was 
used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b"). 
(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help readers 
identify the levels of exposure at which adverse health effects first appear and the gradation of effects 
with increasing dose.  A brief description of the specific end point used to quantify the adverse effect 
accompanies the LOAEL.  The respiratory effect reported in key number 18 (hyperplasia) is a Less 
Serious LOAEL of 10 ppm.  MRLs are not derived from Serious LOAELs. 
(10) Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE tables and 
figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer 
increases. 
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive 
an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log scale 
"y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 corresponds to 
the entry in the LSE table.  The dashed descending arrow indicates the extrapolation from the exposure 
level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table). 
(17) CEL. Key number 38r is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the LSE 
table. 
(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
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EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response 
curve at low dose levels (q1*). 
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure. 
 
 
         
 















































































→ Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation 
LOAEL (effect)
Exposure 
Less serious Serious (ppm) frequency/ NOAEL 


























2 →INTERMEDIATE EXPOSURE 

5 6 7 8 9 10 
Systemic→ ↓ ↓ ↓ ↓ ↓ ↓
18 Rat 13 wk Resp 3b 10 (hyperplasia) 
→ 5 d/wk 
6 hr/d 












40 Mouse 79-103 wk 10 (CEL, lung tumors, NTP 1982 
5 d/wk hemangiosarcomas) 
6 hr/d 
12 →a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy
DOL Department of Labor 
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DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 


























C-3 SYNTHETIC VITREOUS FIBERS
APPENDIX C 
MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
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OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit 
pg picogram
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States
USDA United States Department of Agriculture 
USGS United States Geological Survey
VOC volatile organic compound 
WBC white blood cell 



































greater than or equal to 
equal to 
less than 








cancer slope factor 
negative 
positive 
weakly positive result 
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alveolar retention models .................................................................................................................. 126, 128 

ambient air ........................................................................................ 179, 182, 184, 185, 189, 193, 202, 204 





biodegradation..................................................................................................................................... 15, 179 

biomarker .................................................................................................. 139, 140, 141, 155, 156, 207, 214 

body weight effects ............................................................................................................................. 31, 108 

breast milk............................................................................................................................................. 8, 200 

bronchoalveolar lavage fluid....................................................................................................... 87, 140, 214 

C102/C104 blend fibrous glass ........................................................................... 19, 20, 86, 90, 97, 149, 151 
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carcinoma......................................................................... 20, 96, 97, 102, 104 103, 105, 106, 107, 134, 151 
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cardiovascular effects.................................................................................................................................. 94 

chest x-ray............................................................................................... 10, 18, 83, 141, 142, 154, 156, 214 
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death........................................................................................ 29, 31, 80, 94, 95, 98, 99, 100, 107, 108, 141 

decreased pulmonary function ........................................................................................ 80, 82, 83, 143, 144 

deposition and clearance models..................................................... 22, 23, 27, 128, 135, 149, 150, 152, 158 
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dissolution.....................................15, 17, 110, 115, 116, 117, 118, 119, 120, 121, 122, 123, 125, 127, 130, 

131, 132, 134, 145, 156, 158, 159, 166, 179, 184 

DNA.................................................................................................................. 111, 133, 134, 139, 143, 153 
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gastrointestinal effects ................................................................................................................................ 95 

GB100R .......................................................................................................................... 19, 90, 97, 149, 151
 
general population............................................................................................. 139, 150, 179, 188, 189, 204
 
genotoxic............................................................................................................................. 29, 110, 134, 153 

genotoxicity............................................................................................................................... 110, 130, 153 

glass wool .......2, 4, 5, 6, 7, 11, 13, 15, 16, 17, 19, 20, 21, 22, 27, 82, 83, 84, 85, 86, 89, 90, 91, 92, 93, 94, 

95, 96, 97, 98, 99, 100, 101, 102, 103, 105, 106, 108, 109, 110, 111, 113, 116, 118,
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hepatic effects ............................................................................................................................................. 95 

hydroxyl radical ................................................................................................................................ 111, 153 

IARC...............................................................7, 13, 14, 21, 95, 99, 103, 110, 133, 134, 145, 160, 163, 168,  

171, 174, 175, 185, 190, 203, 217, 218, 219 

immune system ......................................................................................................................................... 154 

immunological .................................................................................................................................... 29, 154 

immunological effects............................................................................................................................... 154 

inhalation MRLs ................................................................................................... 27, 30, 150, 152, 157, 159 

Integrated Risk Information System (see IRIS) .......................................................................... 22, 217, 219 

IRIS (see Integrated Risk Information System) .......................................................................... 22, 217, 219 

irritation effects................................................................................................................................. 144, 159 

lymphatic .......................................................................................................................... 102, 115, 130, 158 

lymphoreticular ......................................................................................................................................... 154 

metabolic effects ....................................................................................................................................... 107 

micronuclei ....................................................................................................................................... 111, 153 

mineral wool ................................................................. 13, 83, 102, 165, 171, 174, 175, 187, 194, 203, 218 

MMVF10 .................19, 20, 22, 27, 86, 90, 97, 105, 106, 111, 119, 120, 124, 127, 133, 149, 150, 151, 152 

MMVF10a ............................................................................................................................ 20, 90, 105, 113 

MMVF11 .........................................19, 20, 22, 27, 86, 90, 97, 105, 106, 120, 124, 127, 149, 150, 151, 152 

MMVF21 ...................................19, 20, 22, 27, 86, 92, 93, 97, 107, 120, 121, 127, 133, 136, 149, 150, 152 

MMVF22 .........................................................19, 20, 22, 27, 86, 93, 97, 106, 120, 127, 149, 150, 151, 152 

MMVF33 .............................................................................. 19, 20, 86, 90, 97, 98, 105, 113, 120, 149, 151 

mucociliary ............................................17, 95, 113, 115, 116, 117, 123, 125, 127, 131, 145, 156, 157, 159 

mucociliary translocation.......................................................................................................... 123, 125, 145 

National Toxicology Program............................................................................................. 21, 146, 217, 219 
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nonmalignant respiratory disease........................................................ 18, 80, 81, 83, 84, 102, 135, 151, 155 
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PCM .....................................................15, 181, 182, 185, 186, 189, 190, 193, 207, 208, 209, 210, 211, 213 

pharmacodynamic ............................................................................................................................. 125, 135 

pharmacokinetic.................................................................................. 16, 125, 126, 130, 135, 137, 138, 160 

photolysis ............................................................................................................................................ 15, 179 

pleural plaques .......................................................... 5, 10, 18, 79, 80, 82, 83, 130, 142, 150, 151, 155, 156 

pulmonary fibrosis ...................................................6, 7, 16, 25, 93, 104, 110, 135, 142, 143, 151, 159, 214 
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quartz ........................................................................................................................ 165, 181, 198, 200, 202 
RCF1.......................................18, 19, 20, 22, 23, 24, 25, 26, 27, 85, 86, 87, 88, 89, 97, 103, 104, 105, 111, 
118, 127, 128, 131, 133, 135, 136, 148, 149, 151, 152 
RCF1a ............................................................................................................................. 25, 86, 88, 120, 152 
RCF2..................................................................................................... 19, 20, 86, 88, 89, 97, 104, 149, 151 
RCF3..................................................................................................... 19, 20, 86, 88, 89, 97, 104, 149, 151 
RCF4..................................................................................................... 19, 20, 86, 88, 89, 97, 104, 149, 151 
refractory ceramic .................2, 5, 6, 7, 13, 15, 16, 17, 18, 19, 20, 21, 22, 25, 27, 31, 79, 80, 81, 85, 86, 87, 
89, 94, 97, 98, 103, 104, 108, 110, 111, 114, 118, 126, 128, 130, 133, 134, 
135, 136, 140, 143, 144, 149, 150, 151, 152, 154, 155, 156, 157, 158,
163, 164, 165, 168, 170, 171, 175, 177, 181, 182, 184, 189, 190, 
193, 198, 199, 200, 202, 203, 214, 217, 219, 220 
renal effects................................................................................................................................................. 96 
respiratory tract irritation ...................................................................................................................... 17, 82 
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